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ABSTRACT 
With the global scale-up of universal health coverage and a renewed interest in reducing 
poverty and vulnerability in the context of health, there have been substantial efforts 
towards including a representation of the economic impact of illness on patients and their 
households more formally in the evaluation of health care and development of health 
policy. Programmes increasingly need to track progress against disease-specific global 
targets, such as the End Tuberculosis (TB) Strategy which identifies a target of “no TB-
affected family facing catastrophic cost due to TB” by 2020. There is also an increasing 
interest in understanding the impact of disease on impoverishment, and the broader 
dynamics of the interaction between health service delivery, health service expenditures 
and poverty as part of the economic evaluation of new technologies.  
This shift towards including the household perspective in health economics research 
requires consideration of whether the methods and data currently being used are 
appropriate. There are inconsistencies in current methodological approaches to estimate 
disease-specific costs from the patient perspective, and the applicability of methods for 
different study purposes is unclear. This thesis aims to improve the estimation of disease-
specific patient, household, and catastrophic costs collected in the context of facility-level 
intervention-focused studies for different policy purposes. Focusing specifically on the case 
of TB in South Africa, this thesis evaluates existing methods for estimating catastrophic 
costs for TB and highlight methodological issues that researchers need to consider when 
collecting these costs.  
The research presented in this thesis confirms that people in South Africa continue to 
encounter catastrophic costs due to TB and provides some indications where investment 
from the South African government can reduce this burden. The thesis also identifies 
several important limitations in the current implementation of methods to estimate 
disease-specific catastrophic costs, and makes a strong argument in favour of a reference 
case on estimating patient, household, and catastrophic costs. 
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CHAPTER 1. INTRODUCTION 
BACKGROUND 
The last five years have seen a global scale-up of universal health coverage and a renewed 
interest in reducing poverty and vulnerability in the context of health. Alongside these 
developments, consideration of the economic impact of illness on the patient and their 
household has taken a more prominent role in the evaluation of health care and 
development of health policy [1–7]. In addition to the monitoring of Universal Health 
Coverage, there is a growing interest in including poverty-related outcomes such as 
catastrophic costs as part of disease-specific economic evaluations and global targets used 
for programme evaluation, such as the End Tuberculosis (TB) Strategy which identifies a 
goal of “no TB-affected family facing catastrophic cost due to TB” by 2020 [8]. These 
developments stem from an increasing interest in understanding the impact of specific 
diseases on impoverishment and the broader dynamics of the interaction between health 
service delivery, patient and household expenditures, and poverty.  
This shift towards broad inclusion of a patient and household perspective in economic and 
programme evaluation requires consideration of whether the methods and data to 
measure patient and household costs and impoverishment in the context of specific 
diseases are adequate. There has been some recent progress in methodological 
development alongside this increasing interest, most notably with the WHO Task Force to 
Estimate Catastrophic Costs, and the Global Health Cost Consortium. As part of my position 
as a Research Fellow at LSHTM, I have been involved with both institutions the past four 
years. My work with these institutions has highlighted some gaps remaining on these 
issues, and brought to light the fact that while disease-specific household and patient cost 
data are critical to help policy-makers and planners understand barriers to access and 
include the patient perspective in economic and programme evaluation, there remains no 
consensus on methods for collecting this data. A wide diversity of methods are currently 
employed for estimation of patient, household and catastrophic costs, and the evidence to 
support the choice of one practice over another is weak. There is a need for a conversation 
around estimation of disease-specific patient and household cost, to help researchers and 
policymakers recognise the impact of varying methodologies and understand the validity of 
current approaches to address different policy questions.  
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To measure progress towards the high-level End TB Strategy target, the WHO Global TB 
Programme developed a handbook for nationally representative cross-sectional surveys to 
estimate catastrophic costs due to TB which was published in 2017. As part of the WHO 
Task Force to Estimate Catastrophic Costs, I input into developing these methods, which 
have been used to carry out surveys in 11 countries in 2015-2018 [9], with a further 13 
planned. The handbook specifies a standardised methodology for measurement of 
catastrophic costs due to TB at the national level. The primary target audience for the 
handbook includes national TB programmes and partners involved in supporting TB 
programme planning, implementation, and evaluation, and guidance is specific to the 
policy purpose of estimating the national prevalence of catastrophic costs due to TB. 
Methods identified in the handbook are not validated as a gold standard, and it is currently 
unclear to what extent researchers can adapt the recommended methods for other 
purposes.  
Within the Global Health Cost Consortium, I contributed to writing the Reference Case on 
Global Health Costing, which aimed to improve the quality of cost estimates through 
improved consistency and transparency of methods, assumptions, and reporting. In 
recognition of the work taking place within the WHO Task Force at the time and in order to 
minimize duplication of effort, the GHCC Reference Case was focused exclusively on 
methods to estimate provider-side costs.  However, at the request of the WHO the GHCC 
funded research to further develop methods and answer remaining questions after the 
completion of the Handbook (Chapters 8 and 9 of this thesis; further described below). 
This thesis brings together my experience within the WHO Task Force and the GHCC, as 
well as additional research and experience from other projects and my own independent 
research. 
AIMS AND OBJECTIVES 
This thesis aims to assess and improve the measurement of patient, household and 
catastrophic costs collected in the context of disease-specific economic and programme 
evaluation, focusing specifically on the case of TB in South Africa.  
The thesis has five main objectives: 
1. Estimate the prevalence of catastrophic costs among a cohort of people with TB 
using primary data, collected using conventional methods 
2. Identify and critically review the methods used in measuring patient costs for TB 
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3. Evaluate the impact of methodological variation in catastrophic cost estimation on 
study findings 
4. Estimate nationally representative catastrophic costs due to TB in South Africa 
using existing data 
5. Identify the policy implications and next steps for research in this area 
I draw on existing data from research projects conducted within my team at LSHTM to 
address these objectives. Through case studies and comparative analyses, I evaluate 
existing methods for estimating catastrophic costs for TB and identify methodological 
issues researchers need to consider when collecting these costs and applying cost 
estimates to economic or programme evaluation. 
ORGANISATION OF THE THESIS 
This PhD is structured in a research paper style and is comprised of five different papers, 
along with some introductory and linking material. The first three chapters focus on 
explaining the methods and background of this PhD. This first chapter provides an 
introduction and justification for the research conducted. In Chapter 2, I present the 
theoretical background to my thesis; in Chapter 3 I describe the case study used for this 
PhD: TB in South Africa. Chapter 4 presents the methodological approaches used in the 
subsequent research papers.  
In Chapter 5, I present a study of catastrophic costs for TB, HIV and TB/HIV co-infection in 
South Africa - the first of its kind for the country (Research Paper #1). Funding for data 
collection and my time for analysis on this chapter was provided by the President’s 
Emergency Fund for AIDS Relief (PEPFAR).  Chapter 6 (Research Paper #2) is a reflection and 
the development of a framework for the methodological challenges faced by researchers 
collecting patient costs in pragmatic intervention-based settings such as the one presented 
in Chapter 5. Data and input for this paper was drawn from four previously published 
studies; my time for writing this paper was not funded. Chapter 7 reports the results of a 
bibliometric review of methods for estimating patient costs of disease. This review aims to 
identify the availability, accessibility, relevance and use of methodological resources to 
limit the bias introduced into cost estimates due to these methodological compromises.  
My time for the initial search was funded by the Bill and Melinda Gates Foundation through 
the Global Health Cost Consortium grant; additional time for the ‘second round’ search, 
and patient cost-specific analysis and write-up was not funded. Chapters 8 and 9 (Research 
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Papers #3 and #4) then assess the applicability of current methods to track and evaluate 
programmatic progress against the target of “zero catastrophic costs due to TB by 2020”. In 
Research Paper #3 (Chapter 8), I present an analysis to illustrate the potential impact of 
different methodological approaches on study results. Next, in Research Paper #4 (Chapter 
9), I use modelling and regression methods to examine whether the existing data is 
sufficient to predict catastrophic costs at a national level given the current availability of 
data and the variability in methods identified in earlier chapters. Funding for data collection 
for Chapter 8 was funded by the Joint Global Health Trials scheme; data for Chapter 9 was 
drawn from three previously published studies. My time for analysis on both Chapters 8 
and 9 was funded by the Bill and Melinda Gates Foundation through the Global Health Cost 
Consortium grant. 
Finally, in Chapter 10 I summarise the findings of the thesis, its contributions to policy, the 
limitations inherent in the methods, and areas where further research is necessary. 
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CHAPTER 2. ESTIMATION OF CATASTROPHIC 
COSTS 
THEORETICAL BACKGROUND 
Defining the Household 
The main unit for much social science research is the household. Defining the ‘household’ 
can be somewhat challenging in many settings where the household is not necessarily 
synonymous with the nuclear family. Anthropologists and sociologists working in South 
Africa describe households as dynamic and complex. Restrictive laws during apartheid, and 
continued differentials in economic opportunities in post-apartheid South Africa, have 
contributed to a pattern of frequent migration away from the family for work [10] and 
fluidity of households as children are moved to stay with extended family [11]. 
Despite this trend being observed across South Africa, demographic and health surveys in 
South Africa have consistently used the criteria of co-residence and sharing resources to 
define a household. Statistics South Africa defines a household as “A group of persons who 
live together and provide themselves jointly with food and/or other essentials for living, or 
a single person who lives alone” [12]. Similarly, the Demographic and Health Surveys define 
a household as “a person or group of related or unrelated persons who live together in the 
same dwelling unit(s), who acknowledge one adult male or female as the head of the 
household, who share the same housekeeping arrangements and who are considered a 
single unit” [13]. The definition of a household used by the National Income Dynamics 
Survey (NIDS) is more fluid and allows for self-definition – potentially including people who 
are recognised as part of a unit but have migrated for work (or for other reasons) [14].  
This simplification is often adopted for convenience, and to enable study populations to be 
easily grouped by location.  However, particularly when looking at household ability to 
cope with health-related costs, this definition introduces potential bias.  By excluding 
family members not living in the same location, researchers may miss important sources of 
financial support such as remittances sent home by migrant workers. Equivalently, 
researchers may miss instances where payments are sent to support children living with 
extended family members – thereby over-estimating the resources available to pay for 
health care. 
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A Model of the Household Economy 
According to the Sustainable Livelihoods framework [15], all households are subject to 
some fluctuations in income and earning capacity over time, and therefore face some level 
of risk to income or expenditure shocks. Households can limit their exposure to shocks ex-
ante (for example through joining an insurance scheme or diversifying income or crops), or 
they can cope with shocks ex-post through mobilising wealth stores. Potential stores of 
wealth for households can include: human capital (skills, good health and ability to work); 
natural capital (land, water, environmental resources); physical capital (housing, water, 
transport, electricity); financial capital (savings, credit, pensions); and social capital 
(networks, associations, institutions) [15–21].  
Households can accumulate, exchange, deplete, or otherwise put these assets to work in 
their day-to-day management of risk and generation of income [22]. For example, a 
household may invest in human capital through diversifying skills through education, or it 
may cope with a shock ex-post by drawing on underused labour available within the 
household. The various forms of capital are also linked, and different kinds of capital may 
be substitutable in some cases – for example investing in a piece of machinery to reduce 
the need for physical labour or reducing social life (decreasing social capital) to spend more 
time working.  
This idea of a dynamic pattern of investing and divesting household assets is also reflected 
in the permanent income hypothesis, which poses that income tends to be lumpy and 
intermittent and is expected to rise and fall over the course of one’s life in a pattern of 
saving and dissaving [23]. In contrast, consumption expenditure tends to be smoothed over 
time and stays relatively constant according to one’s socio-economic status. Consumption 
expenditure, or the money spent on goods and services eventually consumed by the 
household, is thought to be a more accurate reflection of household living standards than 
current income [24]. When faced with income shocks (including crime, natural disasters or 
illness), households can typically draw on their assets to mitigate income shocks ex-post to 
keep consumption constant [15–18]. Common coping strategies include mobilising savings, 
deferring expenditure, selling assets, taking loans, income diversification, taking on 
additional labour, gifts/mutual support, or reducing consumption [25–28]. These coping 
strategies can help households to avoid any long-term impact on wellbeing.  
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Affordability in Health Care 
However, consumption smoothing or other risk management mechanisms can break down 
under repeated or long-term shocks such as chronic illness [29–31]. For example, Gertler 
and Gruber found that while families can typially cope with minor ailments, repeated or 
chronic illnesses will diminish the household’s ability to smooth consumption over time and 
can push a household into ‘chronic’ poverty [31]. 
Substantially large or prolonged income shocks represent a more serious threat to the 
current and future economic welfare of the household and have prompted policymakers to 
consider affordability in health care to reduce this burden. Affordability is a normative 
concept and often involves a judgement based on external values. As such, the precise 
definition of affordability is problematic not only in the health sector but also those of 
housing, transport, utilities and education [32–36]. An early theorist defined affordability as 
“some given standard of [service]…at a price or rent which does not impose, in the eye of 
some third party (usually government) an unreasonable burden on household incomes” 
[37]. This concept of identifying a price for services which does not affect a household’s 
ability to pay for other necessary goods requires the development of some thresholds of 
‘unreasonable’ burden.  
Across sectors, affordability is most commonly defined in terms of the proportion of 
income spent on any basic subsistence good [32,34–40]. In the health sector, most studies 
evaluating poverty and vulnerability in the context of health expenditure focus on the 
relationship of health-related expenses with total income or expenditures. The most 
common affordability metrics in the health care sector include catastrophic expenditure 
(where health spending exceeds a threshold percentage of household income) and 
impoverishing expenditure (where health spending pushes a household below the poverty 
line) [41–43]. Measures of absolute poverty have been developed most notably by the 
World Bank, which currently defines poverty as having an average income below $1.25 per 
day, at 2005 purchasing power parity (PPP) [44]. A recent update to this approach by 
Wagstaff and Eozenou [42] extends the definition of impoverishing to include 
‘immiserizing’ expenditure, which is defined where health care expenditure pushes an 
already poor household further below the poverty line.  
Several variations on these metrics have been proposed to clarify or re-define the 
threshold of ‘unacceptable burden’ to the household [45–49]. The argument has been 
made that the term ‘catastrophic’ should be adjusted to account for people who encounter 
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zero expenditures because they cannot afford to access care (and therefore cannot be said 
to be financially protected) [50]. Suggestions have also been made to include measures of 
dissaving or other coping strategies, to give a better perspective on the long-term 
economic impact of health spending on household welfare [27,51–53]. 
Calculating catastrophic expenditure 
The term ‘catastrophic expenditure’ was first coined by Birnbaum in the context of the 
United States’ health care system, in 1978 [54]. ‘Catastrophic expenditure’ was defined at 
an arbitrary fixed threshold of $5,000 annual total health expenditure. Further US-based 
studies further clarified the term [55,56] and popularised its use. The popularity of the term 
‘catastrophic total health expenditure’ grew along with growing concern that user fees 
were limiting access to health services in low- and middle-income countries (LMICs) in the 
mid-1990s [57–65]. The metric aims to capture whether out of pocket spending on health 
care exceeds some percentage of household income beyond which health spending is likely 
to have a substantial impact on the household’s ability to pay for basic subsistence needs 
[41,43]. This concept is based on capturing a substantial sacrifice of current consumption 
rather than applying any absolute measure of basic need and reflects society’s value of risk 
avoidance.  
The occurrence of ‘catastrophic’ expenditures is usually defined as a binary variable, taking 
the value 1 if total health spending (T) is greater than a defined percentage (x) of 
household capacity to pay (z), and 0 otherwise. Catastrophic overshoot can also be 
calculated as a continuous variable, taking the value 𝑇 𝑧 − 𝑥⁄  if 𝑇 𝑧 > 𝑥⁄ , and zero 
otherwise. The following section describes each of the elements of the ‘catastrophic’ 
expenditures formula in further detail.  
Costs associated with illness 
First, total health spending (T) must be defined. Figure 2-1 depicts a pathway of the 
potential costs incurred by people with an illness and their households. When a person 
feels ill, they may or may not choose to seek care. If they seek care, they will likely incur 
some direct ‘out of pocket’ costs. Direct costs include any direct expenditures associated 
with illness, or with accessing care [64,66,67]. Direct costs include, for example, transport 
costs to attend a health facility, costs of any special foods or supplements taken because of 
illness, and money paid for medicines, diagnostics, consultation fees, or informal payments 
made to health workers.  
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People seeking health care will also encounter some indirect (opportunity) costs [68,69]. 
Indirect costs refer to the opportunity costs of time incurred by the patient while seeking 
care, and time with reduced productivity due to illness. It also represents the opportunity 
cost of time spent by household members who care for the patient. If an individual does 
not seek care, they will avoid direct and indirect costs of care; however, they are likely to 
incur higher costs associated with lost productivity due to illness. They will also likely incur 
some indirect costs of informal care provided for example by a family member [70,71].  
Figure 2-1 Patient/household cost pathways 
 
The traditional definition of ‘catastrophic total health expenditure’ used to inform health 
financing and risk protection includes only direct medical costs (out-of-pocket expenditure) 
in the numerator of the equation, not including any non-medical costs, time costs, or 
income loss due to lost productivity.  
Capacity to pay 
Calculation of catastrophic expenditures also requires definition of the household’s 
capacity to pay for health care (z). There are several potential indicators of household 
capacity to pay for health care, including permanent income, current income, and wealth. 
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Current income is defined as the amount earned by a person or household at any one given 
time; this tends to be lumpy and can be seasonal or dependent on the local labour market. 
Current income does not reflect important assets (such as savings) that can be drawn upon 
to finance health care without affecting economic wellbeing within the household [51,72]. 
In contrast, permanent income is assumed to be reflected through consumption 
expenditure and represents the long-term average income expectations of a person and/or 
household [24,73,74]. 
The indicator of ‘catastrophic expenditures’ is intended to capture where spending 
associated with illness imposes an economic burden that is non-recoverable, beyond 
typical day-to-day wealth management. Theoretically, permanent income is the best 
comparator to reach this aim. Measures of permanent income will more appropriately 
reflect the impact of health costs on the total resources available to the household, thus 
capturing any potential long-term depletion in financial wellbeing in the household. 
According to the permanent income hypothesis, permanent income can be captured 
through consumption expenditure [24], as consumption stays relatively constant according 
to one’s socio-economic status [23].  
Catastrophic threshold 
 In practice, the definition of the denominator of the ‘catastrophic expenditures’ equation 
varies in the literature, as does the threshold for defining costs as ‘catastrophic’ (z). In the 
late 1990’s it was proposed that 3-5% of the annual income spent on healthcare 
expenditures are affordable, based on observations from health expenditure surveys in 
LMIC countries that a ‘typical household’ spends between 2-5% of income on health care 
[75,76]. More recent studies have used thresholds falling anywhere between 5-20% total 
household income , or, or 30- 40% of a household’s capacity to pay [77,78][79,80]..  
In all recent cases, these thresholds for catastrophic spending have been defined arbitrarily 
with no empirical basis. Recommendations generally encourage researchers to report 
catastrophic expenditures across a variety of thresholds and allow policymakers to decide 
the most appropriate threshold for their setting [41,43]. Due to this arbitrary nature of 
thresholds, an argument could also be made that the definition of ‘catastrophic’ spending 
as a binary variable is not useful. For households that already lie very near the poverty line, 
even a very small proportion of household income may lead to financial catastrophe; 
alternatively, better-off households may choose to incur very high health-related costs 
without limiting their spending. Some studies have attempted to address this concern by 
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using variable thresholds at different income levels or testing the use of dissaving as an 
alternative indicator of financial hardship [49,81].  While it is always difficult to accurately 
capture the complexity of financial flows within a household, some flexibility in defining 
financial ‘catastrophe’ is often needed to appropriately grasp the pressures that many 
households face. Qualitative methods may also be useful for researchers looking to 
represent the economic impact of health-related spending on households.  
DISEASE-SPECIFIC MEASURES OF AFFORDABILITY 
As described above, the metric of “catastrophic total health expenditures” has been 
traditionally measured in terms of direct out-of-pocket expenditure as a proportion of total 
household expenditure, with the aim of informing health financing and risk protection [82]. 
This metric has been used to understand the impact of direct out-of-pocket payments 
incurred by the household as a result of insufficient prepayment mechanisms such as tax or 
insurance [83]. Catastrophic total health expenditures are a key indicator used by the 
World Health Organization (WHO) and the World Bank to track the performance of health 
financing systems and universal health coverage. In this context, the population of interest 
for the metric ‘catastrophic total health expenditures’ is the whole population of a country.  
There is also a growing interest in estimating the impact of specific illnesses on household 
economic wellbeing. Numerous studies in recent years have estimated the prevalence of 
disease-specific catastrophic costs for a wide range of conditions, including: surgery [84]; 
diarrhoea [85]; maternal health [86–88]; HIV [89,90]; neglected tropical diseases [91–93]; 
chronic non-communicable diseases [94–101]; and TB [87–91]. Some studies have also 
compared the relative impact of various diseases on medical impoverishment [102,103].  
Disease-specific measures of catastrophic costs serve different policy purposes to that of 
‘catastrophic total health expenditures’ and have different data needs. For example, the 
population of interest for these disease-specific measures is often not the whole 
population of a country but instead the population affected by these diseases. Some 
estimates of disease-specific catastrophic costs also include non-medical and indirect costs 
in addition to direct out-of-pocket expenditures, to understand the broader impact of 
diseases on the household economy.  
Policy applications for disease-specific measures of catastrophic cost 
The advent of studies examining disease-specific catastrophic costs serves to address two 
distinct policy purposes: to inform the allocation of health-related spending, and to inform 
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targeting of social protection. First, policymakers need to understand how their 
investments in health interventions may impact the poor so that they can make informed 
trade-offs.  
Methods for economic evaluation are evolving to include considerations such as equity and 
catastrophic costs more formally. Modelling exercises linked to ‘extended’ cost-
effectiveness analysis can predict the number of catastrophic costs averted by an 
intervention [104]. ‘Distributional’ cost-effectiveness analysis allows decision-makers to 
simultaneously evaluate the cost and equity impact of health-related interventions, 
allowing them to take decisions which maximise health and minimise unfair variation in 
health care services [105]. Economic evaluation methods are also being developed to allow 
researchers to account for demand or supply constraints in a health system, potentially 
including access barriers due to high patient costs [106], following evidence that high costs 
of accessing health care can dissuade patients from seeking health care or encourage loss 
to follow-up resulting in poorer health outcomes [89].  
Policymakers are also increasingly using multiple criteria decision analysis (MCDA) to 
inform resource allocation [107]. MCDA is a method that enables policymakers to 
simultaneously evaluate the impact of potential interventions on several (sometimes 
conflicting) concerns. For example, an MCDA approach might allow policymakers to 
consider a proposed intervention in the context of the cost of implementation, impact on 
health outcomes, impact on catastrophic costs or social protection, and political impact or 
consequences. 
Disease-specific measures of affordability can also inform programme evaluation more 
broadly. Programmes are increasingly being asked to demonstrate an impact on poverty 
and progress towards the Sustainable Development Goals (SDGs). Although disease-specific 
measures of affordability can underestimate the effect of total health-related spending on 
a household, for diseases where there is a strong link with poverty (such as TB) this 
information can be critical in tracking progress. This may be especially important where 
health-related funding is vertical and where disease-specific programmes interact 
independently with donors. 
Due to the characteristics of certain illnesses and the exceptional vulnerability of 
populations affected, health-related costs also pose a cross-sectoral concern in that they 
can be a substantial source of economic hardship and can lead to a downward spiral often 
referred to as the ‘medical poverty trap’ [108–110]. There is a strong association between 
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certain health risks and socio-economic status, and evidence suggests causal links in both 
directions. For example, poverty is a risk factor for TB and the costs encountered due to TB 
can push households into poverty [111].  
Social protection is a mechanism that governments can use to interrupt this vicious cycle 
[112]. Implementation of social protection floors is an indicator under SDG Target 1.3, to: 
“Implement nationally appropriate social protection systems and measures for all, 
including floors, and by 2030 achieve substantial coverage of the poor and the vulnerable” 
[113]. Countries seeking to implement adequate social protection floors struggle with 
limited budgets and often rely on targeting mechanisms to ensure the greatest benefit 
within a given funding envelope [114,115]. Targeting can be based on the level of poverty, 
social category (i.e. gender or age), geography, or other criteria such as disability. Better 
information about the comparative impact of different illnesses on household 
impoverishment could theoretically help governments make decisions about including 
those illnesses in social protection targeting mechanisms to achieve an overall aim of 
reducing poverty or providing support to a particularly vulnerable group. 
An important limitation of use of this metric in policymaking is that by including only costs 
incurred due to TB in the estimate, the metric involves an implicit assumption that the 
household is able to pool all income in order to finance TB care. This necessarily omits 
other health-related costs incurred by household members and potentially underestimates 
the impact of health spending on the economic wellbeing of the household. Disease-
specific measures of affordability, therefore, cannot serve as a replacement for the broader 
metric of ‘catastrophic total health expenditures’. Both metrics are necessary to monitor 
progress and inform decision-making.  
Current standardisation of data collection methods 
Despite the growing use of disease-specific catastrophic costs to inform policy, systematic 
reviews on the economic impact of illness on households have consistently found that 
methods to estimate the household-incurred costs and poverty impact of specific diseases 
vary widely. First, the design of studies evaluating patient, household, or catastrophic costs 
is currently inconsistent and often haphazard. A review of statistical methods used for cost 
data collection in economic evaluations of clinical trials found that only 16% of articles 
mentioned sample size calculations [116]. Studies included in a review by Kankeu et al. [94] 
varied widely in terms of sampling methodologies, with many using convenience samples. 
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Sample sizes amongst papers included in other reviews were also wide-ranging, and 
methods for choosing samples were unclear [117,118].  
Studies also differed widely in terms of which costs were included. Both McIntyre, et al. 
and Russell, et al. reported that while direct medical costs are usually included, direct non-
medical costs and indirect costs were sometimes left out of cost estimates [64,117]. 
Tanimura et al. and Raban et al. also report wide variation in cost components reported 
and disaggregation of cost ingredients [118,119].  
Methods for estimation of resource use are highly variable across studies. Study timing and 
recall periods are different across studies in several reviews [64,118,119]. In one review, 
this was true even where the same metric was being assessed, and across trials funded by 
the same agency [120]. 
Methods for the estimation of indirect costs also vary widely. Measurement methods 
typically include either lost income or some monetisation of lost time. Methods for 
soliciting estimates of lost income or lost time were found to be inconsistent [94], as were 
methods for valuation of lost time [64,117]. Some studies chose to include the indirect 
costs of other household members or guardians, while others did not [94,117].  
Finally, the threshold percentage of ‘catastrophic’ costs and the definition of income for 
the denominator of the catastrophic costs function were very different across studies 
[94,118,119]. Threshold percentages varied from 10-60%. Various income definitions used 
in the denominator of the ‘catastrophic cost’ equation included: monthly household 
income, annual household income, non-subsistence household income, ‘capacity to pay’, or 
total expenditure. Some alternative definitions were also used, including employment of 
coping strategies [119], or “high health care expenditure” as compared with other 
households within the same caste group in India [94]. 
The reasons behind this wide methodological variation, and the overall impact of this 
variation on findings and policy decisions, are currently unclear. The potential data quality 
issues associated with the use of data collected for a different purpose for estimation of 
prevalence of catastrophic costs have not thus far been formally addressed. Tanimura et al. 
[119] report a pattern in which indirect costs represented as lost income tended to be 
lower than indirect costs estimated through the valuation of lost time. Other reviews did 
not comment on the potential bias that this variation in methodology introduced on review 
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findings. All of the reviews mentioned above found that synthesis of findings across studies 
was difficult due to wide variation in the methods adopted to estimate patient costs.  
This uncertainty about the impact of methodological variation on findings makes it difficult 
for policymakers to interpret and compare findings from economic evaluations. It is also 
difficult for a global body such as the WHO to rank country performance against targets or 
track country progress through time if results are dependent on data collection methods 
[121]. In order to be able to compare and interpret findings from multiple studies, there 
needs to be confidence that data on patient costs and capacity to pay are collected and 
presented in a way that enables standardisation. For these efforts to be relevant to 
decision-makers, researchers must take steps to reduce bias in data collection as much as 
possible [122].  
Data requirements for disease-specific measures of affordability 
The above-described policy purposes for estimating catastrophic costs require different 
kinds of data to that of ‘catastrophic total health expenditures’. Catastrophic total health 
expenditure is usually estimated using household expenditure surveys. These are large, 
household-based surveys with sampling frames typically designed to be nationally 
representative. These surveys, for example the Living Standards Measurement Survey 
(LSMS), can cost anywhere from $400,000 to $1.5 million, with each interview lasting 
roughly an hour [123].  
In contrast, due to the often-low prevalence of specific diseases at the household level, 
disease-specific data will pragmatically need to be captured at health facilities rather than 
as part of a national household survey. To estimate the impact of specific interventions on 
economic wellbeing within the household and facilitate economic evaluation, data 
collection is usually linked to a facility-based trial or study. Sampling requirements for 
estimating catastrophic costs in the context of economic evaluations are currently unclear; 
sample sizes are often arbitrary and vary widely from study to study. Studies are often not 
nationally representative as they usually are focused on answering a specific research 
question, targeted to a specific intervention or population. 
[9]  
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CHAPTER 3. CASE STUDY: TB IN SOUTH AFRICA 
Although many of the lessons in this thesis are applicable to the estimation of disease-
specific catastrophic costs in any LMIC setting, TB in South Africa is used as a case study in 
this PhD. This chapter gives a short background on TB and the policy context surrounding 
the disease in South Africa. 
TUBERCULOSIS 
TB is believed to have affected humans for thousands of years. The earliest evidence of 
human infection is from the Neolithic C period more than 8,000 years ago [124]. The first 
non-Western reference to the disease appeared in the Vedas [125]; references also appear 
in writings from ancient China [126]. In Europe, the disease has been referred to under 
many names, including ‘consumption’, ‘phthisis’, and ‘white plague’ [126].  
The disease was the leading cause of death in Europe in the 18th century, accounting for 
nearly 50% of all deaths in those 15-35 years of age [127]. The epidemic declined in 
Western Europe in the mid-19th century. Specific causes for this decline are not confirmed; 
it is widely noted that the decline occurred alongside advancements in social protection, 
nutrition, and other living standards [126], however other postulations point to increased 
pasteurization of milk, the introduction of sanatoriums, and natural selection as potential 
causes of the decline [111]. Despite this decline in western Europe, TB remains the leading 
cause of death from an infectious agent, affecting around 10 million people and causing 
around 1.6 million deaths each year [128]. The disease exists in all countries globally, but 
the burden is highest in 30 countries (including India, China, Indonesia, the Philippines, 
Pakistan, Nigeria, Bangladesh, South Africa, and others), which together account for 84% of 
the world’s cases. 
TB is caused by the bacillus Mycobacterium tuberculosis, discovered by Dr Robert Koch in 
1882 [127]. The bacillus spreads through droplets in the air and commonly infects the 
lungs, although it can also present in other parts of the body, including but not limited to 
the lymph nodes, spine, joints, nervous system, and abdomen. Primary infection with the 
bacillus M. tuberculosis is usually asymptomatic. A relatively small proportion of those 
infected with M. tuberculosis (about 5-10%) will develop active TB; this can occur any time 
from 4 weeks to two years following primary infection. Active TB is more likely to develop 
in people with reduced immune function, including young children, the elderly, and people 
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with HIV, diabetes, or malnutrition. The infection will remain latent in remaining cases. 
Latent TB does not cause transmission of the bacterium. 
The signs and symptoms of active TB are not consistent and are commonly confused for 
symptoms of flu or the common cold. Pulmonary TB most commonly presents as a 
persistent cough, sometimes associated with fever, chills, night sweats, weight loss, and 
fatigue. Extrapulmonary TB is usually not associated with a cough; signs and symptoms of 
extrapulmonary TB vary widely depending on which part of the body is infected with TB 
[129].  
TB Diagnosis 
Diagnosing active tuberculosis is often difficult as the signs and symptoms are non-specific. 
Latent TB infection can be identified through a tuberculin skin test. Tests for active TB 
disease include sputum smear microscopy, sputum culture, or rapid molecular tests (such 
as the Xpert MTB/RIF assay). Drug-susceptible TB can be diagnosed with sputum smear 
microscopy; this involves visual examination of sputum samples through a microscope to 
determine whether the bacteria are present. A chest X-ray is also often examined to 
confirm smear results. Smear microscopy is relatively cheap and can be conducted 
relatively quickly; however, it has low sensitivity in people living with HIV and cannot test 
for drug resistance. Culture-based methods involve placing sputum samples in a culture to 
promote growth of the bacteria so that it can be more easily observed. Culture can also 
allow for drug-susceptibility testing, by introducing sputum alongside anti-TB drugs. Culture 
tests are currently the reference standard for diagnosis and drug-susceptibility testing. 
However, the culture process can take up to 12 weeks to obtain results and requires more 
sophisticated equipment than smear microscopy. 
Xpert MTB/RIF is a diagnostic system developed by Cepheid Inc., which detects DNA in the 
M. tuberculosis bacteria. It can process up to four samples at a time and has a running time 
of 2 hours. The machine has improved sensitivity for those with HIV and can detect 
rifampicin resistance. This new technology looks like a promising avenue to reduce the long 
delays often faced by TB patients in receiving a diagnosis and has been found to fall below 
established cost-effectiveness thresholds in high-burden settings [130]. GeneXpert tests 
have been approved by the WHO and rolled out globally in the last ten years, despite some 
concerns about the practical affordability of the tests [131,132]. 
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TB Treatment 
Although the bacillus which causes TB was discovered in 1882, effective treatment 
remained elusive for a very long time. The popularity of sanatorium care for those with TB 
grew in the early 1900s. A vaccine to prevent TB infection and progression (BCG) was 
developed in the early 1920s. Unfortunately, it was quickly determined that the BCG 
vaccine was not as effective as had been originally hoped. The vaccine prevents against 
infection in around 20% of vaccinated children and protects against progression to active 
TB in 50% of children vaccinated. It has not been shown to have any protective effects in 
adults [133]. Nevertheless, BCG vaccination in children is still recommended in high-burden 
areas by WHO. 
Drugs to treat TB were finally discovered in 1945 [126]. The typical treatment regimen for 
drug-susceptible TB (DS-TB) is a 6-month drug regimen divided into an intensive phase and 
a continuation phase. During the intensive phase in the first two months of treatment, 
patients receive a fixed-dose combination (FDC) of four drugs: isoniazid, rifampicin, 
pyrazinamide, and ethambutol. During the continuation phase in the following four 
months, isoniazid and rifampicin are used to eliminate remaining bacilli and cure the 
patient.  
Treatment for multi-drug resistant TB (MDR-TB) can be much more difficult, with treatment 
regimens generally recommended to continue for at least 20 months. Treatment regimens 
generally involve at least four anti-TB drugs, including an injectable agent in the intensive 
phase. Drug regimens to treat MDR-TB are designed on a per-patient basis, depending on 
drug susceptibility and the history of TB treatment [129]. MDR-TB treatment regimens 
typically involve drugs that are more toxic and can lead to stronger adverse effects. 
Treatment success for MDR-TB is low, with 55% of cases globally successfully being treated 
[128]. 
TB in South Africa 
History of TB in South Africa 
The high prevalence of TB in South Africa has roots in the social inequality prevalent under 
the apartheid regime - a system of institutionalised racial segregation that existed in South 
Africa from 1948 until the early 1990s. During this time, black South Africans were 
systematically oppressed, disenfranchised, forced into unsanitary and crowded living 
conditions, and deprived of economic opportunity by the ruling white minority 
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government. Legislation designed to restrict the black population to rural reserves also 
caused a substantial increase in the number of black migrant labourers working in South 
African mines [134]. There was high turnover in mines, and those too ill to be productive 
were forcibly repatriated to rural reserves.  
These conditions caused a rampant spread of TB, which has long been recognised as a 
‘disease of the poor’ [135][125,136,137]. Risk factors for TB include poor nutritional status, 
crowded living conditions, smoking, harmful alcohol use, indoor air pollution, silicosis, and 
stress [111,138–143] – all often unavoidable aspects of life in poverty and results of 
systematic oppression under apartheid. By the late 1920s, more than 90% of adults in some 
rural reserves were infected with TB [134]. 
Following democratisation in 1994, the TB epidemic was exacerbated by soaring rates of 
HIV/AIDS. Following a resurgence of TB in the 1980s and 90s, and in order to counter 
increasing drug resistance and improve control of TB, the WHO launched a strategy of 
“directly observed therapy (short-course)” (DOTS) in 1994; this was taken up by the South 
African National Tuberculosis Control Program in 1996. The DOTS strategy involves direct 
supervision (usually by health care workers or community volunteers) of patients taking 
their drugs for the full duration of treatment. Fixed-dose combination drugs for TB were 
introduced two years later, making it easier for patients to maintain adherence to drugs. 
Observation and support for patients were shown to improve adherence to treatment, but 
the decline in TB incidence following DOTS introduction was slower than anticipated [111]. 
In 2007 a five-year National Strategic Plan for TB was formed, and GeneXpert MTB/Rif was 
introduced in 2011 as a replacement for sputum smear microscopy.  
The long history of social inequality in the country’s health care system continues to make 
it difficult for many poor South Africans to access health care services [134]. Many state 
hospitals are in crisis, with only 30% of the country’s doctors working in the public sector 
and consistent underfunding and mismanagement plaguing the public health sector [144]. 
Nationally, governmental expenditure on health care only accounts for about 48% of total 
health expenditure [145]. Eighty-one per cent of private expenditure on health care is 
funded through private health insurance; this is mostly only available to those working in 
the public sector or otherwise formally employed – covering only about 16% of the 
population [146,147]. In 2011 the South African government published a Green Paper to 
introduce a national health insurance (NHI) scheme, aiming to provide universal access to 
health insurance [148]. The government is currently in the second phase of 
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implementation, focusing on finalising the legislation for NHI and establishing the NHI 
Fund. 
Current status of the epidemic 
Today, South Africa still has one of the highest burdens of TB in the world, with an 
estimated incidence of 454,000 cases and 25,000 deaths in 2015. The country carries 30% 
of the world’s HIV-associated TB cases (roughly 270,000 people) and has the fourth largest 
prevalence of MDR-TB in the world [149]. More than half (57%) of those infected with TB 
are also HIV positive.  
In 2012, the South African government integrated the National Strategic Plans for HIV/AIDS 
and TB, creating the National Strategic Plan for HIV, STIs and TB. This and the draft updated 
Strategic Plan (2017-2022) emphasise the importance of integration of TB, HIV, and STI 
services. The draft strategic plan for 2012-2022 reaffirms the importance of decentralised 
care, improved social protection and targeted interventions to address the social and 
structural drivers of disease, and multi-sectoral cooperation in the national efforts against 
HIV and TB [150].  
The South African National Strategic Plan is aligned with global priorities for TB 
management, and there is a high degree of political will in South Africa to address the high 
incidence and impoverishing effects of TB in the country. Recognition that the effectiveness 
of DOTS was limited led to an increasing number of investigations on the social and 
structural drivers of TB. Several studies in the last decade have shown that variation in TB 
trends is more strongly associated with biological, social and economic factors than with 
National TB Programme (NTP) performance [112,151,152]. This realisation has led to an 
increase in calls for improved social protection and other interventions to limit 
socioeconomic factors that may cause a high TB burden in some settings.  
There is a strong tradition of social protection in South Africa. In the 2014/15 financial year, 
South Africa spent R121 billion (USD 10.05 billion) on social protection, including R18.7 
billion on sickness and disability grants [153]. Further guidance is needed on targeting and 
implementation in order for these schemes to be useful for TB patients. For example, the 
country’s Temporary Disability Grant is theoretically available to TB patients, however it is 
often inconsistently implemented [100,154], there is a lack of evidence on its impact on 
welfare and health status for beneficiaries, and there is concern that it may provide an 
incentive for patients not to adhere to treatment [155]. Other social protection schemes 
available within the country (including the child support grant and old age pension) could 
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also potentially be targeted to TB patients. However further information is necessary to 
inform this targeting [156].  
Current evidence of catastrophic costs due to TB in South Africa 
There is good availability of recent data on patient costs for TB, making the analysis 
presented in this PhD possible [100,157,166,158–165]. The most recent evidence comes 
from four papers published in 2015; two presenting patient-incurred costs of drug-
susceptible TB, and two presenting costs of drug-resistant TB. Results from these papers 
are presented in Table 3-1. There is considerable variation in estimates between these 
existing studies, both for direct and indirect costs. To date, there is no evidence at the 
national level of patient-incurred costs of TB or how this varies by determinants nationally.  
The existing evidence on catastrophic costs due to TB in South Africa is minimal. Verguet et 
al. report a modelled baseline of 16,848-24,278 households encountering catastrophic 
costs over 20 years, equivalent to 16-25% of those with TB [104]. Although there are 
several other studies reporting costs (and several suggesting that costs are likely to be 
catastrophic), no other studies report a prevalence of catastrophic cost. As part of the 
effort to gather data on catastrophic costs globally as countries aim to reach the WHO 
post-2015 target of zero catastrophic costs by 2020, a national TB costing study is planned 
for South Africa in the next two years. Planning for this national study has just begun, and 
cost data collection is likely to take place in 2019.  
Page 35 of 276 
 
Table 3-1 Recent Evidence on Patient Costs of TB in South Africa 
Author Time frame 
(Subgroup) 
Sample 
Size 
Mean 
direct cost  
Median direct cost  Mean indirect cost Median indirect cost  
Drug-susceptible TB (DS-TB) 
Foster, et 
al. [100] 
Pre-diagnosis 49  $45.82 / episode* $0.00 / episode* $39.26 / episode* $0.00 / episode* 
Foster, et 
al. [100] 
Post-diagnosis 175  $66.01 / episode* $0.00 / episode* $15.56 / episode* $0.00 / episode* 
Chimbindi 
et al. [164] 
Post-diagnosis 296  $16.74 /month 
(SD 21.19) 
N/R $7.49 / month  
(SD 4.82)  
N/R 
Drug-resistant TB (DR-TB) 
Du Toit, et 
al. [166] 
Pre-diagnosis  
(LPA) 
89 N/R  $6.70 / episode 
(IQR 1.1 – 28.2)  
N/R $40.00 / episode 
(IQR 20.4 – 105.9)  
Du Toit, et 
al. [166] 
Pre-diagnosis  
(Xpert) 
64 N/R  $4.40 / episode 
(IQR 0.0 – 22.2)  
N/R $22.1 / episode 
(IQR 11.0 – 54.5) 
Ramma, et 
al. [165] 
Post-diagnosis  
(inpatients) 
82 $26.45 / month* N/R $247.13 / month* N/R 
Ramma, et 
al. [165] 
Post-diagnosis  
(outpatients) 
52 $56.98 / month* N/R $64.30 / month* N/R 
DS-TB Drug-susceptible TB; DR-TB Drug-resistant TB; SD Standard Deviation; IQR Inter-quartile range; N/R Not reported   
*uncertainty not characterized 
All costs in 2015 USD 
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CHAPTER 4. METHODS  
METHODS FOR ESTIMATING DISEASE-SPECIFIC CATASTROPHIC COSTS 
Collecting cost data is an estimation process involving five steps: defining the problem, 
identifying costs, measuring resources, valuing resource use, and calculating total and unit 
costs. Costs are typically estimated using a range of approaches and assumptions, often 
combining data obtained as part of research studies with data collected as part of routine 
program implementation. As costing is an estimation process, methods and quality in cost 
data can vary widely.   
Several characteristics are often desired from cost data. For most purposes, cost estimates 
should be as precise and accurate as possible; meaning they should not be too far off the 
‘true’ value, and there should not be too much uncertainty around the estimates. Estimates 
should be timely if they are to inform policy decisions. Estimates should also ideally be 
generalizable to other settings as much as possible; this often requires explicit 
consideration of any heterogeneity.  Finally, methods for estimation should be reliable; 
ideally if the same costs were collected using the same methods by two different people, 
results should be consistent. 
However, data availability in real-world settings is often variable, and it is not always 
possible to achieve all of these desirable properties simultaneously.  Data collection might 
be limited for practical reasons (ie. survey budget or timing), or it might be impossible to 
collect certain types of data. This is true of both high- and low-income settings, although 
there may be different pressures on data collectors in different settings. For example, in 
some LMIC settings there might be no generation of routine data, thus requiring this data 
to be sourced from other places. In contrast, in some high-income settings where routine 
data is generated in the national health system, researchers might struggle with datasets 
that are too large or too complex to appropriately analyse within a given set of time. 
Although pressures may be different, the quality of cost data should not differ between 
settings; cost estimates should be as high-quality as possible in both high-income and low-
income settings. 
Often a balance needs to be struck between the above-listed desirable characteristics, 
within the context of the study, in order to produce an estimate that is fit for purpose given 
the data available. Transparency in reporting is essential in striking this balance. I use the 
broad outlines of GHCC principles [122] to describe the process of estimating patient costs 
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below. Where relevant, I also describe practical limitations that researchers might 
encounter when collecting data.  
Study Design 
Study design involves identifying the purpose and perspective of cost estimation, the type 
of costs estimated, the ‘units’ in unit costs, the sample and study population, and the time 
horizon and scope of the costing [122]. Different methodological approaches can be used 
for different purposes of costing. For example, estimation of household costs as part of an 
economic evaluation may require sampling for a certain level of confidence around the 
impact of the intervention on household costs. In contrast, the estimation of catastrophic 
costs at a national level requires nationally representative sampling.  
Disease-specific patient cost data is generally collecting using a ‘micro’ approach. A ‘micro’ 
approach involves first estimating quantities of resources and then assigning prices to 
reflect the value of those resources. This can be used both for direct costs (where resources 
include visits to health providers, drugs, diagnostic tests, food, accommodation, and 
travel), and indirect costs (where resources include time). Given the choice of methods for 
data collection, valuation, and analysis, as well as variation in underlying assumptions, cost 
estimates should be communicated clearly and transparently to support interpretation and 
use. As noted in the GHCC reference case, several properties are desirable in a ‘good’ cost 
estimate [122]. These include accuracy, precision, generalizability, transferability, 
comparability, and reliability.  
Before data collection begins, the analyst must design the study to limit bias as much as 
possible. The population for data collection should be selected in accordance with the 
study aims, with efforts to avoid bias due to over-inclusion of populations using higher 
quantities of services or encountering complications [167,168].  
Sample size considerations are critical in the planning stages of a study and will depend on 
the aims, nature, and scope of the study, and the degree of precision (confidence interval 
and margin of error) deemed appropriate [169]. Household surveys generally follow United 
Nations guidelines of a 5-10% margin of error at the 95% confidence interval, with further 
adjustment to account for clustering and non-response [170]. For any study, the sample 
should be selected to enable statistically significant inferences about the true costs 
encountered by the population from which the trial sample was drawn [116].  
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Estimation of Resource Use 
Resource use can be estimated through diaries, review of administrative records, or survey 
questions. There are several potential biases associated with the estimation of resource 
use. These include: recall error, respondent error, rounding error, cognitive errors, survey 
fatigue, and ‘desirability’ errors [171]. These potential errors are also applicable to 
estimation of income and indirect costs and are summarised below. Survey design can 
reduce (or increase) the likelihood of these errors.  
If adequately filled, the diary method of recording expenditures is regarded as the gold 
standard [171] as it reduces the potential for recall error. Recall error refers to the inverse 
relationship between the length of time over which survey respondents are asked to recall 
something, and the accuracy of the estimates [172]. Recall has often been regarded as the 
‘second best’ option in the measurement of consumption/expenditure. It has also long 
been recognised that the timing of the recall period can have a significant impact on 
answers to questions on expenditure [173]. Generally, a shorter recall will result in higher 
estimates due to telescoping bias. Lu et al. [80], for example, found that in the LSMS and 
World Health Survey, more detailed questionnaires and shorter recall periods resulted in 
higher estimates of out-of-pocket payments. However, short recall periods can also be 
problematic as expenditure on some goods/services is seasonal and can be lumpy, and 
therefore not accurately represent household wealth or earning capacity if not captured in 
the right period.  
Respondent error is the inability to accurately capture expenditure by household members 
that occur outside the purview of the survey respondent. This is most problematic where 
the respondent of a patient cost survey was not the individual making payments, or where 
individuals are asked to estimate the income or expenditures of the whole household 
[174,175].  
Cognitive error occurs where excessive cognitive demands are placed on a survey 
respondent, resulting in diminished quality of answers. For example, there is evidence that 
the cognitive demands associated with using a hypothetical ‘usual month’ in recall reduces 
accuracy and increases interview time [171]. Frequent changes of the reference period in a 
survey (for example, asking for some estimates ‘per month’ and some estimates ‘per 
week’) can also introduce cognitive error. 
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Survey fatigue occurs where survey length is exceptionally long, and respondents tire of 
answering detailed questions. Fatigue can also impact data collection through diaries, 
where respondents stop recording expenditures [176,177]. 
Finally, ‘desirability’ error occurs where the respondent gives inaccurate responses due to 
various social pressures [178]. For example, depending on the attitude and socio-economic 
position of the enumerator, respondents might feel pressure to inflate their estimations of 
income or spending. On the other hand, if respondents are not suitably informed of the 
purpose of a patient costing study or believe that they may receive subsidies to cover the 
costs of care they may alter their responses to give the impression that they are poorer 
than they may be in reality. 
Valuation of Direct Costs 
Direct costs for health care include any direct expenditures associated with illness, or with 
accessing care. This could include, for example, transport costs to attend a health facility, 
costs of any special foods or supplements taken as a result of illness, and money paid for 
medicines, diagnostics, or consultation fees. Estimation of direct costs involves first 
estimating quantities of resource use (i.e. the number of visits, number and types of drugs, 
number and types of diagnostics), and second valuing those resources. 
To estimate direct costs, researchers often solicit the actual amount that the respondent 
paid for the given resources. In the context of economic evaluation, this may not always be 
appropriate if the actual price paid by respondents does not reflect the societal value of the 
resource, for example if a drug is donated or if care is paid for by a third party. However, in 
the context of estimating catastrophic costs, where the focus is on the actual financial 
impact of health-related costs on the household, direct solicitation of the actual money 
paid for goods and services is appropriate.  
The valuation of direct costs is susceptible to the same types of survey error as the 
estimation of resource use; respondents may not accurately recall the amount they paid 
for a consultation or transportation to a health facility – especially if this took place a long 
time ago.  
Valuation of Indirect Costs 
The measurement and valuation of indirect costs have been the subject of much debate in 
the literature over the last 20 years. There are several proposed methodologies used for 
measurement of indirect costs of illness and valuation of patient time (also called 
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productivity costs), and there is substantial literature devoted to the controversy 
surrounding choice of methods [69,179–185]. The appropriate methods to estimate 
indirect costs are different depending on whether the analysis aims to estimate the 
economic impact of illness on the patient and their household or to estimate the impact of 
illness on society more broadly. 
One of the most common approaches to value time spent seeking care or productivity loss 
due to illness is the human capital approach (HCA). The HCA is based on Grossman’s human 
capital model, which regards participation in health care as an investment in human capital 
– increasing productive ability and therefore (theoretically) the income of the individual 
(measured as the wage rate) [186]. The typical unit of measurement for HCA is the 
household – as consumption decisions are typically made at the household level. The HCA 
takes account of indirect costs of illness by measuring the monetary value of lost 
productivity – for example by measuring income loss due to a lost job or lost days of work, 
less uptake of paid work, and the opportunity cost of time spent by caretakers providing 
informal care.  
When seeking to include indirect costs in the estimate of total costs incurred at the societal 
level as part of an economic evaluation, the HCA has been criticized in the ‘real-world’ 
applicability of many underlying assumptions, including: full productivity, full employment 
in the market, competitive labour markets, and wages in direct proportion to productivity 
[187]. There has also been a good deal of criticism of the HCA’s ability to capture the value 
of non-paid work or labour substitution [75,188]. Firstly, the cost of illness estimates made 
using the human capital method will be skewed in favour of diseases that affect ‘rich white 
men’, due to the tendency for their wages to be higher. Similarly, income/earnings will vary 
substantially according to cohort, time period, and business cycle [189] and therefore can 
be extremely unreliable when attempting to compare costs of illness between two cohorts. 
Finally, the HCA may overestimate the actual production lost, as it does not typically 
account for coping strategies such as selling capital, substitution of labour, or the ability to 
make up work after recovering from an illness [190]. 
The friction cost approach (FCA) was proposed in the mid-1990s as a way to estimate the 
cost to society from absence from work, disability and mortality without the above-named 
methodological problems [181]. The FCA is intended as more of a decision-makers 
approach to evaluation rather than staying strictly in line with welfarist economic theory. 
The FCA adopts the perspective of employers/society rather than estimating the 
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affordability or economic impact on the individual. Use of the FCA is therefore not 
applicable in the estimation of catastrophic costs, as it does not evaluate the economic 
impact of illness on the household. The basic tenets of the FCA argue that in the long-run 
from a societal perspective, no production loss will result from a person dropping out of 
the workforce due to illness – as that person will be replaced by somebody who was 
previously unemployed. The productivity costs incurred, therefore, are limited to the 
‘friction period’ before the ill person is replaced, and includes any lost productivity through 
presenteeism, lost productivity before a replacement is hired, and the costs of hiring and 
training a replacement worker. The FCA has been criticised for its lack of underlying theory 
and the fact that it does not value leisure time, resulting in a vast underestimation of the 
value of lost time or productivity [180–182,191]. It is also challenging to operationalise – as 
there is a lack of reliable data on the length of friction periods. To date, due to these 
conceptual and practical limitations, the friction cost has not been implemented in 
measuring indirect costs in a low- or middle-income country. 
When including indirect costs in an economic evaluation, there has been some historical 
debate as to whether loss of productivity is already included as part of the health outcome 
measures (e.g. QALYs or DALYs). Lost productivity should not be represented in both the 
numerator and the denominator of an incremental cost-effectiveness ratio (ICER), as this is 
double-counting. This concern was raised by the first Panel on Cost-Effectiveness in Health 
and Medicine with the recommendation to exclude costs of productivity loss in the 
numerator [179]. Upon revision, the Second Panel on Cost-Effectiveness in Health and 
Medicine agreed that it is unlikely that productivity loss will have been accurately captured 
in most preference-based measures, and so the costs related to productivity loss should be 
included in the numerator of an incremental cost-effectiveness ratio [192]. 
In the context of economic evaluation, recommended practice on inclusion and valuation 
of indirect costs varies substantially across countries. Table 4-1 summarises and compares 
the recommended approaches for patient costs from the national economic evaluation 
guidelines from 33 countries. Of 21 countries that either recommend inclusion of indirect 
costs in economic evaluations or consider it an optional additional analysis, only 7 make a 
recommendation as to which approach to take. Of these, five countries recommend HCA 
and two (Canada and the Netherlands) recommend FCA. A further five countries state that 
either method is acceptable, while the remainder do not mention methodology in the 
guidelines at all.  
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The WHO guide to identifying the economic consequences of disease and injury makes the 
distinction between ‘marketed’ losses and non-market losses. For marketed losses, 
recommendations are based on the HCA – however econometric approaches to account for 
endogeneity between health and wealth and long-term effects of coping strategies are also 
advocated. For non-market losses, the recommendation is to use an evaluation of 
willingness to pay (WTP) for health as the valuation method [190].  
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Table 4-1 Country costing guidelines on patient cost estimation 
Guidelines Recommended Perspective Include direct 
costs? 
Include indirect 
costs? 
How to value 
indirect costs? 
Indirect costs in numerator 
or denominator? 
Include 
intangible costs? 
Belgium [193] Costs: health care payer  
Outcomes: society 
No Optional to  
present separately 
- - No 
France [194] "Widest possible perspective" Yes Yes Either HCA or WTP Denominator No 
Germany [195] Primary perspective: health care sector 
Optional perspectives can be social security or 
societal perspectives  
Yes Optional to  
present separately 
Either HCA or FCA Due to mortality: 
Denominator 
Due to incapacity for work: 
Numerator 
No 
Switzerland [196] Society, third-party payer/ reimbursement 
agency, health care provider, patient, 
employer  
No No - - No 
Netherlands [197] Societal perspective; report indirect costs 
separately  
Yes Present separately FCA Numerator No 
Austria [198] Societal perspective; other perspectives such as 
payer / social insurance are optional 
Yes Present separately HCA Numerator No 
Baltic (Latvia, 
Lithuania, Estonia) 
[199] 
Mainly health care perspective; societal 
perspective if relevant  
Present separately Present separately Not specified Numerator No 
Ireland [200] Costs: health and social care system 
Outcomes: all health benefits accruing to 
individuals  
Reimbursable only Optional to  
present separately 
Not specified Numerator No 
Norway [201] Societal perspective, but with some limitations Not mentioned Optional to  
present separately 
Either Numerator No 
Sweden [202] Societal perspective Yes Yes HCA Numerator No 
British Medical 
Journal [203] 
Advocate: societal perspective (however 
patient perspective only mentioned on effects 
side) 
Not mentioned Present separately Either Not indicated No 
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Denmark [202] Social perspective Yes Present separately Not specified Not indicated Present 
separately 
England & Wales 
[204] 
Payer perspective Reimbursable only No - - No 
Finland [205] Societal perspective Yes Yes Not specified Numerator No 
Scotland [206] Scottish healthcare system, patients and their 
families  
Optional to 
present separately 
Not mentioned - - No 
Portugal [207] Societal perspective; should be broken down 
into other relevant points of view namely third 
payer  
Yes Optional to  
present separately 
Not specified Numerator No 
Croatia [208] Croatian Institute for Health Insurance (as 
public payer) 
Societal perspective may be presented 
separately 
No No - - No 
Italy [209] Societal perspective; Italian National Health 
Service  
Yes Yes HCA Numerator Include in 
denominator 
Spain [210] Societal and payer perspectives to be 
presented separately 
Yes Yes Not specified Numerator No 
Poland [211] Payer perspective 
Advised to present social perspective 
separately 
Present separately Present separately HCA Numerator No 
Hungary [212] The audience to whom the analysis is 
addressed. If more than one perspective, be 
reported clearly and separately.  
Optional  
(depending on 
perspective) 
Optional 
(depending on 
perspective) 
Both to be 
explored in 
sensitivity analysis 
Numerator No 
Russia [213]  Costs: Health care payer perspective 
Outcomes: societal perspective 
Not mentioned Not mentioned - - Not mentioned 
Canada [214] Publicly funded health care system. 
Optional to present wider perspective 
separately 
Present separately Present separately FCA Numerator No 
Malaysia [215] Provider or funder. Patient and societal 
perspective are encouraged  
Yes Yes Either Numerator Yes 
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Taiwan [216] Mainly societal perspective; may separate into 
payer and others  
Yes Yes HCA Numerator No 
Israel [217] Sick Funds of the National Health Insurance  No No - - No 
Thailand [218] Costs: societal perspective 
Outcomes: depends on the objectives of the 
study. 
Yes Yes FCA or WTP Numerator Can be included 
in WTP 
New Zealand [219] The health budget and patient, with respect to 
PHARMAC’s decision criteria.  
No No - - No 
Australia [220] Societal and health care sector perspective Not mentioned Not mentioned - - Not mentioned 
Egypt [221] Perspective “should be relevant to the research 
question and adapted to benefits gained by the 
health care system”  
Not mentioned Not mentioned - - Not mentioned 
South Africa [222] Third-party payer perspective  
Optional to use a broader perspective where 
justified 
No No - - No 
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In the context of estimating catastrophic cost, the aim of estimating indirect cost is to 
estimate the actual financial loss to the specific household incurring the cost, rather than to 
estimate the overall loss at the societal level. The two most common methods to estimate 
the value of reduced time for catastrophic cost estimates are the HCA and an output 
approach [9]. 
Using the HCA, the number of hours spent seeking care or otherwise unable to work due to 
illness can be estimated, and the value of these hours approximated with an estimate of 
the earning capacity of the patient for that time (e.g. hourly income): 
𝐷𝑖𝑟𝑒𝑐𝑡 𝐶𝑜𝑠𝑡 + (𝐻𝑜𝑢𝑟𝑠 × 𝐻𝑜𝑢𝑟𝑙𝑦 𝑤𝑎𝑔𝑒)
𝐻𝑜𝑢𝑠𝑒ℎ𝑜𝑙𝑑 𝑐𝑎𝑝𝑎𝑐𝑖𝑡𝑦 𝑡𝑜 𝑝𝑎𝑦
> 𝑇ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 𝑣𝑎𝑙𝑢𝑒 (%) 
Alternatively, when estimating indirect costs for inclusion in catastrophic cost estimates, 
the total income lost due to illness can be directly solicited using an ‘output’ approach. 
First, household income can be estimated before and after the illness episode; any direct 
income loss due to illness is then captured by taking the difference. 
𝐷𝑖𝑟𝑒𝑐𝑡 𝐶𝑜𝑠𝑡 + (𝐻𝐻 𝐼𝑛𝑐𝑜𝑚𝑒𝑃𝑅𝐸 − 𝐻𝐻 𝐼𝑛𝑐𝑜𝑚𝑒 𝑃𝑂𝑆𝑇)
𝐻𝑜𝑢𝑠𝑒ℎ𝑜𝑙𝑑 𝑐𝑎𝑝𝑎𝑐𝑖𝑡𝑦 𝑡𝑜 𝑝𝑎𝑦
> 𝑇ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 𝑣𝑎𝑙𝑢𝑒 (%) 
The HCA approach captures all time off work necessitated by symptoms and treatment 
seeking, but may not include any household mitigation of that loss. The output approach 
captures only the loss of paid work. Both approaches are is subject to recall error and may 
be biased where the expected income from a day’s work is not easily predictable. The 
output approach may also not include the value of time that was productive but not 
income-earning – for example self-production of goods, food, or childcare. 
Estimating Capacity to Pay 
A fundamental question around the estimation of catastrophic total costs due to TB is the 
appropriate denominator to represent the resources available to the household. This is 
discussed briefly in Chapter 2 above, which explains that consumption expenditure (or 
some other measurement of permanent income) is the most theoretically appropriate 
metric for the denominator of the ‘catastrophic’ equation, as it best represents where 
health-related costs push a household beyond their typical day-to-day management of 
wealth. 
Consumption expenditure tends to be more accurately measured than income [223,224]. 
This is especially the case where employment is informal or unsalaried. Households with 
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fewer resources are more likely to remember expenditures than income and may be more 
willing to disclose what they have spent than what they have earned, counteracting 
desirability bias [223]. There is also evidence that detailed questions regarding 
consumption expenditure help to counteract recall and cognitive bias [171].  
The above-described sources of bias can impact the estimation of consumption 
expenditure [174,225–230]. For example, longer recall periods can cause recall bias, where 
participants may not accurately remember expenditure occurring a long time ago; shorter 
recall periods are often advised for accurate answers [171,231]. The relationship of the 
interviewer to the participant may lead to desirability bias, where an individual may under- 
or over-report their expenditure based on perceived attitudes of the interviewer; this can 
be minimised through training of enumerators. The burden on the respondent can 
potentially be minimised by using closed brackets rather than an open-ended format 
requiring a numerical response [231]. However, the use of brackets can potentially lead to 
anchoring bias and provides less informative data [232,233]. Unclear framing of questions 
around expenditure can potentially cause cognitive bias, where the question is difficult to 
understand or answer. Adding further detail to questions may improve understanding of 
the question and increase the accuracy of answers, but may also increase non-reporting 
bias [234]. Finally, there is potential for error in capturing expenditure outside the purview 
of the survey respondent [171]; in the case of household income, this can often be 
addressed by interviewing the head of the household where possible. 
Researchers have opted to take various approaches to estimate ‘capacity to pay’, with the 
majority using self-reported current annual individual income in the denominator of the 
catastrophic costs equation [235]. Current income is often believed to be quicker and 
cheaper to measure [228], especially in middle-income and high-income settings where 
there is more formal employment and fewer consumption items are self-produced. Current 
income is therefore often the measure of choice for researchers despite the potential for 
inaccuracy and under-reporting [236].  
The WHO guide to estimating catastrophic costs for TB suggests several different 
approaches to measuring income for catastrophic costs [237], including self-reported 
household income, estimated household income based on the average net wage rate (from 
national income data), or estimated household income based on asset scoring. Following 
on from indications that financial catastrophe is linked with coping strategies [81], the 
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WHO is also considering a recommendation that household use of coping strategies is in 
itself an indicator of catastrophe, regardless of total cost or household income.  
Reporting study estimates 
There is currently no standardised reporting framework applicable to patient, household, 
or catastrophic costs. Reporting frameworks for economic evaluations, such as the 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement [238] 
or the guidelines for authors and peer reviewers of economic submissions to the British 
Medical Journal [238] currently provide little to no guidance on reporting costing methods. 
Although a more thorough reporting checklist on cost estimation methods is currently 
being developed as part of the GTHCC for Estimating the Costs of Global Health Services 
and Interventions, this is exclusively focused on provider-side costs [238]. 
Many of the items to include in reporting patient, household, or catastrophic costs are 
similar to those described in the GHCC Reference Case checklist. For example, researchers 
should describe the population of interest, setting, location, time horizon, and sampling 
methods. It is good practice to present patient/household costs by provider type, cost type, 
and phase of illness in order for researchers and policymakers to identify the pathways 
driving catastrophic costs. Given the inconsistency and uncertainty around income 
estimation methods, some studies also choose to present time spent travelling/seeking 
care in hours, rather than only presenting indirect costs incurred. Uncertainty and 
heterogeneity in estimates should be appropriately considered where applicable. 
Incorporating equity considerations using asset indices 
Many studies present the prevalence of catastrophic costs by socioeconomic quintile to 
facilitate the interpretation of the results of estimating catastrophic costs. Chapters 8 and 9 
of this thesis both classify the respective study populations by income quintiles to allow for 
a comparison of the costs of TB on the household economy by socioeconomic status (SES). 
Households can be classified based on their household income where this data is available 
or based on their asset holdings if income data is unavailable or unreliable. 
If asset data is used to determine SES, researchers need to aggregate a number of variables 
to come to a uni-dimensional measure of SES. Vyas and Kumaranayake [239] recommend a 
principal components analysis (PCA) approach to estimate a wealth index. PCA is a 
multivariate statistical technique that transforms a set of variables into a set of 
‘dimensions’ or principal components. Researchers can then identify the component 
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explaining the largest possible amount of variation in the data and use this to classify 
households into a predetermined number of groups (i.e. quintiles).  
PCA was designed for use with continuous, normally-distributed variables and therefore its 
application to the categorical variables in a wealth index is considered by some to be 
inappropriate [240,241]. MCA is analogous to PCA but is designed for use with discrete 
data and is more appropriate to categorically coded asset data available in most datasets. 
In settings where asset ownership and inequality tend to be different in rural and urban 
areas [242], it is recommended that an MCA is conducted separately for rural and urban 
households. Both Chapters 8 and 9 of this thesis use an MCA in order to generate an asset 
index. 
EXTRAPOLATING FROM LOCAL DATA TO NATIONAL ESTIMATES 
Although it can sometimes be useful to present cost or cost-effectiveness estimates for a 
single study cohort or another small group of people, much of the usefulness in the 
practical implementation of health economics research involves using locally-collected data 
to inform national decision-making. This often necessarily involves extrapolation of study-
specific data (drawn on a sample which may or may not be nationally representative) to 
represent how an intervention or service will play out on a larger scale.  
Different studies have taken different approaches to extrapolate data from a sample of 
patients to the program level, and typically involve some degree of modelling. Model 
structure can be determined a priori if researchers are sure about the relevant pathways, 
or informed by empirical data if the relationship between different pathways is uncertain 
or unknown.  
The process of designing a model has been described as “inherently uncertain” [243] 
because it is almost always impossible to gather complete information on all of the possible 
consequences of introducing an intervention. Researchers need to determine how best to 
structure and parameterize the model given the available information. Uncertainty in 
designing and parameterizing a model can come from several sources, including a lack of 
appropriate data, insufficient data quality, or differences in methodological choices across 
different studies. 
The first concern for modellers is a lack of data.  Where data is lacking, assumptions can in 
some cases be used to fill gaps if the assumed values are not the primary drivers of the 
model outcome.  Values can come from consultation with experts, previous experience, or 
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other sources. If assumptions are used, it is critical to evaluate uncertainty around these 
assumptions through a sensitivity analysis or other formal consideration.  
Where data does exist, it is important to consider the quality of the data when applying it 
to a model.  Several elements of data quality are discussed above, including accuracy, 
precision, timeliness, generalizability, and consistency of methods. The quality of 
parameterization in a model is dependent on the accuracy (the extent to which the 
estimate reflects the true value) and precision (the extent of clustering around the central 
estimate) of the estimator. There is no universal definition of ‘acceptable’ accuracy or 
precision of cost data, as much depends on the purpose for which the data is collected and 
the manner in which it is applied. To suit the purposes of some applications, researchers 
may need to adjust estimates to account for heterogeneity in demography, epidemiology, 
or resource prices in different settings [244,245]. When not adequately addressed, the 
presence of strong bias or imprecision in model parameters can influence the conclusions 
drawn from a model; models based on biased data can lead to the wrong conclusions, 
whereas models with a high degree of uncertainty or imprecision may make interpretation 
of the results for policy purposes difficult.  
Finally, if using multiple data sources to parameterize a model it is important to consider 
any differences in methodological choices across the different studies. Different 
methodological choices may be fit for different purposes, however if data is not 
appropriately adjusted before pooling this might lead to biased results.  Methods for 
pooling data from multiple studies are discussed further below. 
There are several possible estimators that could be used to parameterize a model, 
including the mean, an adjusted mean, median, or a regression coefficient (amongst 
others); each of these has different strengths and weaknesses. A simple mean or median is 
likely to lead to heavily biased results, especially in a population where there is skewness in 
cost data and/or where costs vary substantially by subgroup. In the following sections, I 
describe the strengths, limitations, and steps involved in two popular approaches: meta-
analysis of summary statistics, and regression analysis of pooled primary data. I also 
describe methodological choices taken in the chapters of this PhD where appropriate. 
Meta-analysis 
Researchers seeking to parameterize a model may choose to use a meta-analysis of 
summary statistics stratified by subgroup to obtain input values. A meta-analysis obtains a 
weighted average from the results of individual studies. Weights are derived from study 
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sample size and uncertainty around each estimate, and sometimes also from the quality of 
the data. Non-normally distributed data (such as cost data) needs to be log-transformed 
before a meta-analysis is carried out, as the process for conducting a meta-analysis 
includes an assumption of normality. Researchers also need to choose between a fixed-
effect model or a random-effects model. The fixed-effect model assumes one true effect 
size that underlies all studies in the analysis, with all variation caused by random sampling. 
The random-effects model allows for variation in effect sizes between studies, for example 
because the populations in different studies may have different demographic 
characteristics or might be receiving different interventions [246].  
A meta-analysis has several potential benefits over a simple mean or median value. Meta-
analyses can improve the precision of estimates and can identify variability across different 
studies. Where study quality is readily determined, meta-analyses can limit bias in the 
pooled estimate using quality weighting. Finally, a meta-analysis is often convenient as 
summary statistics by subgroup are often reported in papers, and can be input into models 
without the need to obtain and pool primary data.  
There are some limitations associated with meta-analysis. Study quality is sometimes 
difficult to determine using only the reported summary statistics or a manuscript, making it 
difficult to adjust for bias where this is unknown. Meta-analysis involves some a priori 
assumption of the model structure and relevant subgroups and does not allow for 
interaction between the different explanatory variables, ultimately often making the model 
less specified or less accurately specified. Finally, where summary statistics have a high 
degree of imprecision, the results of a meta-analysis will also be imprecise making the 
results of a model challenging to interpret. 
Regression analysis of pooled primary data 
If primary data is available, researchers can pool the primary data for regression analysis. 
There are a number of benefits associated with pooling primary data from multiple studies. 
With the primary data, researchers can better understand data quality and can recalculate 
variables if necessary to ensure consistency across the pooled dataset. Pooling data from 
several studies can increase the sample size, improving statistical power and potentially 
reducing imprecision across multiple datasets [247]. It can also improve the cultural and 
economic diversity of patient populations reflected in the data to enable a more 
appropriate representation of the national population [248]. It can also facilitate better 
specification of model parameters, by allowing the analyst to include additional 
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demographic characteristics in the estimation of parameters and understand the 
interactions between different explanatory variables. Finally, pooled primary data can help 
describe determinants of unit cost variation more accurately than summary statistics, and 
can improve understanding of the uncertainty around estimates [249,250]. 
Pooling data 
One strong disadvantage of pooling primary data is that gaining access to primary data has 
historically been a great challenge for researchers. A survey conducted in 2002 found that 
47% of requests for primary data had been declined [251]. Authors might decline requests 
to share data because of the time required to reformat the data, concerns about how the 
data will be used, or plans to publish further analysis on the data in the future. This is 
changing to some degree, with many research funders now requiring that data be made 
openly accessible. Where data is not already in an online repository, negotiations to access 
the data might take some time, as often multiple stakeholders must agree to share data. A 
data-sharing agreement is recommended to facilitate negotiations and address 
researchers’ concerns [251].  
Once data sharing arrangements have been agreed, the researcher seeking to pool data 
must draw up a data coding protocol and resolve differences in data coding across studies. 
The primary concern in pooling data is to ensure that “variables apparently representing 
the same phenomenon indeed [do]” [247]. Often this will require recoding or recalculation 
of variables. Researchers will need to address a number of concerns in maintaining 
consistency in the data, including: coding of demographic characteristics; currency year and 
time frame for cost data; discount rate; recall periods; and cost estimation method. There 
may be some differences in the datasets that are difficult to identify. For example, it is 
possible that the different studies which represent different patient groups across different 
settings will exhibit some heterogeneity in the variables of interest which could confound 
the analysis. There may also be an intervention effect on the variables of interest (e.g. cost) 
that must be accounted for in the pooled analysis, understanding that there will be 
variation in interventions themselves and therefore in the intervention effect. 
Dealing with missing data 
Primary datasets may have data missing; researchers will need to determine the 
mechanism for missingness; this will help to determine methods to deal with missing data. 
Reasons for missing data are classified as: missing completely at random (MCAR); missing 
at random (MAR); and missing not at random (MNAR).  
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If data is determined to be MCAR (i.e. there is no pattern to missingness of data, and no 
systematic differences between the missing values and the observed values), a complete 
case analysis will not lead to bias. The analyst can in this case comfortably conduct analysis 
without any imputation, taking the assumption that results drawn from the observed data 
will not be statistically different from results if there were no missing observations. 
However, data in the real world are not often truly MCAR. Missing values are often related 
to observed values; for example, costs are often determined by demographic 
characteristics such as age, gender, level of education, or income quintile – the frequency 
of which may vary between observed and non-observed data. In these cases, a complete 
case analysis will lead to bias, and the researcher must impute the missing observations. 
There are a number of possible approaches statistical approaches to conducting analysis 
with missing data; arguably the most widely applicable and practical approach is multiple 
imputation [252]. The process of multiple imputation uses statistical packages to allow for 
uncertainty by creating several different plausible imputed datasets based on the observed 
relationship of various characteristics to the data. The model of interest is then fit to each 
of the imputed datasets; the variation between the multiple plausible datasets allows for 
better representation of standard errors around overall associations. 
There are several model-based imputation procedures available to researchers. The choice 
of procedure is dependent on the distribution of the data and characteristics of outcomes. 
For example, if data is normally distributed and outcomes are binary, a Tobit model may be 
appropriate; if data is normally distributed and outcomes are semi-continuous, a two-part 
model (such as the Heckman selection model) may be appropriate. Multiple imputation of 
non-normally distributed data requires non-parametric techniques for imputation. 
Predictive mean matching (PMM) is one such non-parametric technique for dealing with 
non-normally distributed data. PMM imputes missing values using a specified number of 
‘nearest neighbours’, based on the expected values of the missing variables conditional on 
the observed covariates [253]. This allows for maintenance of the original distribution of 
data.  
As imputation is dependent on regression analysis, where there are missing values in 
several variables univariate imputation can still result in missing values. A popular solution 
to this is the use of multivariate imputation by chained equations (MICE); using this 
approach researchers can identify a series of conditional models which are automatically 
cycled through by statistical software. Using MICE, different model types can be designated 
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for each variable as appropriate; for example, a Tobit model may be identified for binary 
outcomes or PMM model identified for non-normally distributed data as above. 
Choosing and fitting the regression model 
The process for fitting a regression model begins with the determination of covariates 
which are likely to influence the outcome. Following the Grossman model of demand for 
health, people are likely to seek health care as long as the rate of return on investment in 
health care (in terms of productivity and utility gained from improving health) is greater 
than the costs of doing so [254]. Health-related costs are therefore likely to be driven by 
indicators of earning capacity (including wage rate, education, gender, and urbanicity), and 
anticipated benefits of gaining health (including age and disease/disability). 
Researchers will then need to identify the most appropriate functional form for a model. 
The model specification process often involves testing the efficiency of several functional 
forms as applied to data. Two functional forms have been recommended as appropriate for 
non-normally distributed data: a generalized linear model (GLM) with a gamma distribution 
and log link, and a quantile regression model [255]. In Chapter 9 I choose a quantile 
regression model to estimate income, and a GLM model to estimate TB-related costs; 
methods for the analysis are described further in Chapter 9 and in the supplementary 
materials for Chapter 9. 
The goodness of fit for a GLM is generally tested using the Akaike information criterion 
(AIC). Unlike an R2 value, the AIC does not provide an absolute estimation of the predictive 
value of a regression. Instead, the AIC is an estimator of the relative quality of statistical 
models for a given set of data. Fitting a GLM model involves a process of fitting a series of 
candidate models; the model with the lowest AIC is then determined to be the highest 
quality model. Normality of residuals for a GLM model can be tested using the Shapiro-Wilk 
normality test.  
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CHAPTER 5. THE PATIENT COSTS OF CARE FOR 
THOSE WITH TB AND HIV: A CROSS-SECTIONAL 
STUDY FROM SOUTH AFRICA 
PREAMBLE FOR RESEARCH PAPER #1 
This paper presents the results of a patient costing study for people with TB and/or HIV 
presenting to health facilities in Ekurhuleni North Sub-District, South Africa. At the time this 
paper was written, there was no comprehensive evidence on the economic impact of 
illness on people with both TB and HIV, despite the fact that this population group accounts 
for over 60% of those with TB. The aim of this analysis was to add to the evidence base on 
the patient costs incurred by people living with TB and/or HIV in order to support 
policymakers as they assessed potential benefits from the improved implementation of 
TB/HIV integration. 
The study was nested within the MERGE trial, which evaluated the effect of implementing 
an intervention to optimise/improve TB/HIV integration on morbidity, mortality and 
retention in care at public primary health care clinics (PHC clinics) . Integration is not 
binary, but rather encompasses a range of dimensions, including clinical coordination and 
linkages, physical integration, and/or temporal integration. Theoretically, integration of 
health services can reduce patient costs associated with time and travel to the health 
facility through economies of scope, although there is very little practical evidence that this 
occurs in the real world.  
We include an estimate of the number of ‘integrated’ TB/HIV visits received by patients in 
this paper (defined for this sub-study as receipt of both TB and HIV services at the same 
facility, on the same day). However, the practical extent and characteristics of integration 
at health facilities within the study varied widely. For example, in some study facilities 
services may have been physically integrated but not temporally integrated, while in other 
study facilities there may have been clinical coordination but no physical integration.  Due 
to this complexity, it was not possible to estimate economies of scope in this study. 
The data for this paper was collected April-October 2013. The methods of this study were 
in line with the standard for estimating patient costs at the time of cost data collection. The 
patient questionnaire was adapted from the USAID Tool to Estimate Patient Costs. A 
descriptive analysis presents the monthly costs of people with TB-only, HIV-only, and 
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TB/HIV. Catastrophic costs were estimated as occurring when direct and indirect costs 
exceeded a baseline threshold of 10% of monthly individual participant income; this 
threshold was varied in sensitivity analysis.  
We found high proportions of all patients encountering high catastrophic costs using this 
definition – ranging from 50-68% of TB/HIV participants, 31-46% of TB-only participants 
and 33-54% of HIV-only participants depending on the threshold. The results of the paper 
made a strong case for increased social protection of those living with TB and/or HIV, and 
improved integration of TB and HIV services. The results of this paper were valuable to 
policymakers in the context of very little evidence about the relative costs of combined 
TB/HIV infection.  
This was a multi-authored work based on cost data collected during the MERGE trial. All co-
authors contributed comments and edited the paper. DM oversaw the collection of the 
patient cost data. DM and I jointly conducted the analysis and co-wrote the paper. 
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ABSTRACT 
Background: This study describes the post-diagnosis care-seeking costs incurred by people 
living with TB and/or HIV and their households, in order to identify the potential benefits of 
integrated care.  
Methods: We conducted a cross-sectional study with 454 participants with TB or HIV or 
both in public primary health care clinics (PHC clinics) in Ekurhuleni North Sub-District, 
South Africa. We collected information on visits to health facilities, direct and indirect costs 
for participants and for their guardians and caregivers. We define ‘integration’ as receipt of 
both TB and HIV services at the same facility, on the same day. Costs were presented and 
compared across participants with TB/HIV, TB-only and HIV-only. Costs exceeding 10% of 
the participant`s income were considered catastrophic.  
Results: Participants with both TB and HIV faced a greater economic burden (USD 
$74/month) than those with TB only (USD $68/month) or HIV only (USD $40/month). On 
average, people with TB/HIV made 18.4 visits to health facilities, more than TB-only 
participants or HIV-only participants who made 16 and 5.1 visits respectively. However, 
people with TB/HIV had fewer standalone TB (10.9) and HIV (2.2) visits than those with TB-
only (14.5) or HIV-only (4.4). Although people with TB/HIV had access to ‘integrated’ 
services, their time loss was substantially higher than for other participants. Overall, 55% of 
participants encountered catastrophic costs. Access to official social protection schemes 
was minimal. 
Conclusions: People with TB/HIV in South Africa are at high risk of catastrophic costs. To 
some extent, integration of services reduces the number of standalone TB and HIV of visits 
to the health facility. It is however unlikely that catastrophic costs can be averted by service 
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integration alone. Our results point to the need for timely social protection, particularly for 
HIV-positive people starting TB treatment.  
INTRODUCTION 
The launch of the Sustainable Development Goals (SDGs) and Universal Health Coverage 
reflect an increased global focus on the interaction between health outcomes and poverty. 
Health sector policy-makers are becoming increasingly interested in interventions and 
service delivery models that may best prevent impoverishment. While there has been 
much investigation into the impact of service integration on provider costs, much less 
attention has been focussed on the potential economic and poverty reduction benefits to 
service users, particularly vulnerable groups (World Bank, 2009; World Health Organization 
et al., 2009; Atun et al., 2010).  
Household and patient-incurred costs associated with health shocks have long been 
recognized as key contributors to impoverishment (Heltberg and Lund, 2009; Alam and 
Mahal, 2014; Wagstaff and Lindelow, 2014). In the case of tuberculosis (TB), patient-
incurred costs are a major barrier to access to health services in low-income countries 
(Ensor and Cooper, 2004; Donnell, 2007), and have been associated with negative TB 
treatment outcomes (Wingfield et al., 2014). Even where TB services are offered free of 
charge, the high costs of access such as transportation and opportunity cost of time spent 
accessing care may provide obstacles for vulnerable groups, while worsening or creating 
poverty in those that proceed to seek care (Xu et al., 2007). When faced with high costs of 
accessing TB care and a reduced ability to earn income due to illness, some TB patients 
resort to selling off their assets and taking interest-bearing loans (Lönnroth et al., 2014). 
This can result in a long term poverty impact for both patients and their households (Xu et 
al., 2003; Gottret and Schieber, 2006; Etienne et al., 2010; Lönnroth et al., 2014).  
For people accessing care for both TB and HIV, health service integration has the potential 
to reduce this economic burden. Integration may benefit patients by enabling health 
improvements and cost reductions through less fragmented services, improved continuity 
of care, and better retention in care (Sweeney et al., 2012). Integration may also facilitate 
cost reductions through fewer visits to facilities and reduced delays in accessing treatment 
(Legido‐Quigley et al., 2013). 
In 2012, TB was the primary cause of death for 25% of all HIV-associated deaths in South 
Africa, and 61% of all people with TB were HIV-positive (WHO, 2015). The country has 
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developed guidelines for the integration of TB and HIV services with preference for a “one-
stop shop”, where services are provided under one roof (National Department of Health 
South Africa, 2014). TB/HIV integration is expected to “ensure comprehensive management 
of the patient, reduce morbidity and mortality and improve treatment outcomes” (Chehab 
et al., 2013; Republic of South Africa Department of Health, 2014). Integration however 
remains poorly implemented in South Africa (Churchyard GJ et al., 2014). Although services 
are commonly provided ‘under one roof’, they may often not be provided by a single 
provider, nor will patients be correctly referred between providers. As a result the evidence 
base on the impact of TB/HIV integration on patient-relevant outcomes is small and 
inconsistent (Kaplan et al., 2014; Jacobson et al., 2015; Ledibane et al., 2015).  
To date, TB patient costing studies in South Africa (Chimbindi et al. 2015, Foster et al. 2015) 
have not comprehensively assessed the economic impact of illness on people with both TB 
and HIV. The purpose of this paper is to comprehensively describe the post-diagnosis care-
seeking behaviour, patient costs incurred and coping strategies adopted by people living 
with TB and/or HIV and their households, in order to identify the potential benefits of 
integrated care. To present this, we collected data on the costs incurred by participants in 
the period immediately following receipt of a TB and/or HIV diagnosis and including the 
first 3-5 months of care, as this is the period when previous studies have shown patients to 
incur the highest costs (Foster et al. 2015). We present this evidence in order to support 
policymakers as they assess the potential benefits from the improved implementation of 
TB/HIV integration.  
METHODS    
Study setting 
The study was conducted in Ekurhuleni North; a sub-district in Gauteng province, South 
Africa. Ekurhuleni had approximately 3.2 million inhabitants in 2013 (City of Ekurhuleni, 
2013) and a population density of approximately 1609 people per square kilometre 
(Statistics South Africa, 2011). Ekurhuleni has a high unemployment rates of 28.8% in the 
general population and 36.9% among persons between ages of 15 and 35 (City of 
Ekurhuleni, 2013, 2014). In 2013, 8% of the people living in Ekurhuleni reported that they 
did not have any source of income and 27.9% were considered to be living below a 
nationally defined minimum living standard (City of Ekurhuleni, 2013). The South Africa 
District Health Barometer of 2013 estimated a TB case notification rate of 336 per 100 000 
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for Ekurhuleni (Massyn et al., 2014). According to a national HIV prevalence, incidence and 
behaviour survey, the HIV prevalence for Ekurhuleni was 14.3% (10.3% - 19.5%) in 2012 
(Simbayi et al., 2014).  
Study design and baseline data collection 
This was a cross-sectional study nested within a cluster randomised trial – the MERGE trial. 
The MERGE trial evaluated the effect of implementing an intervention to optimise/improve 
TB/HIV integration on morbidity, mortality and retention in care at public primary health 
care clinics (PHC clinics) (Kufa et al., 2014). A total of 18 PHC clinics, the study clinics, were 
randomly allocated to the intervention or control arm. To be eligible for inclusion in the 
trial, the clinics had to meet the following criteria: no conflicting research study in progress 
at the clinic, clinic has at least 40 TB cases per year, and the clinic has available TB data.  
Participation in the MERGE trial was not a requirement for inclusion in the patient costs 
study. Instead MERGE trial participants had an equal chance of also being enrolled in the 
patient costs study if eligible. Cost data were collected using structured questionnaires at 
the 18 study clinics between April and October 2013. Participants were selected 
consecutively and enrolled if they met any one of the following criteria: i) received a TB 
diagnosis 3-5 months prior to interview AND had a positive HIV test at any time (“TB/HIV”); 
ii) received a TB diagnosis 3-5 months prior to interview and was HIV negative at time of 
enrolment (“TB-only”) iii) tested HIV positive for the first time 3-5 months prior to 
interview and was not on treatment for TB at the time of enrolment (“HIV-only”). The time 
period was informed by previous research which showed that participant recall becomes 
diminished at around 4 months onwards (Mauch et al., 2011). All participants reported a 
known positive or negative HIV status. Unlike TB, HIV positive reporting was not confirmed 
with clinic records. Participant numbers were capped at 50 per site, although only 3 of 18 
sites reached this cap due to low participant numbers at the facilities.  
Questionnaires 
Questionnaires were adapted from the Tool to Estimate Patients’ Costs that was developed 
by the Tuberculosis Coalition for Technical Assistance (TBCTA) and the United States 
Agency for International Development (USAID) (USAID et al., 2008). Separate 
questionnaires were developed for people being treated for TB (regardless of HIV status) 
and for HIV-positive people not being treated for TB to accommodate different pathways of 
care. Both questionnaires captured similar level of detail on the different events in the 
pathway of care. Questionnaires focused on the period in the first 3-5 months after 
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participants knowing or being told they had TB (‘post-diagnosis’) to understand the costs of 
accessing integrated services. 
Demographic characteristics such as gender, age, ethnicity and nationality, levels of 
education, marital status, employment at the time of receipt of diagnosis, and the impact 
of illness on normal productive patterns were collected. Questionnaires also included 
detailed questions on the number of visits made to a range of providers, including the 
participant’s local PHC clinic (our study clinic), other public facilities, general practitioners, 
hospitals, traditional healers and pharmacies. A distinction was made between integrated 
visits and stand-alone visits for TB and/or HIV services at the study clinic. We define 
‘integration’ as physical and temporal integration, or receipt of both TB and HIV services at 
the same facility, on the same day (Mayhew et al., 2016).  
It was not feasible to measure costs for every visit made by participants; questions 
therefore elicited estimates of direct costs, time spent and income loss for the most recent 
visit to each provider, and the number of visits made to each provider type during the 
treatment period. The questionnaires also captured information about strategies adopted 
by participants to cope with costs of illness. Coping strategies enquired of include: taking 
interest-bearing loans from lenders, borrowing money from friends or relatives, selling 
personal goods, and receipt of grants or charitable donations. 
Data analysis  
The data were captured in a secure electronic database and exported into Stata 14 and 
Microsoft Excel for analysis (Microsoft, 2014; Stata and Stata Corp, 2015). An ‘available 
case analysis’ assumed unavailable data values were missing at random. All costs were 
converted to an average monthly cost to facilitate comparison across participants who had 
received diagnosis between 3-5 months prior to interview.  
Direct costs were defined as medical and non-medical expenses paid out-of-pocket (OOP). 
Medical expenses included consultation fees and any OOP payment for medicines and 
diagnostics paid at any provider. Direct non-medical expenses included the travel costs of 
participants and guardians if any, food costs incurred while in hospital, money spent buying 
any special foods or dietary supplements due to illness, and any interest incurred on loans 
taken out to meet the costs of OOP payments. Direct medical and non-medical costs were 
determined as the product of the reported expense for the most recent visit to each 
provider type and the number of visits made to that provider during the post-diagnosis 
period; these were then divided by the number of months in the post-diagnosis period.  
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We use reported income loss as our primary measure of indirect costs for participants. To 
facilitate comparison with other patient cost studies, we also report separately on time the 
participants spent seeking care or were unable to work. We estimated the mean time spent 
per month using the total time reported for the most recent visit to each provider time, 
multiplied by the total monthly visits to each provider. Indirect costs for guardians and 
carers were defined as the opportunity cost of time spent away from their daily productive 
routine, including travel to health facilities, consultation time, and covering household 
chores usually done by the participant. As guardians and carers were not interviewed 
directly about their income loss, the opportunity cost of this time for guardians and carers 
was estimated using median income of elementary occupations in South Africa, R 1517 per 
month (Statistics South Africa, 2010) multiplied by the mean time loss. Loan costs were 
calculated as the difference between the borrowed amount and the amount paid back.  
We also estimated catastrophic costs incurred due to TB and/or HIV. Catastrophic costs are 
calculated as a proportion of total costs (direct and indirect) to an income (personal or 
household). The principle of catastrophic costs is rooted in identifying when patients and 
their households involuntarily reduce expenditure on basic household needs such as food, 
clothing and education in order to pay for health care (Ranson, 2002). According the World 
Health Organization (WHO) approach, costs are defined as catastrophic when total costs 
incurred (direct and indirect combined) exceed a given threshold of household income 
(World Health Organization, 2015). In the absence of reliable data on household income, 
we adopted a threshold of 10% of individual participant income (Barter et al., 2012). This 
threshold has been a widely used benchmark for catastrophic costs in many patient costing 
studies (Xu et al., 2003; Russel, 2004; Tanimura et al., 2014; Wingfield et al., 2014; Foster et 
al., 2015), due to the challenges of measuring household rather than individual income. An 
alternative 20% threshold of household income is also being increasingly used in the case 
of TB, due an observed association between this level of cost and negative health outcomes 
in Peru (Wingfield et al. 2014). We varied the catastrophic cost threshold in our analysis 
from 5-25% to understand the impact of this arbitrary threshold (Russell 2004, Ukwaja, 
Alobu & Hopewell 2013). To avoid mathematical errors associated with division by zero, an 
arbitrary value of USD1 was assigned to income for those participants who reported zero 
income or where income was a missing value (Foster et al., 2015).  
We adopted a descriptive cost analysis due to the small sample size of some of the 
comparison groups. Prior to analysis, all costs were converted from the South African Rand 
(ZAR) to the United States dollar (USD) using the average rate during the period of data 
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collection in 2013; ZAR 9.62= USD 1 (OANDA, 2016). Despite skewness and non-normality 
of cost data, arithmetic means were used in all calculations as was done in previous studies 
(Wingfield et al. 2014) and in line with the principles of economic evaluation (Bill and 
Melinda Gates Foundation et al., 2014). Standard deviations were used as measures of 
dispersion for cost data and inter-quartile ranges for continuous descriptive data.  
Ethical considerations 
Ethical approval was obtained from the authors’ institute. The study was also registered in 
the clinical trials register for South Africa (registration number DOH-27-10113846) and 
additional permission to conduct the study was sought from the Ekurhuleni health 
department. 
RESULTS 
We invited 475 participants meeting the inclusion criteria to participate in the study, and 
463 consented to participate. The most common reason for non-inclusion was receipt of 
diagnosis outside of the window of 3-5 months prior to interview. Of the 463 enrolled, 454 
participants from 18 PHC clinics were included in the analysis, with nine participants 
excluded because data on their gender were missing at analysis stage. The majority of the 
participants included in the analysis had received a diagnosis of HIV only (n = 298; 66% of 
sample). Forty TB-only participants and 116 TB/HIV participants were recruited. Of the 
TB/HIV participants, 20 received both TB and HIV diagnoses on the same day, and an 
additional 46 received both diagnoses within two months of each other.  
Descriptive characteristics 
Characteristics of the study population are presented in Table 5-1. The majority of 
participants were unmarried (58%). Most participants were female (64%), and educated 
above grade 8 (84%). Participants born in South Africa and those of African origin made up 
83% and 97% of the study population respectively. Unemployment was very high across all 
participant groups; 45% of enrolled participants were unemployed at the time of receiving 
their diagnosis, as compared to a national unemployment rate of 25% (Statistics South 
Africa, 2011). Median monthly income was $128 at the time of diagnosis of TB and/or HIV. 
Of those who were employed at the time of diagnosis, 6% had a monthly income below the 
national poverty line of $52 per month (Statistics South Africa and Statistics SA, 2014). The 
highest income at the time of diagnosis was reported by the TB/HIV group (median $150 
per month), while the TB-only group had the lowest average income ($88 per month). 
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Table 5-1 Demographic characteristics at time of interview, by participant group 
 
TB/HIV 
[n=116] 
TB only 
[n=40] 
HIV only 
[n=298] 
Female n (%) 63 22% 16 6% 210 73% 
Age n (%) 
18-24 10 9% 5 13% 22 7% 
25-34 43 37% 21 53% 131 44% 
35-44 48 41% 6 15% 96 32% 
≥45  13 11% 8 20% 43 14% 
South African n (%) 100 86% 32 80% 244 82% 
Black/African n (%) 111 96% 38 95% 291 98% 
Grade 8 and above n (%) 95 82% 34 85% 251 84% 
Unmarried n (%) 69 59% 24 60% 169 57% 
Employed at diagnosis n (%) 60 52% 20 50% 168 56% 
Had informal carers in post-diagnosis period 
n (%) 
56 48% 22 55% 111 37% 
Missed work in post diagnosis period n (%) 36 31% 11 28% 37 12% 
Median CD4 count at last test (IQR) 125 275     244 216 
Median monthly income at diagnosis 
 (2012 USD) (IQR) 
$150  381 $88  342 $135  312 
Median days from diagnosis to interview 
(IQR) 
115 28 119 32 115 33 
 
A large proportion of participants had informal carers; 55% of those with TB, 37% of those 
with HIV and 48% of those with TB/HIV. The impact of illness and care-seeking had variable 
effects on participants’ and household members’ income-earning activities. Across all 
participant groups, 19% of participants missed work due to illness and 21% of participants 
were unable to complete their normal household duties in the post-diagnosis period. 
People with TB were more likely to miss work with the highest proportion being 31% 
among TB/HIV participants.  
Health service use 
All study facilities offered integrated care for both TB and HIV as defined in the methods 
section. Actual practice at study facilities varied considerably; in some facilities visits were 
integrated at the provider level where both services delivered by the same provider or the 
consultation level where both services delivered within the same consultation, though the 
latter was rare. Table 5-2 shows the overall mean number of clinic visits and by visit type, 
for each participant group. TB/HIV participants on average made 5 ‘integrated’ visits in the 
post-diagnosis period. TB only participants also received integrated visits when for HIV 
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testing and collecting test results – on average this was 0.8 visits per person across study 
facilities.  
 In the post-diagnosis period, all participants made relatively few visits to providers outside 
the public health system. The average total number of visits to other facilities and providers 
ranged from 0.6 in the TB only group to 0.2 in the HIV only group. The total number of 
participants accessing other types of health provider, and mean number of visits by those 
participants, is presented in Supplementary Table 5-1. The largest proportion of 
participants accessing care from providers outside the public health system was among the 
TB/HIV participant group, at 23.28%. Fifteen percent of TB-only participants and 14% of 
HIV-only participants reported use of providers outside the public health system 
respectively. Thirteen TB/HIV participants were hospitalized, as compared to 2 HIV-only 
participants and zero TB-only participants. 
Table 5-2 Visits to any health care provider in the post-diagnosis period, by participant group 
Patient group TB/HIV (n=116) TB only (n=40) HIV only (n=298) 
Visit type 
TB/ HIV 
visits 
TB 
visits 
HIV 
visits 
TB/ HIV 
visits 
TB 
visits 
HIV 
visits 
TB/ HIV 
visits 
TB 
visits 
HIV 
visits 
Study clinic visits, 
mean (SD) 
5.0 (4.6) 
10.9 
(14.2) 
2.2 
(4.6) 
0.8 (.6) 
14.5 
(14.6) 
0.1 
(.2) 
0 0 
4.4 
(2.0) 
Visits to other 
providers**, mean 
(SD) 
 0.3 
(0.7) 
0.2 
(0.7) 
 0.6 
(2.6) 
0.1 
(0.2) 
 0 
0.2 
(0.7) 
Subtotal, all 
providers, mean 
5.0 11.2 2.2 0.8 15.1 0.1 0 0 4.6 
Total Visits, all visit 
types, all providers 
18.4 16.0 5.1 
SD standard deviation 
**Other public clinic, pharmacy, general practitioner, hospital-outpatient, hospital-inpatient and 
traditional healers 
 
All people with TB visited the study health facilities at least 4 times per month in the post-
diagnosis period. HIV only participants made the fewest visits to study facilities over the 
study period (mean 1 visit per month).  
Patient costs 
Table 5-3 presents patient-incurred costs in the post-diagnosis period. The highest total 
costs in the post-diagnosis period were reported by TB/HIV and TB-only participants; 
$74.07 and $68.33 per month respectively. Costs for the HIV-only group ($40.41 per 
month) were substantially lower. Indirect costs contributed the majority of the total costs, 
at 71% of total cost for TB/HIV participants, 86% of total cost for TB-only participants, and 
55% of total cost for HIV-only participants. 
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Table 5-3 Monthly direct and indirect costs (USD 2013), by participant group 
 
TB/HIV (n=116) TB only (n=40) HIV only (n=298) 
  mean (SD) Mean (SD) mean (SD) 
Direct costs             
  Patient medical             
    Study clinic 0.00 0.00 0.00 0.00 0.00 0.00   
Any other facility 1.71 10.23 0.07 0.42 0.87 4.12 
  Patient travel               
Study clinic 4.12 8.91 1.69 3.31 1.25 3.07 
    Any other facility 0.63 2.89 0.05 0.20 0.24 1.37 
  Guardian travel                
Study clinic 0.43 2.37 0.00 0.00 0.27 2.78 
    Any other facility 0.51 3.11 0.00 0.00 0.17 1.52 
  Food               
Hospital 0.26 1.31 0.00 0.00 0.04 0.47 
    Special foods 13.14 17.33 8.06 11.05 9.76 14.91 
  Loan interest 0.93 9.78 0.00 0.00 5.68 89.11 
Total direct costs 21.72 (29%1) 9.86 (14%1) 18.28 (45%1) 
Indirect costs             
  Patient income loss             
  
 
Job loss income loss  15.40 126.17 17.78 76.69 2.99 24.30 
  
 
Care-seeking income loss 30.45 105.56 34.60 98.99 13.81 59.03 
  Opportunity costs of time              
Guardian               
Study clinic 1.13 2.37 0.23 0.00 3.92 2.78 
    Any other facility 0.94 6.16 0.04 0.24 0.22 1.24 
  Carer 4.42 11.35 5.81 13.52 1.19 5.77 
Total indirect costs 52.34 (71%1) 58.47 (86%1) 22.13 (55%1) 
Grand total  74.07 68.33 40.41 
SD standard deviation 
1 percentage of the overall total 
 
Direct OOP costs incurred by participants ranged from $9.86 per month for TB-only 
participants to $21.72 per month for TB/HIV participants (Table 5-3). Detailed costs 
incurred at all facility types are listed in Supplementary Table 5-2. Direct costs were largely 
driven by costs of special foods purchased as nutritional supplements for the illnesses in 
question. Monthly costs of special foods ranged from $8.06 to $13.40 per month, 
representing 53% of direct costs for HIV-only participants, 60% of direct costs for TB/HIV 
participants, and 82% of direct costs for TB-only participants. Expenditure on special foods 
alone represented an average of 30%, 13%, and 27% of total income for HIV-only, TB-only, 
and TB/HIV participants respectively. None of the interviewed participants incurred direct 
medical costs at the study clinic, or at any other PHC clinic. Participants who sought care 
from health facilities outside the public health system, particularly those with TB/HIV, 
incurred some direct medical costs; an average of $1.71 per month was observed for 
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TB/HIV participants. The highest direct medical costs from providers outside the public 
health system were incurred by participants accessing care from traditional healers, 
however this was driven by one participant reporting a very high cost of $415.  
Indirect costs were high for all participant groups, particularly those participants being 
treated for TB. Job loss and other income losses were major drivers for indirect costs; 
accounting for 62% of cost in the participants with TB/HIV and 77% of cost for TB-only 
participants. Participants with TB (both TB-only and TB/HIV) lost an average of 
$32.53/month in income due to time spent seeking care. HIV-only participants lost 
substantially less income due to seeking care on average than other participant groups, at 
an average of $2.99 /month.  
About 4% of participants with TB and 3% of those with HIV their job entirely due to illness. 
Among those who lost their jobs due to illness, the mean and median income losses were 
$321.62 and $207.90 respectively. The average income loss due to job loss across all 
participants was $17.78/month for TB-only participants, $15.40/month for TB/HIV 
participants, and $2.99/month for HIV-only participants. The monetary value of time lost by 
guardians was particularly high for HIV-only participants. Table 5-3 shows the monthly 
guardian opportunity costs of time varying from $2.07 in the TB/HIV group to $4.14 in the 
HIV-only group. In contrast, the cost of informal caregiving was particularly high for 
participants with TB (regardless of HIV status); this cost averaged $5.81 per month for TB-
only participants and $4.42 per month for TB/HIV participants.  
Patient time loss 
The time that participants lost while travelling to health facilities and accessing (and 
waiting for) care in the post-diagnosis period is presented in Table 5-4. TB/HIV participants 
lost the most time, averaging 91 hours per participant over the post-diagnosis period. This 
was more than the combined time loss of TB-only and HIV-only participants (33.8 hours 
and 23.4 hours respectively). The time lost by TB/HIV participants was driven by long 
hospitalisations for 11 out of 116 (9.4%) participants who were hospitalised for an average 
of 17.7 nights over the post-diagnosis period. The average time loss for TB/HIV participants 
not hospitalized was 50 hours over the post-diagnosis period. Travel time, particularly for 
visits to the study clinic, was also substantial. TB/HIV participants lost an average of 20 
hours travelling, while TB-only and HIV-only participants lost an average of 15 and 6 hours 
travelling, respectively.  
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Table 5-4 Total time loss in post-diagnosis period (hours), by participant group 
    TB/HIV 
(n=116) 
TB only 
(n=40) 
HIV only 
(n=298) 
    mean (SD) Mean (SD) mean (SD) 
Study clinic Consulting 28.2 27.7 17.5 17.3 13.9 11.7 
Travel 20.7 20.7 15.4 17.3 5.6 6.4 
 Subtotal 48.9 (54%) 32.9 (97%) 19.6 (83%) 
Other clinic Consulting 0 0.2 0.3 1.0 0.1 0.5 
Travel 0.1 0.5 0.5 1.4 0.2 1.3 
 Subtotal 0.1 (0%) 0.8 (2%) 0.2 (1%) 
Pharmacy Consulting 0 0.2 0 0.1 0 0.4 
Travel 0 0.3 0 0.1 0.1 0.4 
 Subtotal 0.1 (0%) 0 (0%) 0.1 (0%) 
General 
practitioner 
Consulting 0.1 0.7 0 0.3 0.3 1.8 
Travel 0.2 1.2 0 0 0.2 0.8 
 Subtotal 0.3 (0%) 0 (0%) 0.4 (2%) 
Hospital-
inpatient 
Consulting 40.3 146.8 0 0 2.9 25.5 
Travel 0.3 1.0 0 0 0.1 0.7 
 Subtotal 40.6 (45%) 0 (0%) 3.0 (13%) 
Hospital-
outpatient 
Consulting 0.2 1.0 0 0 0 0 
Travel 0.5 3.2 0 0 0 0 
 Subtotal 0.7 (1%) 0 (0%) 0 (0%) 
Traditional healer Consulting 0 0.3 0 0 0 0.2 
Travel 0.1 0.8 0 0 0.1 0.9 
 Subtotal 0.1 (0%) 0 (0%) 0.2 (1%) 
Grand total 90.8 33.8 23.4 
SD standard deviation 
Catastrophic costs 
Figure 5-1 illustrates the percentages of participants facing catastrophic cost, varying 
thresholds from 5% to 25%. All participants had high rates of catastrophic expenditures, 
across thresholds. The results show that more than 60% of all participants face catastrophic 
costs at the 10% threshold. TB/HIV participants show the highest proportions facing 
catastrophic costs, with 73% of participants encountering catastrophic costs at the 5% 
threshold and 61% at the 25% threshold. More than 70% of HIV-only participants 
experienced catastrophic at 5% threshold, however this proportion dropped at higher 
thresholds. Considering only direct costs reduced the proportion of participants 
encountering catastrophic costs to 68-50% of TB/HIV participants, 46-31% of TB-only 
participants, and 54-33% of HIV-only participants depending on threshold (Supplementary 
Figure 5-1)  
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Coping Strategies 
Table 5-5 shows the range of strategies adopted by participants and their households to 
cope with income loss and/or direct out of pocket payments incurred due to TB and/or HIV 
(Table 5-5). Fifteen percent of HIV-only participants, 6% of TB/HIV participants, and 8% of 
TB-only participants adopted at least one coping strategy. The most common coping 
strategy was loan-taking, which was done by 11% of HIV-only participants, 8% of TB-only 
participants, and 3% of TB/HIV participants. Interest charged on loans to the TB/HIV and 
HIV-only group were relatively high, at 27% and 22% of the initial value respectively. In 
contrast, TB-only participants were able to source loans at zero interest from friends or 
family. Government grants and charitable donations were rarely accessed across all 
participant groups. Similarly, asset sales were not used by the majority of participants as a 
means to cope with TB and/or HIV-related costs.  
Table 5-5 Coping strategies, by participant group 
 
TB/HIV 
(n = 116) 
TB only 
(n = 40) 
HIV only 
(n = 298) 
Grants and donations    
Patients receiving government grants n (%) 1 (1%) 0 5 (2%) 
Patients receiving charitable donations n (%) 0 (%) 0 4 (1%) 
Asset Sale    
Patients selling assets n (%) 3 (3%) 0 7 (2%) 
Mean value of assets sold (USD) $11.54 - $9.15 
Loans    
Patients taking loans n (%) 4 (3%) 3 (8%) 34 (11%) 
Mean interest on loans (% of initial withdrawal) 27% 0% 22% 
Total adopting any coping strategy 7 (6%) 3 (8%) 46 (15%) 
Total adopting multiple strategies 1 (1%) 0 4 (1%) 
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Figure 5-1 Catastrophic costs due to illness, by participant group 
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DISCUSSION 
All participants interviewed in this study encountered high costs associated with HIV and/or 
TB. Over 45% of all participants experienced catastrophic costs even at thresholds as high 
as 25% of individual income. People with both TB and HIV on average face higher levels of 
post-diagnosis catastrophic costs than those with TB-only or HIV-only, especially at higher 
thresholds.  
In principle, integration has the potential to reduce the overall number of visits. We found 
many participants were receiving integrated care, defined as receiving multiple services 
within one visit. TB/HIV participants received an average of 5 ‘integrated’ TB/HIV visits in 
the post-diagnosis period, where both TB and HIV services were delivered on the same day. 
As a result, participants received fewer TB-only visits than the TB-only group, and fewer 
HIV-only visits than the HIV-only group. However, the total time loss for TB/HIV participants 
was still considerably higher than time loss for other participants. Similarly, travel costs for 
people with TB/HIV were substantially higher than all other participants. Given the high 
costs faced by those with TB/HIV, further gains may be achieved by ensuring that 
‘integrated’ visits are delivered by the same provider or within the same room, reducing 
waiting periods between multiple visits in a day. 
The gain in reduced visits observed for people with both TB and HIV may be extended by 
further integration, where services are provided by one provider, minimising the need for 
separate appointments. However, given the existing level of integration in terms of 
numbers of joint TB/HIV visits, it is unlikely that catastrophic cost can be averted by 
integration alone, and our results point to the need for timely social protection schemes 
such the government temporary disability grant, particularly for HIV-positive people 
starting TB treatment.  
To some degree, patients are able to cope with the costs of care, for example through 
taking loans with little or no interest from family and friends. However, where costs are 
particularly high or where patients lack social capital, coping strategies may place patients 
at risk of worsened long-term economic burden. For example, access to loans in some 
instances can show a level of credit worthiness; particularly where loans are taken from 
family or friends with no interest they have been regarded in the literature as an indicator 
of social capital and a possible way for households to reduce the economic burden of 
illness (Chuma et al., 2007). However, where loans are taken out with high interest rates or 
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where productive assets are sold, households face the risk of long-term economic hardship 
(Madan et al., 2015; Squire et al., 2015). The extent of loan-taking at high interest in order 
to meet the costs of health care suggests that people with HIV may be at high risk of long-
term economic hardship. People with HIV were also more likely to sell assets in order to 
pay for care; this may also translate to diminished financial status because assets may have 
been sold for less than their replacement values.  
In addition to loans and asset sale, some people received grants as well as donations to 
deal with costs of illness. Currently, the South African government offers a temporary social 
relief of distress grant for patients who at the discretion of a doctor are deemed unfit to 
undertake remunerative work (Department of Social Development, 2006). However, access 
to these were consistently low, with 1% of participants overall accessing government 
grants. People with TB in particular had little access to the temporary disability grant, even 
when they were encountering catastrophic costs. This may be due to difficulty accessing 
the required certifications of disability within a rapid time frame. Access to charitable 
donations was similarly low, with only 4 of the 454 participants interviewed accessing a 
donation. This notable absence of donations and grants for all participants, and TB 
participants in particular, shows a policy implementation gap for the most vulnerable TB 
patients. Further research on the reasons for this implementation gap is needed, and the 
South African government should thus consider alternative social protection mechanisms, 
such as unconditional immediate cash transfers to TB patients to close this gap (Boccia et 
al., 2011).  
Participants with HIV (both HIV-only and TB/HIV) encountered relatively high costs due to 
accompaniment by guardians to the study facility. South African HIV treatment policy 
encourages use of a ‘treatment buddy’ to support adherence, however this is not 
considered a requirement for initiation onto treatment (South African Department of and 
South African Department of Health, 2010). Nearly all HIV-only participants reported that a 
guardian accompanied them to their most recent PHC clinic visit. Participants with TB-only 
were not as frequently accompanied to the PHC clinic, and therefore had relatively lower 
costs.  
Our study supports previous findings that the primary drivers of TB patient costs are 
income and job loss associated with time spent care-seeking and inability to work due to 
illness (Muniyandi et al., 2005; Aspler et al., 2008; Ukwaja et al., 2013; Chimbindi et al., 
2015). All people with TB had high numbers of health facility visits and these were reflected 
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in time and travel costs. Study participants with TB also had a high rate of job loss, no 
matter their HIV status. South Africa is currently scaling-up community based approaches 
to treatment supervision that may reduce these costs in the future.  
Our study also supports previous findings that supplementary food is an important driver of 
TB patient costs in South Africa (Bond et al., 2008; Foster et al., 2015), raising the question 
of whether patients are getting appropriate education regarding nutrition and TB. Previous 
studies have indicated that patients may perceive that TB and HIV drugs must be 
supplemented with higher food intake, often including foods outside of the normal South 
African diet including eggs, fruit, soft drinks, and meat (Bond et al., 2008). Improved 
nutrition counselling for people with TB and/or HIV is needed to help households meet 
dietary needs within their normal spending capabilities. 
As with any patient-level costing effort, this study faced several methodological limitations. 
Primarily, our comparisons are made on a small sample and the participant groups we 
compared did not have equal numbers of participants because eligible participants were 
recruited consecutively, and the MERGE study had fewer participants with TB. 
Methodological choices taken in this study, and the potential limitations of these are 
discussed in detail by Sweeney et al (Sweeney et al., 2016). In practice, when conducting 
patient cost interviews alongside intervention studies and trials, analysts are faced with 
either obtaining comprehensive costs of a smaller sample or limited costs (usually OOP) 
from a larger sample. Due to the importance of indirect costs as highlighted by previous 
studies, we chose the former. We chose a recall period of 3 to 5 months; this poses some 
risk of recall bias, which we weighed against the potential to miss costs. Second, the patient 
costs questionnaire was time consuming taking up to 60 minutes. The long survey times 
required also pose some risk of survey fatigue for interviewees, as well as interviewers. A 
number of training sessions were conducted with the interviewers and a number of 
recruitment guides were developed to make the recruitment process more feasible. Finally 
there is considerable debate in the literature surrounding the measurement of indirect 
costs, and the approach taken in previous studies is inconsistent (Zhang et al., 2011; Krol et 
al., 2013; Krol and Brouwer, 2014; Laurence et al., 2015). We chose to report income loss 
as our primary measure of indirect cost in order to avoid double-counting and possible bias 
against people with zero income, and report on time loss separately to facilitate 
comparison with other studies (Wingfield et al., 2014; Chimbindi et al., 2015). Further 
methodological research on measurement of indirect costs would facilitate future analyses 
of patient costs.  
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CONCLUSIONS 
Given the catastrophic costs associated with TB and HIV, even in settings where TB and HIV 
treatment are provided for ‘free’, social and income protection policies are likely to be 
required to protect these patients if global targets on catastrophic cost reduction are to be 
met. Integration of services has potential to reduce the number of visits to the health 
facility, and our data shows patients are receiving this care already in South Africa. 
However, we also find that those with TB/HIV suffer the highest costs, and integration 
should be further extended to ensure that both the economic burden of ill-health and that 
of treatment are minimised for vulnerable households.  
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CHAPTER 6. METHODOLOGICAL ISSUES TO 
CONSIDER WHEN COLLECTING DATA TO 
ESTIMATE POVERTY IMPACT IN ECONOMIC 
EVALUATIONS IN LOW-INCOME AND MIDDLE-
INCOME COUNTRIES  
PREAMBLE FOR RESEARCH PAPER #2 
The production of Research Paper #1 included several methodological choices in data 
collection and analysis, for example: which costs were included, the survey design and 
implementation, and the most appropriate measure of income. These decisions were made 
based on guidelines, learning from previously published studies, the experience of the 
senior author, and practical feasibility. Research Paper 2 systematically reflects on these 
methodological choices used in patient costing studies and presents a framework for 
considering the impact of methodological choices in estimating catastrophic costs.  
We present and discuss the different methodological challenges incurred by four patient 
costing studies, and place these within the broader context of existing literature on survey 
methods. We discuss the impact of methodological decisions taken due to limitations of 
time, budget, or study setting to enable researchers to make informed decisions about the 
impact of their choices. 
This paper was part of a supplement published by the journal Health Economics on 
economic evaluation in low- and middle-income countries. The supplement shows the 
increasing implementation and sophistication of economic evaluation in LMICs. In this 
context of increasing estimation of disease-specific catastrophic costs for economic 
evaluation, we challenge researchers to address fundamental data gaps for measuring the 
impact of illness on economic vulnerability through stronger reporting of methods and 
further methodological work.  
This was a multi-authored work based on the experiences of several practitioners collecting 
patient cost data. All co-authors contributed comments and edited the paper. NF, GK, and 
DM provided data and valuable feedback on their experiences in collecting costs. VS 
provided a helpful perspective on sampling. All other work, including the design of the 
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analytical framework, analysis, and writing the first and consecutive drafts of the paper, 
was my own. 
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ABSTRACT 
Out-of-pocket spending is increasingly recognized as an important barrier to accessing health 
care, particularly in low- and middle-income countries (LMICs) where a large portion of 
health expenditure comes from out of pocket payments. Emerging universal health care 
policies prioritize reduction of poverty impact such as catastrophic and impoverishing health 
care expenditure. Poverty impact is therefore increasingly evaluated alongside and within 
economic evaluations to estimate the impact of specific health interventions on poverty. 
However, data collection for these metrics can be challenging in intervention-based contexts 
in LMICs due to study design and practical limitations. Using a set of case studies, this letter 
identifies methodological challenges in collecting patient cost data in LMIC contexts. These 
components are presented in a framework to encourage researchers to consider the 
implications of differing approaches in data collection and to report their approach in a 
standardised and transparent way. 
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INTRODUCTION 
As universal access to health care becomes a greater international priority, interest has 
grown in reducing the level of financial catastrophe and impoverishment caused by health-
related expenditure (Sixty-fourth World Health Assembly, 2011). As a result, there is 
increased recognition that the impact of health interventions on poverty and equity should 
be incorporated into economic evaluations (Bill and Melinda Gates Foundation, Nice 
International, University of York Centre for Health Economics, & Health Intervention and 
Technology Assessment Program (Thailand), 2014) – particularly in low- and middle-income 
countries (LMICs) where out of pocket (OOP) expenditures make up a large proportion of 
total health expenditure (World Health Organization, n.d.). This is evidenced by the 
growing popularity of ‘extended’ economic evaluations, which incorporate assessments of 
the potential financial risk protection impact of an intervention or technology (Asaria, 
Griffin, Cookson, Whyte, & Tappenden, 2015; Verguet, Laxminarayan, & Jamison, 2015). In 
the context of this growing importance of poverty impact metrics in health planning and 
decision-making, there is need for high quality data to estimate the impact of health 
expenditures on poverty and vulnerability. To date, the majority of research reporting the 
poverty impact of health expenditures has drawn on data from large cross-sectional 
surveys such as the Living Standards Measurement Survey (LSMS) or World Health Survey 
(WHS). While these datasets facilitate equity analyses evaluating the distribution of health 
impacts or financial pooling mechanisms across socioeconomic status analysis at the 
national level, for example in the context of insurance reforms (Lu, Chin, Li, & Murray, 
2009; Xu et al., 2003), they cannot be easily used to capture the impact of a specific health 
intervention on poverty and may not always include detail on indirect costs or income loss, 
which can be key aspects of the poverty impact of illness.  
Collecting this type of data within a smaller-scale study setting can substantially increase 
the time and cost of data collection. Many studies therefore avoid collecting data for a 
poverty impact analysis altogether. Furthermore, where poverty impact data are collected 
as part of intervention evaluations there are notable inconsistencies in data collection 
methods. Systematic reviews of existing patient cost studies in LMICs highlight a lack of 
standard approaches across cost ingredients, data sources, sampling methodologies and 
recall periods, even where the same measure of poverty impact is used (Alam & Mahal, 
2014; Barter, Agboola, Murray, & Bärnighausen, 2012; Kankeu, Saksena, Xu, & Evans, 2013; 
McIntyre, Thiede, Dahlgren, & Whitehead, 2006; Tanimura, Jaramillo, Weil, Raviglione, & 
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Lönnroth, 2014). This can lead to challenges in assessing the comparability, quality and 
accuracy of results. In part, this heterogeneity may stem from limited practical guidance or 
standards on collecting patient-incurred cost data. Reporting guidelines for economic 
evaluations largely cover provider perspectives (Drummond & Jefferson, 1996; Husereau et 
al., 2013), and are neither updated to reflect information necessary for poverty impact 
metrics, nor provide guidance when constraints in data collection require compromise, 
such as limiting the sample size or restricting the length of the questionnaire. 
The aim of this letter is to highlight challenges faced in collecting data on patient costs 
within economic evaluation platforms in LMICs. We discuss practical issues around 
collecting patient-incurred cost and household income data, including comprehensiveness 
of the survey instrument, timing of interviews, sampling, and survey administration. To 
illustrate these issues, we use four case studies from our own research as examples (Foster 
et al., 2015; P. G. C. Ilboudo, Greco, Sundby, & Torsvik, 2014; Kufa et al., 2014; Mfinanga et 
al., 2015) (see Table 6-1). Finally, we present a framework of methodological choices in 
planning research on poverty impact metrics (Table 6-2) to encourage researchers to report 
their approach in a standardised and transparent way, and to consider potential 
implications of varying approaches in data collection (Figure 6-1).  
COMPREHENSIVENESS OF SURVEY DESIGN 
There is a rich theoretical literature on the measurement of affordability in health care. The 
most common indicators of poverty impact are catastrophic expenditure (defined where 
health spending exceeds a threshold percentage of household income) and impoverishing 
expenditure (defined where health spending pushes a household below the poverty line) 
(Russell, 1996; Wagstaff, 2008; Wagstaff & Eozenou, 2014; Wagstaff & van Doorslaer, 
2003). A number of theoretical challenges are associated with estimating the poverty 
impact of illness which are not addressed in detail in this letter, including the choice of 
threshold for analysis and assessing the long-term impact of health spending (Chuma, 
Thiede, & Molyneux, 2006; Flores, Krishnakumar, O’Donnell, & Van Doorslaer, 2008; Kruk, 
Goldmann, & Galea, 2009; McIntyre et al., 2006; Moreno-Serra, Millett, & Smith, 2011; L M 
Niëns, Brouwer, Niens, & Brouwer, 2013; Laurens M Niëns et al., 2010; Onoka, Onwujekwe, 
Hanson, & Uzochukwu, 2011; Pal, R., & Pal, 2012; Sauerborn, Adams, & Hien, 1996; 
Wagstaff & Eozenou, 2014; Wagstaff & van Doorslaer, 2003; Wingfield et al., 2014; Xu et 
al., 2003). The data required is defined by the metric of poverty impact chosen, but can 
include data on direct out-of-pocket expenditures for health care, any indirect costs of time 
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associated with being ill or accessing care, and any further economic impact measures such 
as income loss.  
The main challenge in survey design is the representation of complex patient experiences 
within a manageable survey length. Survey length is of particular concern when a patient 
cost questionnaire follows a lengthy clinical investigation, as it increases the risk of survey 
fatigue and participation refusal and increases resources required to conduct the survey. 
Our four case studies had a range of survey durations; this is largely a function of the 
complexity of the patient pathways in question. MERGE and XTEND attempted to cover the 
overall costs of a complex illness episode over a range of different providers, whereas 
ECONPOP covered only a recent hospitalization and REMSTART covered only the current 
visit. Survey durations for each study are detailed in Table 6-1.  
Disaggregation of cost ingredients will also affect survey length, and researchers may need 
to prioritize certain aspects to cover in depth. However, it is known that major drivers for 
patient costs can vary by setting and across income quintiles (Saksena, Xu, & Durairaj, 
2010; Tanimura et al., 2014), making it difficult to pre-suppose any exclusions or the 
relative attention placed on each aspect of expenditure or income measured. Surveys 
should be adapted to accurately represent the setting of interest, and researchers must be 
clear about which ingredients they do include, and how ingredients are disaggregated. 
Another widely recognized challenge is measurement of permanent income in LMICs, 
where informal employment is common and income is often seasonal (Deaton, 1997; 
Ferguson, Tandon, Gakidou, & Murray, 2003). Income data is difficult to collect in a small 
survey setting; as interviews in an intervention evaluation are conducted individually, 
accurate estimation of household income is often impossible. Researchers will need to 
decide whether personal income is an appropriate proxy for household income in their 
study context, and be clear about the limitations of such a decision. 
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Table 6-1 Study characteristics 
  MERGE  
(Kufa et al., 2014) 
XTEND  
(Foster et al., 2015) 
ECONPOP  
(P. G. C. Ilboudo et al., 2014) 
REMSTART  
(Mfinanga et al., 2015) 
Country South Africa South Africa Burkina Faso Zambia & Tanzania 
Aim of study Implementation and evaluation 
of an optimized model for 
scaling up TB/HIV integration at 
primary care clinics 
Evaluation of the 
implementation of a new TB 
diagnostic, XPert MTB/RIF 
Multidisciplinary study to 
estimate costs and consequences 
of abortion 
Trial assessing a complex 
intervention to reduce mortality in 
ART-naive patients beginning ART  
Study Design Cluster-randomized trial Cluster-randomized trial Cross-sectional survey Individually randomised control 
trial 
Timeframe Cross-sectional Cohort Cross-sectional Longitudinal  
Sampling for cost data Convenience sample  
at study facilities 
Random sub-sample  
of study-enrolled patients 
Convenience sample at study 
facilities 
All participants at study clinics. 
Clinics chosen for convenience 
Location of interview Facility Facility Facility Facility 
Sample size 459 for costs 
3478 total for trial 
351 for costs 
4656 total for trial 
304 for economic study 1375 for costs 
1999 total for trial 
Subgroups (n) TB only (n=41) 
TB/HIV (n=119) 
HIV only (n = 299) 
No TB treatment (n = 302) 
Started on treatment (n = 49) 
Induced (n=37) 
Spontaneous (n=267) 
Intervention (n=684) 
Control (n=691) 
Tanzania (n=870) 
Zambia (n=505) 
OOP cost ingredients Transport for individual & 
companion, medicines & 
consumables, diagnostics, 
consultation fees, special foods / 
supplements, inpatient 
accommodation 
Transport for individual & 
companion, medicines & 
consumables, diagnostics, 
consultation fees, special foods / 
supplements, inpatient 
accommodation 
Medicines & consumables, 
consultation fees, ultrasound, 
informal payments, pre-referral 
costs, hospitalisation 
Transport and ‘other’ costs  
Recall period (costs) The last visit to each provider 
(variable; max 5 months) 
The last month ~1 day  
(interviewed on discharge) 
1 day  
(cost of visit only) 
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Household / individual costs Individual and companion Individual and guardian/ 
caregiver 
Individual Individual and companion 
Average length of interview ~ 60 minutes  ~ 45 minutes ~ 20 minutes ~ 25 minutes 
Diary/Recall Recall Recall Recall Recall 
Indirect cost measurement  Human capital approach Income loss None Human capital approach 
Additional health services 
costed 
Pharmacy, GP, outpatient 
hospital, inpatient hospital, 
traditional healer 
Pharmacy, GP, outpatient 
hospital, inpatient hospital, 
traditional healer 
None  None 
Income data? (proxy) Individual income  
before diagnosis (3-5 months 
prior to interview) 
Annual individual income None  
(GDP per capita) 
Individual level income in last 
month 
Interviewers used  Research assistants Nurses and Research assistants Trained female interviewers Trained field workers 
Medium of recording Paper survey Electronic survey Paper survey Paper survey 
Mean cost (95% CI) Monthly OOP expenditures: 
$25.82 ($16.33 - $35.33) 
Monthly opportunity costs of 
time: 
$43.36 ($32.64 – $54.08) 
Monthly income loss: 
$13.70 ($12.03 – $15.38) 
Total OOP expenditures: 
$111.83 
Total loan interest: $43.32 
Reported income loss: $54.82 
Total guardian costs: $32.11 
Total carer costs: $81.99 
Total episode cost: $324.07 
Total OOP expenditures  
associated with abortion:  
$52.80 ($47.36 – $58.24) 
OOP expenditures for one visit to 
study facility: 
$1.96 ($1.80 – $2.13) 
Average annual income 
(95% CI) 
$ 2,564.96 
($2,224.90 - $2,905.03) 
$1,237.44 
($1,000.88 - $1,474.00) 
Not measured 
(GDP per capita used as proxy) 
Tanzania: $244.24  
($212.25 – 276.23) 
Zambia: $218.88  
($198.94 – 238.82) 
Nationally-defined poverty 
line (annual income) 
$773.39 $773.39 $183.60 Tanzania: $233.60 
Zambia: $266.45 
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GDP per capita 
(annual) 
$6.617.91 $6.617.91 $530.50 Tanzania: $694.77 
Zambia: $1,844.80 
Frequency of catastrophic 
expenditure  
(20% threshold) 
40%  
(36% - 45%) 
59%  
(54% - 65%) 
10%  
(6% - 14%) 
4%  
(3% - 5%) 
Minimum sample size 
required to estimate 
proportion of catastrophic 
expenditure with 95% 
confidence 
Error margin 5%: 2,282 
Error margin 10%: 570 
Error margin 15%: 254 
Error margin 5%: 1,057 
Error margin 10%: 264 
Error margin 15%: 117 
Error margin 5%: 13,689 
Error margin 10%: 3,422 
Error margin 15%: 1,521 
Error margin 5%: 36,504 
Error margin 10%: 9,126 
Error margin 15%: 4,056 
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In the XTEND and MERGE case studies, respondents consistently reported themselves to be 
the primary breadwinners in the household; personal income was therefore collected, with 
the limitation that these analyses may have underestimated the economic burden on the 
family as they did not account for the fact that income is shared amongst household 
members. On the other hand, within the ECONPOP sample respondents were often not the 
primary breadwinners and often could not estimate household income. The decision was 
therefore made to use an assumption of gross domestic product (GDP) per capita as a 
proxy rather than risk breaking the confidentiality of the interview by asking family 
members. This decision has implications for the metrics used, as in this case we did not 
have a firm understanding of where households lay in relation to the poverty line at 
baseline – and therefore would not have been able to report on impoverishing 
expenditures.  
Where a trial is unable to collect income directly, researchers may also use asset indices as 
a proxy measure of household socio-economic position. Information on assets can be 
simpler to collect than income or consumption, but result in ordinal data. In order to 
convert an asset index into monetary terms (Ferguson et al., 2003), necessary for the 
denominator of threshold metrics such as catastrophic or impoverishing expenditures, 
these data need to be mapped to an absolute wealth metric (Howe et al., 2012; Hruschka, 
Hadley, Gerkey, & Hadley, 2015). This may pose issues if income diversity in the population 
of interest is substantially different from that of the national population. 
TIMEFRAME 
Deciding on the appropriate timing for the survey may also be difficult in a study where 
survey timing is based primarily on outcome measurement. The clinical pathways for some 
types of illness (for example TB) can be long and complex, making recall bias a significant 
concern. This is illustrated in the XTEND survey; where patients enrolled in the trial could 
only be interviewed at the end of the 6 month follow-up date. To accommodate this, an 
additional sample of those on TB treatment outside the trial enrolees were also surveyed 
to increase sample size and allow for shorter recall periods between interviews. When 
capturing income loss as a result of illness in the case of complex clinical pathways, 
researchers will also need to weigh the risks of recall bias against the anticipated benefit of 
soliciting information on income before the illness. 
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There is also the potential for cost truncation in chronic illness or conditions with 
complications. The long-term economic impact of illness can be substantial (P. Ilboudo, 
Russell, & D’Exelle, 2013). This can be captured by following a cohort along the clinical 
pathway (as in the XTEND study), or with follow-up surveys conducted later (P. Ilboudo et 
al., 2013). However, it is a particular problem for lifelong treatments such as anti-retroviral 
therapy.  
Finally, dissaving or other coping strategies can also be an important reflection of the long-
term impact of illness (Wilkes et al., 1997), and where possible it may be helpful to include 
questions on coping strategies in the survey. Surveys may directly ask how households 
mobilized payment for health care services (Flores et al., 2008), or longitudinal surveys may 
be able to conduct repeated asset surveys, capturing any depletion of assets caused by 
illness (P. Ilboudo et al., 2013). This is only a partial measure of the economic impact of 
illness on households, however it is a useful proxy where income measurement is 
impossible or the poverty line unknown. 
SAMPLE SIZE AND REPRESENTATIVENESS 
Sample size considerations are key in the planning stages of a study, and will depend on the 
aims, nature, and scope of the study, and the degree of precision (confidence interval and 
margin of error) deemed appropriate (Lwanga & Lemeshow, 1991). Household surveys 
generally follow United Nations guidelines of a 5-10% margin of error at the 95% 
confidence interval, with further adjustment to account for clustering and non-response 
(United Nations Statistical Division, 2008). However this degree of precision may be difficult 
to achieve in an intervention-based context and researchers need to be pragmatic. Some 
trade-off in error margin will likely need to be made in the interests of practicality of the 
survey; this is especially true for outcomes which are particularly rare in the population of 
interest, as illustrated in Table 6-1. This decision should also be taken within the context of 
the larger uncertainty associated with the survey – for example, spending more time in the 
interview to avoid recall bias may produce more reliable results than spending additional 
time interviewing a great many more patients. 
In each of our case studies, the sampling for OOP expenditures was restricted due to 
practical considerations of the study – for MERGE, XTEND and ECONPOP a sub-sample of 
the study population was taken, while in REMSTART the number of follow-up visits was 
limited. Table 6-1 shows the sample size for each case study, and the ideal sample sizes 
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necessary for various specifications of relative precision to estimate catastrophic 
expenditure.  
Sampling considerations pose particular issues for the estimation of impoverishing 
expenditures when most patients are already below the poverty line – for example where 
targeting those already in poverty may be a desired feature of interventions or where 
investigating diseases such as HIV and TB, which disproportionately affect those below the 
poverty line (Bates et al., 2004). When this is the case, impoverishment becomes 
infrequent, making power to detect the true proportion of impoverishment very low; a 
different metric of poverty impact should be used in these cases. All three case studies 
estimating income had a large proportion of poor patients: 64% of XTEND patients, 45% of 
MERGE patients and 70% of REMSTART patients had a pre-diagnosis income below the 
national poverty lines (Chibuye, 2014; Laokri et al., 2013; OECD, 2013; Statistics South 
Africa, 2014).  
DATA SOURCES AND SURVEY ADMINISTRATION 
Finally, researchers will need to identify data sources and plan administration of the survey. 
DIRUM researchers working in a high-income country setting (Ridyard, Hughes, & DIRUM 
Team, 2015) propose a taxonomy for methods of resource use measurement (RUM) 
including: the source of data, who completes the RUM, how it is administered, how it is 
recorded, and the medium of recording. Work in LMICs requires some additional 
consideration, described below.  
Cost diaries are considered to be the gold standard in patient cost collection (Goossens, 
Rutten-van Molken, Vlaeyen, & Van Der Linden, 2000; Wiseman, Conteh, & Matovu, 2005), 
but they can be time- and cost-intensive for researchers, especially where there is high 
illiteracy; patient recall is more common in low-income settings (Beegle, De Weerdt, 
Friedman, & Gibson, 2012). This can be supplemented with geographic information system 
(GIS) or other mapping data to facilitate estimation and verification of travel costs where 
patients are unable to estimate distances (Siedner et al., 2013), and retrospective records 
review can also combat recall bias in the case of frequent health facility visits (Das, 
Hammer, & Sánchez-Paramo, 2012). Information on resource use can also be matched with 
price data to minimize recall bias, however in LMIC there is much wider variation in price 
and market prices may not accurately reflect the economic value of resources (Hutton & 
Baltussen, 2005).  
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There may also be a distinction in survey quality depending on the interviewer and where 
the interview takes place. Independent research assistants may be preferable to nurses if 
the subject material is sensitive. Individual income and spending can be sensitive, and 
patients may be inclined to under- or over-report income if the purpose of the interview is 
not well understood (Morris, Carletto, Hoddinott, & Christiaensen, 2000). Using 
interviewers who understand the principles and rationale for collecting patient costs also 
substantially affects the quality of the data; for example the MERGE study initially 
experienced poor data quality, which improved after retraining interviewers. Similarly, the 
location of the interview will affect data quality; perceived privacy will impact patient recall 
and willingness to disclose details on income and spending. 
Finally, the medium of recording will require particular consideration in LMICs. Electronic or 
telephone surveys may facilitate survey completion (Walther et al., 2011), but will require 
some further training of interviewers in data entry and security, and planning for power 
and connectivity issues in fieldwork. 
DISCUSSION 
Using the four case studies above, we have highlighted important considerations in 
measuring patient costs and income in order to estimate the impact of illness on economic 
vulnerability in intervention-based contexts in LMICs.  
Poverty impact metrics are currently data-hungry and are therefore often excluded from 
study surveys due to time- and budgetary constraints in a research study. Going forward in 
these settings, economists first and foremost have a responsibility to communicate data 
requirements in the study design phase and advocate for the collection of patient cost data 
as an essential part of the economic evaluation. Additional information on patient costs 
and the poverty impact of health spending is more costly to collect, but these forms of 
analysis are increasingly important to policy makers and programme planners and 
therefore have a high value of information. 
Inevitably some degree of variation in methods will occur across studies where context and 
data availability vary. Economists therefore also must communicate with each other where 
different approaches are possible, or where compromise as to the gold standard of data 
collection may be managed. Robust reporting of data collection methods can help other 
researchers understand and interpret findings, and facilitates standardization of methods. 
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Our recommendations for reporting data collection methods for patient costs are 
summarized in Table 6-2.  
Finally, it may be possible to minimize the additional cost of collecting patient cost and 
poverty impact data, through restricting data needs and clarifying where alternative 
methods are acceptable. Several alternative methodological approaches are available, and 
researchers must weigh the limitations of potential alternatives in their own setting. The 
potential advantages and limitations of various methodological approaches are described 
in Figure 6-1. We advocate for further methodological work to investigate the means to 
minimize the impact of cost ingredient aggregation, cost truncation, and other forms of 
compromise when planning poverty impact studies in LMICs, and investigate the external 
validity of results that parallel effect estimates particularly in clinical trials.  
This supplement confirms the increasing implementation and sophistication of economic 
evaluation in LMICs (Harker & Others, 2015; Pitt & others, 2016). Going forward in these 
settings, evaluations need to tackle policy concerns around equity and poverty. 
Researchers should be challenged to address fundamental data gaps for measuring the 
impact of illness on economic vulnerability through stronger reporting of methods and 
further methodological work.  
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Table 6-2 Framework for planning/reporting data collection 
STUDY PLANNING COMPONENT ITEMS FOR CONSIDERATION 
COMPREHENSIVENESS  
OF SURVEY DESIGN  
• Which OOP expenditures are included? 
• What is the level of disaggregation in cost ingredients and how long is the survey? 
• Are any context-specific variables included? 
• How is income measured, and whose income is collected (i.e. personal or household income)?  
TIMEFRAME &  
RECALL PERIOD 
• What is the recall period for the survey? Is it appropriate to capture all economic outcomes? 
• What is the complexity of the disease pathway? Is there resulting potential for recall bias? 
• Is there a potential for cost truncation in the context of chronic disease and/or future complications? 
• Are coping strategies used to estimate the long-term economic impact of health spending? 
• What is the recall period for income measurement (i.e. current vs. pre-diagnosis)? 
SAMPLE SIZE • What is the confidence interval and margin of error deemed acceptable? 
• If estimating impoverishing expenditures, what is the distribution of pre-diagnosis income below the poverty line? 
• Are any adjustments to sample size required to account for clustering, or non-response? 
DATA SOURCE & 
ADMINISTRATION 
• Is a cost diary or recall used to capture expenditures? 
• Is data supplemented with any additional data sources, such as retrospective records review or GIS data? 
• Where is the interview conducted, and by whom? 
• What is the medium of collecting and recording data (i.e. electronic, paper, or telephone surveys) 
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Figure 6-1 Potential Advantages & Limitations of Alternative Approaches in Data Collection 
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Figure 6-1 (cont) 
  
Page 113 of 276 
 
ACKNOWLEDGEMENTS 
The authors are grateful to the study teams for the MERGE, XTEND, REMSTART and 
ECONPOP trials for use of their data and for their insight on challenges encountered in data 
collection. The MERGE study team includes Tendesayi Kufa, Piotr Hippner, Salome 
Charalambous, Katherine Fielding, Alison Grant, and Gavin Churchyard. The ECONPOP 
study team includes Johanne Sundby, Katerini T Storeng, Ouattara Fatoumata, Hanne 
Lichtwark, Drabo Seydou, Ramatou Ouédraogo, Patrick Ilboudo and Torsvik Gaute. The 
XTEND study team includes Susan Cleary, Lucy Cunnama, Gavin Churchyard and Edina 
Sinanovic. The REMSTART study team includes Sode Matiku, Bernard Ngowi, Duncan 
Chanda, Sokoine Lesikari, Christian Bottomley, Saidi Egwaga, Amos Kahwa, Peter Mwaba, 
Sayoki Mfinanga, and Shabbar Jaffar. In addition, the authors are grateful to Catherine Pitt 
and Ulla Griffiths for their comments on an early draft of this letter 
 
DECLARATIONS 
This work draws on experience from case studies which have been previously published, 
however all methodological recommendations and other work associated with this letter 
are original, and have not previously been published. 
The authors declare no conflicts of interest. 
No ethical approval was required for this work, as it draws only on secondary data. All case 
studies presented in this letter obtained ethical approval for data collection; ethics 
statements for these studies can be found in their corresponding research articles. All case 
studies gave approval for their findings to be included in this letter. 
Page 114 of 276 
 
REFERENCES 
Alam, K., & Mahal, A. (2014). Economic impacts of health shocks on households in low and 
middle income countries: A review of the literature. Globalization and Health, 10(1), 
21. http://doi.org/10.1186/1744-8603-10-21 
Asaria, M., Griffin, S., Cookson, R., Whyte, S., & Tappenden, P. (2015). Distributional cost-
effectiveness analysis of health care programmes – a methodological case study of 
the UK bowel cancer screening programme. Health Economics, 24, 742–754. 
http://doi.org/10.1002/hec 
Barter, D. M., Agboola, S. O., Murray, M. B., & Bärnighausen, T. (2012). Tuberculosis and 
poverty: The contribution of patient costs in sub-Saharan Africa - A systematic review. 
BMC Public Health, 12(1), 980. http://doi.org/10.1186/1471-2458-12-980 
Bates, I., Fenton, C., Gruber, J., Lalloo, D., Lara, A. M., Squire, S. B., … Tolhurst, R. (2004). 
Vulnerability to malaria, tuberculosis, and HIV/AIDS infection and disease. Part II: 
Determinants operating at environmental and institutional level. Lancet Infectious 
Diseases. Elsevier. http://doi.org/10.1016/S1473-3099(04)01047-3 
Beegle, K., De Weerdt, J., Friedman, J., & Gibson, J. (2012). Methods of household 
consumption measurement through surveys: Experimental results from Tanzania. 
Journal of Development Economics, 98(1), 3–18. 
http://doi.org/10.1016/j.jdeveco.2011.11.001 
Bill and Melinda Gates Foundation, Nice International, University of York Centre for Health 
Economics, & Health Intervention and Technology Assessment Program (Thailand). 
(2014). Bill and Melinda Gates Foundation Methods for Economic Evaluation Project: 
Final Report, (January), 1–68. 
Chibuye, M. (2014). Interrogating urban poverty lines–the case of Zambia. Environment and 
Urbanization, 0956247813519047. 
Chuma, J. M., Thiede, M., & Molyneux, C. S. (2006). Rethinking the economic costs of 
malaria at the household level: Evidence from applying a new analytical framework in 
rural Kenya. Malaria Journal, 5, 76. http://doi.org/10.1186/1475-2875-5-76 
Das, J., Hammer, J., & Sánchez-Paramo, C. (2012). The impact of recall periods on reported 
morbidity and health seeking behavior. Journal of Development Economics, 98(1), 76–
88. http://doi.org/10.1016/j.jdeveco.2011.07.001 
Deaton, A. (1997). The analysis of household surveys: A microeconometric approach to 
development policy. The International Bank for Reconstruction and Development / The 
World Bank. Baltimore and London: Johns Hopkins University Press. 
http://doi.org/doi:10.1596/0-8018-5254-4 
Drummond, M. F., & Jefferson, T. O. (1996). Guidelines for authors and peer reviewers of 
economic submissions to the BMJ. British Medical Journal, 313(August), 275–283. 
http://doi.org/http://dx.doi.org/10.1136/bmj.313.7052.275 
Ferguson, B. D., Tandon, A., Gakidou, E., & Murray, C. J. L. (2003). Estimating permanent 
income using indicator variables. Health systems performance assessment: debates, 
methods and empiricism. Geneva, Switzerland: World Health Organization. 
Flores, G., Krishnakumar, J., O’Donnell, O., & Van Doorslaer, E. (2008). Coping with health-
Page 115 of 276 
 
care costs: Implications for the measurement of catastrophic expenditures and 
poverty. Health Economics, 17(12), 1393–1412. http://doi.org/10.1002/hec.1338 
Foster, N., Vassall, A., Cleary, S., Cunnama, L., Churchyard, G., & Sinanovic, E. (2015). The 
economic burden of TB diagnosis and treatment in South Africa. Social Science and 
Medicine, 130, 42–50. http://doi.org/10.1016/j.socscimed.2015.01.046 
Goossens, M. M. E. J. B., Rutten-van Molken, M., Vlaeyen, J. J. W. S., & Van Der Linden, S. S. 
M. J. P. (2000). The cost diary: A method to measure direct and indirect costs in cost-
effectiveness research. Journal of Clinical Epidemiology, 53(7), 688–695. 
http://doi.org/10.1016/S0895-4356(99)00177-8 
Harker, M., & Others. (2015). A systematic review of the use of QALYs in economic 
evaluations in low- and middle-income countries. Health Economics, [Submitted. 
Howe, L. D., Galobardes, B., Matijasevich, A., Gordon, D., Johnston, D., Onwujekwe, O., … 
Hargreaves, J. R. (2012). Measuring socio-economic position for epidemiological 
studies in low-and middle-income countries: A methods of measurement in 
epidemiology paper. International Journal of Epidemiology, 41(3), 871–886. 
http://doi.org/10.1093/ije/dys037 
Hruschka, D. J., Hadley, C., Gerkey, D., & Hadley, C. (2015). Estimating the absolute wealth 
of households. Bull World Health Organ, 93(May), 483–490. 
http://doi.org/10.2471/BLT.14.147082 
Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., … Loder, E. 
(2013). Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 
statement. European Journal of Health Economics, 14(1), 367–372. 
http://doi.org/10.1007/s10198-013-0471-6 
Hutton, G., & Baltussen, R. (2005). Cost valuation in resource-poor settings. Health Policy 
Plan, 20(4), 252–259. http://doi.org/10.1093/heapol/czi025 
Ilboudo, P. G. C., Greco, G., Sundby, J., & Torsvik, G. (2014). Costs and consequences of 
abortions to women and their households: a cross-sectional study in Ouagadougou, 
Burkina Faso. Health Policy and Planning, 30(4), 1–8. 
http://doi.org/10.1093/heapol/czu025 
Ilboudo, P., Russell, S., & D’Exelle, B. (2013). The Long Term Economic Impact of Severe 
Obstetric Complications for Women and Their Children in BurkinaFaso. Plos One, 
8(11). 
Kankeu, H. T., Saksena, P., Xu, K., & Evans, D. B. (2013). The financial burden from non-
communicable diseases in low- and middle-income countries: a literature review. 
Health Research Policy and Systems, 11(1), 31. http://doi.org/10.1186/1478-4505-11-
31 
Kruk, M. E., Goldmann, E., & Galea, S. (2009). Borrowing and selling to pay for health care 
in low- and middle-income countries. Health Affairs (Project Hope), 28(4), 1056–66. 
http://doi.org/10.1377/hlthaff.28.4.1056 
Kufa, T., Hippner, P., Charalambous, S., Kielmann, K., Vassall, A., Churchyard, G. J., … 
Fielding, K. L. (2014). A cluster randomised trial to evaluate the effect of optimising 
TB/HIV integration on patient level outcomes: The “MERGE” trial protocol. 
Contemporary Clinical Trials, 39(2), 280–287. 
http://doi.org/10.1016/j.cct.2014.10.003 
Page 116 of 276 
 
Laokri, S., Drabo, M. K., Weil, O., Kafando, B., Dembélé, S. M., & Dujardin, B. (2013). 
Patients are paying too much for tuberculosis: a direct cost-burden evaluation in 
Burkina Faso. PloS One, 8(2), e56752. http://doi.org/10.1371/journal.pone.0056752 
Lu, C., Chin, B., Li, G., & Murray, C. J. L. (2009). Limitations of methods for measuring out-
of-pocket and catastrophic private health expenditures. Bulletin of the World Health 
Organization, 87(3), 238–244. http://doi.org/10.2471/BLT.08.054379 
Lwanga, S. K., & Lemeshow, S. (1991). Sample size determination in health studies: a 
practical manual. 
McIntyre, D., Thiede, M., Dahlgren, G., & Whitehead, M. (2006). What are the economic 
consequences for households of illness and of paying for health care in low- and 
middle-income country contexts? Social Science and Medicine. 
http://doi.org/10.1016/j.socscimed.2005.07.001 
Mfinanga, S., Chanda, D., Kivuyo, S. L., Guinness, L., Bottomley, C., Simms, V., … Jaffar, S. 
(2015). Cryptococcal meningitis screening and community-based early adherence 
support in people with advanced HIV infection starting antiretroviral therapy in 
Tanzania and Zambia: An open-label, randomised controlled trial. The Lancet, 
385(9983), 2173–2182. http://doi.org/10.1016/S0140-6736(15)60164-7 
Moreno-Serra, R., Millett, C., & Smith, P. C. (2011). Towards improved measurement of 
financial protection in health. PLoS Medicine, 8(9), e1001087. 
http://doi.org/10.1371/journal.pmed.1001087 
Morris, S. S., Carletto, C., Hoddinott, J., & Christiaensen, L. J. (2000). Validity of rapid 
estimates of household wealth and income for health surveys in rural Africa. Journal 
of Epidemiology and Community Health, 54(5), 381–387. 
Niëns, L. M., Brouwer, W. B. F., Niens, L. M., & Brouwer, W. B. F. (2013). Measuring the 
affordability of medicines: importance and challenges. Health Policy (Amsterdam, 
Netherlands), 112(1–2), 45–52. http://doi.org/10.1016/j.healthpol.2013.05.018 
Niëns, L. M., Cameron, A., Van de Poel, E., Ewen, M., Brouwer, W. B. F., & Laing, R. (2010). 
Quantifying the impoverishing effects of purchasing medicines: a cross-country 
comparison of the affordability of medicines in the developing world. PLoS Medicine, 
7(8). http://doi.org/10.1371/journal.pmed.1000333 
OECD (2013). Development co-operation report 2013: Ending poverty. OECD Publishing, 
Paris. 
Onoka, C. a., Onwujekwe, O. E., Hanson, K., & Uzochukwu, B. S. (2011). Examining 
catastrophic health expenditures at variable thresholds using household consumption 
expenditure diaries. Tropical Medicine and International Health, 16(10), 1334–1341. 
http://doi.org/10.1111/j.1365-3156.2011.02836.x 
Pal, R. (2012). Measuring incidence of catastrophic out-of-pocket health expenditure: with 
application to India. Int J Health Care Finance Econ, 12(1), 63–85. 
http://doi.org/10.1007/s10754-012-9103-4 
Pitt, C., & others. (2016). Economic evaluation in global perspective: a bibliometric analysis 
of the recent literature. Health Economics. 
Ridyard, C. H., Hughes, D. A., & DIRUM Team. (2015). Taxonomy for methods of resource 
use measurement. Health Economics, 24, 372–378. http://doi.org/10.1002/hec.3029 
Page 117 of 276 
 
Russell, S. (1996). Ability to pay for health care: concepts and evidence. Health Policy and 
Planning, 11(3), 219–237. http://doi.org/10.1093/heapol/11.3.219 
Saksena, P., Xu, K., & Durairaj, V. (2010). The drivers of catastrophic expenditure: 
outpatient services, hospitalization or medicines. World Health Report. 
Sauerborn, R., Adams, A., & Hien, M. (1996). Household strategies to cope with the 
economic costs of illness. Social Science and Medicine, 43(3), 291–301. 
http://doi.org/10.1016/0277-9536(95)00375-4 
Siedner, M. J., Lankowski, A., Tsai, A. C., Muzoora, C., Martin, J. N., Hunt, P. W., … 
Bangsberg, D. R. (2013). GPS-measured distance to clinic, but not self-reported 
transportation factors, are associated with missed HIV clinic visits in rural Uganda. 
AIDS (London, England), 27(9), 1503. 
Sixty-fourth World Health Assembly (2011). Sustainable health financing structures and 
universal coverage, (May), 4–7. 
Statistics South Africa. (2014). Poverty Trends in South Africa: An examination of absolute 
poverty between 2006 and 2001. Pretoria. Retrieved from www.statssa.gov.za 
Tanimura, T., Jaramillo, E., Weil, D., Raviglione, M., & Lönnroth, K. (2014). Financial burden 
for tuberculosis patients in low- and middle-income countries: a systematic review. 
European Respiratory Journal, 43(6), 1763–1775. 
http://doi.org/10.1183/09031936.00193413 
United Nations Statistical Division. (2008). Designing household survey samples: practical 
guidelines (Vol. 98). United Nations Publications. 
Verguet, S., Laxminarayan, R., & Jamison, D. T. (2015). Universal public finance of 
Tuberculosis treatment in India: an Extended Cost-Effectiveness Analysis. Health 
Economics, 24, 318–332. 
Wagstaff, A. (2008). Measuring financial protection in health (Policy Research Working 
Paper Series No. 4554). Washington, D.C. 
Wagstaff, A., & Eozenou, P. (2014). CATA Meets IMPOV A Unified Approach to Measuring 
Financial Protection in Health. World Bank Policy Research Working …, (May). 
http://doi.org/10.1596/1813-9450-6861 
Wagstaff, A., & van Doorslaer, E. (2003). Catastrophe and impoverishment in paying for 
health care: With applications to Vietnam 1993-1998. Health Economics, 12(11), 921–
934. http://doi.org/10.1002/hec.776 
Walther, B., Hossin, S., Townend, J., Abernethy, N., Parker, D., & Jeffries, D. (2011). 
Comparison of electronic data capture (EDC) with the standard data capture method 
for clinical trial data. PloS One, 6(9), e25348. 
Wilkes, A., Hao, Y., Bloom, G., Xingyuan, G., Yu, H., Bloom, G., … Xingyuan, G. (1997). 
Coping With the Costs of Severe Illness in Rural China. Seven, 100(1415), 1–27. 
Retrieved from http://www.ids.ac.uk/files/Wp58.pdf 
Wingfield, T., Boccia, D., Tovar, M., Gavino, A., Zevallos, K., Montoya, R., … Evans, C. A. 
(2014). Defining Catastrophic Costs and Comparing Their Importance for Adverse 
Tuberculosis Outcome with Multi-Drug Resistance: A Prospective Cohort Study, Peru. 
PLoS Medicine, 11(7), e1001675. http://doi.org/10.1371/journal.pmed.1001675 
Wiseman, V., Conteh, L., & Matovu, F. (2005). Using diaries to collect data in resource-poor 
Page 118 of 276 
 
settings: Questions on design and implementation. Health Policy and Planning, 20(6), 
394–404. http://doi.org/10.1093/heapol/czi042 
World Health Organization. (n.d.). WHO National Health Accounts. Retrieved from 
http://www.who.int/health-accounts/en/ 
Xu, K., Evans, D. B., Kawabata, K., Zeramdini, R., Klavus, J., & Murray, C. J. L. (2003). 
Household catastrophic health expenditure: a multicountry analysis. Lancet, 
362(9378), 111–117. http://doi.org/10.1016/S0140-6736(03)13861-5 
 
  
Page 119 of 276 
 
CHAPTER 7. MEASURING AND VALUING PATIENT 
COSTS IN GLOBAL HEALTH: BIBLIOMETRIC 
REVIEW 
PREAMBLE FOR CHAPTER 
Research Papers #1 and #2 show that the process of estimating patient costs in LMIC 
settings comes with particular challenges, and therefore requires guidance which is 
relevant to this setting. As part of my work as a Research Fellow at LSHTM, I conducted a 
scoping exercise to evaluate the extent of existing guidance on collecting cost data in 2016 
for the Global Health Cost Consortium. This work helped to justify and set the frame for the 
GHCC Reference Case for Estimating the Costs of Global Health Services and Interventions. 
This chapter expands the searches conducted in the above-described exercise to focus 
specifically on guidance for estimating patient cost, and its applicability and accessibility to 
researchers working in LMIC settings. This chapter aims to answer many of the same 
questions that the original exercise addressed, evaluating to what extent current guidance 
is meeting the needs of researchers collecting patient costs, particularly those researchers 
working in LMICs.  
Good costing guidance would facilitate researchers to achieve these desirable properties in 
their work, through a process that is fit for purpose and efficient given the funding and data 
available. Guidance would ideally reflect a consensus in the topic, drawing together 
methodological findings by a community of researchers in order to facilitate 
methodological choices in designing a costing study. Finally, and importantly, guidance 
must be available and accessible to researchers operating in the field and reflected in the 
methods used for costing studies. 
This chapter focuses on four characteristics to evaluate the current guidance: availability, 
accessibility, relevance and use. I conducted a systematic search and bibliometric analysis 
of any existing published literature on methods for estimating patient costs. I found that 
although there were a large number of papers, there were few that were accessible or 
relevant to a low- or middle-income setting or available to researchers working in LMIC 
settings. I highlight a need for improved discussion on methods for patient costing across 
the different institutions and agencies working on the topic. I also call for improved 
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accessibility to methodological guidance for researchers working in low- and middle-
income countries.  
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MEASURING AND VALUING PATIENT COSTS IN GLOBAL HEALTH: A 
BIBLIOMETRIC REVIEW 
INTRODUCTION 
Chapter 2 of this thesis has described the current understanding of the state of the art in 
estimating costs and capacity to pay for health care, drawing on the available guidance in 
the literature on methods for estimating health-related costs from the household 
perspective. As noted in the GHCC Reference Case for Estimating the Costs of Global Health 
Services and Interventions, several properties are desirable in a ‘good’ cost estimate [1]. 
These include accuracy, precision, generalizability, transferability, comparability, and 
reliability.  
However, as noted in Chapter 6, practical constraints for many studies prevent the 
implementation of ‘gold standard’ methods. For example, the diary method is considered 
the ‘gold standard’ for the estimation of direct costs. However, it is rarely used in patient 
costing studies in LMIC settings as it is expensive, requires literacy, and participant fatigue 
is likely [2]. Recall is more commonly used, introducing the potential for bias in 
measurement. Large sample sizes are also often not possible as they may increase the cost 
of data collection and deviate from the main study design; researchers therefore often 
need to make a trade-off between sample size and interview length and depth.  
This is often exacerbated in LMIC settings. As noted by Briggs [3], there are often 
differences in methodology adopted by researchers working in LMIC settings as compared 
to those working in high-income country (HIC) settings, resulting from different contexts. 
For example, in an LMIC context, out-of-pocket payments for health services often account 
for a higher percentage of total health financing and there is often insufficient 
infrastructure for routine data collection to track out-of-pocket spending on specific health 
conditions. Concerns about recall bias in estimation of resource use are more pertinent in 
LMIC settings where retrospective records review often isn’t an option, and where the 
diary method of estimating resource use is difficult to implement due to low levels of 
literacy [2,4]. Valuation of patient time for indirect costs may be different in LMIC settings, 
where informal employment is common and income is often seasonal. Wider variation in 
market prices in LMIC settings may make it more difficult to accurately reflect the 
economic value of resources [5]. Finally, the economic impact of household spending on 
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health care may need to be understood differently in LMIC settings as compared to HIC 
settings. There is lower access to risk pooling mechanisms and other forms of ex-ante 
limitation of exposure to income shocks, increasing the need for coping strategy use. 
As discussed in Chapter 6 of this thesis, in some cases researchers collecting patient cost 
data as part of studies evaluating costs and impacts of health treatment and interventions 
in LMIC settings will need to make compromises in methodology because of cost concerns 
and convenience. These compromises in methods are often unavoidable, and if taken 
appropriately they do not necessarily introduce bias into cost estimates. However, it is 
important that researchers understand and describe the impact of any methodological 
compromises made on the likely bias of the data. Transparency in data collection for 
economic evaluation is critical, and presentation of cost data should be accompanied with 
a full, detailed description of how the data were estimated to prevent misuse or 
misapplication of the data for other purposes [1]. It is essential that these choices are made 
with a full understanding of how the chosen approach might introduce bias into cost 
estimates.  
As discussed in Chapter 2, this is often not the case with patient costing studies. Numerous 
literature reviews have highlighted difficulties in synthesizing findings across published 
patient cost estimates due to differences in methods, or lack of transparency in methods 
used [6–12]. This raises the question of whether current costing guidance is meeting the 
needs of researchers. As noted by the DIRUM project, methods for collecting economic 
data are disparate, mostly un-validated, and challenging to obtain – causing health 
economists in all settings to repeatedly “reinvent the wheel” in development of 
questionnaires and tools to estimate costs of health-related services [13]. Good costing 
guidance would facilitate researchers to achieve these desirable properties in their work, 
through a process that is fit for purpose and efficient given the funding and data available. 
Guidance would ideally reflect a consensus in the topic, drawing together methodological 
findings by a community of researchers in order to facilitate methodological choices in 
designing a costing study. Finally, and importantly, guidance must be available and 
accessible to researchers operating in the field and reflected in the methods used for 
costing studies.  
The aim of this paper is to understand which, if any, methodological resources are 
available, accessible, and relevant to researchers estimating disease-specific patient costs 
in LMIC settings, to what degree the evolution of costing methods has involved the LMIC 
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context, and to what degree the available guidance has been used in collecting disease-
specific patient cost data in LMIC settings with specific reference to TB. The objectives were 
twofold: to conduct a bibliometric review of patient costing guidance and to evaluate the 
use of patient costing guidance for TB in LMICs.  
METHODS 
In order to address the aim of this paper, I took a bibliometric approach rather than 
conducting a systematic review. Bibliometric methods allow researchers to quantify and 
examine patterns in the generation, propagation, and use of large bodies of literature 
[14,15]. I do not seek to summarize the guidance to date or make recommendations on 
which methods are most appropriate, as several previous reviews have provided excellent 
summaries of the current state of the art for various steps in the costing process 
[Supplementary References 189-214]. I combine this with a critical review of guidance used 
in TB patient costing studies as a case study to evaluate the use of guidance in patient 
costing in this field and to inform the aims of the PhD. 
Bibliometric analysis  
Literature Searches 
Searches were structured to capture any guidance on methods for collecting patient- or 
household-incurred costs associated with poor health and included both peer-reviewed 
and grey literature sources. The search process involved two steps. In the first step, 
publications were drawn from a database of references compiled in order to inform the 
development of the GHCC Reference Case for Estimating the Costs of Global Health 
Services and Interventions [1]. This database was developed through a systematic search of 
six databases (Econlit, Global Health, Pubmed, Embase, IBSS, and Web of Science) as well 
as extensive snowball and manual searching for grey literature including Google Scholar 
and the websites of DIRUM, WHO, UNAIDS, and the World Bank. Searches used keywords 
relating to costing, cost collection, or cost estimation; combined with keywords relating to 
methods, guidance, standards, generalizability, validity, or comparability. This search aimed 
to capture any guidance on costing from any perspective for any disease, in any setting; 
guidance in this database was not necessarily specific to patient costing. There were no 
date or language restrictions placed on the search. 
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Preliminary analysis of this database revealed that several papers relating specifically to 
patient costing and estimation of productivity costs were not captured in the first search. I 
therefore conducted additional ‘patient-cost specific’ searches, using different keywords in 
the same databases and grey literature sources listed above. In this second search, I used 
keywords that were more specific to patient costing, including terms relating to: out of 
pocket, productivity, direct, indirect, cost, loss, burden, or expenditure. Search terms were 
adapted for each database, to account for differences in use of Boolean search terms and 
other factors. Additional health-related search terms were added for the Econlit database. 
There were no date or geographical restrictions made on searches, and articles written in 
languages other than English were included in the results. The full search terms and 
strategy is detailed in Appendix 1. Initial searches were also presented to a group of 
experts, who provided input on further references to include.  
Selection 
Article abstracts were screened for inclusion. In the abstract review stage, I included any 
references that were relevant to the collection of cost data from any perspective. I included 
any references containing original research or guidance applicable to researchers collecting 
costs for specific diseases. Publications not presenting original research or guidance in 
written format, including commentaries, conference abstracts, errata, protocols, costing 
tools without any accompanying documentation or guidance, and literature reviews were 
not included during the abstract review process. Existing literature reviews summarizing 
methods in costing or summarizing the current ‘state of the art’ in costing methods were 
not included if they did not add anything new in terms of methods or guidance for future 
work, although they were used for snowballing to ensure all relevant references were 
captured.  
References from the bibliometric review were imported into Excel and a second abstract 
review was conducted. On the second abstract review, guidance on methods estimating 
overall household expenditure, including articles from the topics of labour economics, 
agricultural economics, or other economic topics, were excluded unless they were directly 
related to health. Articles on methods for national household expenditure surveys 
(including DHS and WHS surveys and World Bank LSMS) were also excluded. I excluded 
references that gave guidance only on cost analysis, conducting economic evaluation or 
estimation of catastrophic or impoverishing cost if they did not also give guidance on 
collecting cost data. This includes a number of references amounting to an ongoing debate 
Page 125 of 276 
 
between the Erasmus group and the Washington Panel as to whether productivity costs are 
included in the numerator or denominator within a CEA; see for example [16–25]. It also 
includes a number of papers about estimating the cost of illness – for example 
recommending whether to measure cost of illness through a net cost approach (counting 
specific disease-related costs of those known to have the disease) or a regression-based 
approach (counting all costs for all population, and factoring in disease as an explanatory 
variable); see for example [26–31].  
Extraction and analysis 
Bibliometric data for all included references were extracted using Web of Knowledge data 
where possible, and manually where reference details were unavailable on Web of 
Knowledge. Bibliometric data included: publication date, authors, title, journal name, 
author organization, and author country. All analysis was conducted in Microsoft Excel.  
Availability of guidance 
To understand the availability of methods guidance, I used information in study abstracts 
to sort references into five ‘topics’. Topics were defined following the broad structure of 
the GHCC reference case and conceptual framework described above, as: 1) broad costing 
guidance (articles which include guidance on multiple topics including study design, 
measurement, valuation, analysis, and/or reporting); 2) study design (including sampling, 
selection, type of cost, and/or costing perspective); 3) measurement of quantities of 
resources; 4) valuation of direct costs; 5) valuation of indirect costs; and 6) reporting cost 
estimates.  
I used information in study abstracts to extract information on study methods. I identified 
whether authors had used any form of analysis to support recommendations, or whether 
recommendations were theory-based alone. Types of analysis included: empirical 
comparison, case study, literature review, survey, and expert consultation. I summarized 
the number of references by method to indicate the degree to which methods 
development is driven by primary research vs theory alone. 
Accessibility of guidance 
To measure the accessibility of methods, I identified whether journals were ‘open access’ 
using the Directory of Open Access Journals. It was assumed that all grey literature and 
‘institutional’ publications (e.g. guidance developed and published by the World Health 
Organization or other similar institutions) were freely accessible online. Journals were 
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assigned to three classifications from Pitt, et al. [32]: biomedical journals; health 
economics, policy, services, and/or social science journals; and ‘other’ journals. 
Relevance of guidance 
Where possible, I used the study abstract to identify the study setting to determine if 
recommendations were particular to a high- or low-income country. For several papers, the 
study setting was not explicitly named in the abstract but all authors were from one 
country; in cases like these, the country of affiliation for authors was assumed to be the 
study setting. 
I used the full author list and affiliations for each paper to evaluate the degree to which 
each ‘topic’ was dominated by certain institutions, or by researchers in high-income vs low-
income settings. Institution names were cleaned where possible to allow for aggregation 
and counting of high-output institutions. On multi-author papers, each author was given 
equal credit for the paper. Similarly, each institution of author affiliation was counted 
equally – for example in papers with three authors all working at the same institution, that 
institution would be counted three times. 
Use of guidance in the development of costing methods 
To examine how the literature is being used, I then conducted a citation analysis based on 
the assumption that “the usage given a scientific periodical in any field may be measured 
by the number of times it is cited in the literature of the field” [33]. Citation information 
was drawn from two sources in order to understand how methods have developed and 
evolved over time. First, I gathered the total number of citations per reference per year 
using Google Scholar and Scopus. These reflect the impact that methods papers have had 
on the overall literature, including the degree to which certain methods recommendations 
have been adopted by practitioners in patient costing; these are referred to as ‘total 
citations’.  
Next, I gathered information on the number of times each reference was cited by other 
methods-focused papers on the same topic in order to understand the influence of 
different contributions on the evolution of ideas about methods for estimating costs. This 
data was extracted using the programme CitNetExplorer [34] or manually where this 
information was not available electronically. I termed these ‘methodological citations’, and 
used them as indicators of the degree of discussion between authors thinking about 
methods, and the degree to which particular authors and institutions influence the 
conversation about methods development.  
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I compared ‘total’ and ‘methodological’ citations to identify the correlation between the 
papers that have been widely adopted by practitioners and those which have contributed 
to further methods development. Where high ‘methodological’ citations and low ‘total’ 
citations are seen, this is an indication that while a paper may have had a high degree of 
influence on economic theory, this may not have been taken up by practitioners actually 
collecting cost data. Where high ‘total’ citations and low ‘methodological’ citations are 
seen, this is an indication that recommendations may be frequently adopted by 
practitioners of costing, but have not been recognized in the methodological literature or 
contributed to the progression of the economic theory behind the methods. 
I also used the programme CitNetExplorer to create a visualisation of a ‘citation network’. 
Citation networks display a field of citations arranged by publication, with lines 
representing the citation relations between publications. This depiction of citation relations 
helps to illustrate the development of the field over time. Citation networks are presented 
with papers classified by topic and by country income group. 
Use of guidance in practice: TB patient cost methods review 
Literature search and selection 
In order to understand the uptake of existing guidance by practitioners on estimating of 
disease-specific patient costs for TB, I conducted a review of all studies presenting patient 
costs for TB that have been published in the last 10 years (since 2008). These references 
were obtained from the GHCC Unit Cost Study Repository [35,36].  
Extraction and analysis 
For each study, I extracted any references made in the methods section relating to 
methods for data collection or analysis. Any guidance used in these studies were then 
documented and classified according to their source. Where authors stated that their 
costing methods were an adaptation of a previously used questionnaire with developed by 
the same authors but no other methods were cited, this was recorded as ‘adaptation of 
previously used questionnaire’. It was also noted whether the reference was relevant to 
patient costing. Any references identified were then classified according to the 
methodological area in which they provided guidance, including: study design / sampling, 
estimation of resource use for patient costs, valuation of direct costs, valuation of indirect 
costs, estimation of capacity to pay, and defining a threshold of affordability. 
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RESULTS 
Literature Search Results 
Searches returned a total of 9,912 titles, and I selected 749 papers for the abstract review. 
The full search and selection procedure is illustrated in Figure 7-1 (37). The abstract review 
excluded 372 references: 7 references were impossible to locate, 105 were irrelevant or 
unrelated to health costs, 76 did not discuss costing methods, and 77 were an excluded 
article type (literature review, commentary or conference abstract). Of the 422 papers 
extracted, 239 (57%) were excluded as they were relevant to costing only from a provider 
perspective, and 180 (43%) were deemed relevant to costing from a patient perspective 
and included in this review.  
Figure 7-1 Search and selection process 
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Availability of guidance 
The literature on methods for patient costing has seen enormous growth over time, and 
particularly over the last twenty years (Figure 7-2). The earliest article included was 
published in 1976. By the year 2016, there were 180 references providing guidance 
relevant to patient costing.  
I found 17 references which provided broad guidance for disease-specific costing 
[Supplementary references 1-17] and 11 references providing broad costing guidance that 
was relevant to any disease or service [Supplementary references 18-28]. I identified 87 
references giving guidance on estimating resource use [Supplementary references 29-115], 
45 references focused on valuation of indirect costs [Supplementary references 116-160], 
and 14 references focused on estimation of direct cost or solicitation of information about 
health-related expenditures [Supplementary references 172-185]. Only 2 references 
provided guidance on study design which was relevant to a patient perspective 
[Supplementary references 161, 162] and 2 references provided guidance on reporting 
patient cost data [Supplementary references 163, 164].  
The majority of references (139 of 180; 77%) were methodological papers focused on one 
single aspect of costing, for example investigating recall bias using different measurement 
approaches; all but one of these of these were peer-reviewed journal articles. Twenty-five 
(14%) of the papers included were purpose-written costing guidelines or guidelines 
associated with costing tools, focused on providing practical costing guidance to 
researchers collecting cost data; of these 7 were grey literature published by international 
agencies and available online, 16 were peer-reviewed journal articles, and 2 were book 
chapters. Eleven reports of costing studies with some methodological commentary and 5 
reviews of differences in costing methods across studies were also included; all of these 
were peer-reviewed journal articles. 
Broad costing guidance 
Broad costing guidance covering multiple topics (including study design, measurement, 
valuation, analysis and/or reporting) has been published in increasing numbers over the 
years. I found 28 references which provided broad guidance on multiple issues including 
study design, measurement, valuation, analysis and/or reporting of cost estimates 
[Supplementary references 1-28] (Further detail in Supplementary Table 7-1). The earliest 
reference in this topic was published in 1989 [Supplementary references 9]. Of these, 17 
were disease- or service-specific and 11 were general. Diseases included cystic fibrosis, 
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dengue, diarrheal diseases, HIV, malaria, mental health, and TB, while services included 
immunization, laparoscopic surgery, and vaccines. Twenty-six (93%) of the references were 
theory-based or based on the expertise of the authors; one provided empirical analysis 
underlying guidance on methods, one was based on a literature review. 
Figure 7-2 Availability of costing guidance over time 
 
Searches returned four references providing disease-specific guidance on estimating the 
patient- and household-incurred costs of TB, all of which were classified as ‘broad costing 
guidance’ [Supplementary references 12, 14, 16, 17]. Of these, three were grey literature 
references published by international agencies (e.g. WHO, UNAIDS, and the Bill and 
Melinda Gates Foundation) and freely available online [Supplementary references 14, 16, 
17], and one was published in a biomedical journal [Supplementary references 12].  
Study design 
I found two references relating to study design which were applicable to patient costing 
(Further detail in Supplementary Table 7-2). Both used a systematic review of the literature 
to comment on current practice in study design; one focused on sampling / statistical issues 
in economic evaluations [Supplementary references 161] and one focused on the selection 
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of the population for estimating costs of illness [Supplementary references 161]. Both were 
focused on high-income country settings.  
Estimating resource use (visits / time) 
I found 87 references addressing estimation of visits, time, or other resources used by the 
patient [Supplementary references 29-105, 107-114, 159, 165]; the earliest of these was 
published in 1979 [Supplementary references 55] (Further detail in Supplementary Table 7-
3). All 87 references on estimating resource use were published in academic journals; of 
which 54 were published in biomedical journals, 25 were published in health economics 
and/or social science journals, and 5 were published in other journals. 
When estimating quantities of health visits or resources used, the most commonly 
recommended options are self-reported resource use (recall), self-recorded resource use 
(diary), use of routinely collected administrative data, or use of expert panels 
[Supplementary references 166-171]. The large majority of references (68 of 86; 79%) 
compared self-reported health service utilization data with administrative data 
[Supplementary references 29, 32, 33, 36-38, 41-51, 54, 58, 60-64, 68, 70-75, 77-86, 88, 90-
94, 98-101, 105, 107, 108, 110-114]. Two references gave summaries of the current state of 
the art in estimating quantities of health service use; one published in 1999 
[Supplementary references 66] and one published in 2013 [Supplementary references 103]. 
Finally, 6 references provided guidance on estimating productivity loss 
[Supplementary references 31, 69, 97, 109, 159, 165], and 12 were on other topics. 
Within those references comparing self-reported resource use with other approaches, 
findings varied substantially. Twenty two references (32%) concluded that self-reported 
data was unreliable [Supplementary references 36, 43, 44, 48, 50, 61, 68, 74, 77, 80, 82, 84, 
85, 88, 90-93, 105, 108, 110, 114]; of these, 5 state in the abstract that patients over-report 
utilization [Supplementary references 50, 74, 88, 90, 92], and 9 state in the abstract that 
patients under-report utilization [Supplementary references 36, 44, 61, 80, 84, 91, 93, 108, 
110]. In contrast, 18 studies (26%) state in the abstract that self-reported data was reliable 
[Supplementary references 45-47, 49, 51, 62, 64, 72, 75, 78, 79, 83, 86, 98, 99, 101, 111, 
113], and 19 (28%) concluded that reliability varied by service type 
[Supplementary references 29, 32, 33, 37, 38, 41, 42, 54, 58, 60, 63, 70, 71, 73, 81, 94, 100, 
107, 112]. Sixteen of these studies were included in a systematic review in 2016 (38). The 
review found that within the six studies determined ‘high-quality’, self-reported resource 
use tended to be lower as compared to administrative data. Fifteen of the studies were 
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summarized in a second systematic review (39), which found that the validity of self-
reported resource use as compared to administrative data varied by instrument and by 
type of health resource.  
The vast majority of references concerning estimation of resource use (78 of 86 references; 
91%) use empirical comparison or validation to identify the most appropriate approach to 
measure quantities of health care visits. Supplementary Table 7-3 shows the total number 
of references for estimating resource use by analysis type and by the average number of 
internal and external citations per reference for each type.  
Valuation of direct cost / estimation of expenditures 
I found 14 papers providing some guidance on valuing direct costs from the patient 
perspective [Supplementary references 172-185] (Further detail in Supplementary Table 7-
4). Papers present guidance on data sources [Supplementary references 173, 175], 
measurement error associated with recall bias or survey design 
[Supplementary references 172, 177, 178, 180-185], allowing for market distortions when 
valuing cost in LMIC settings [Supplementary references 186], and survey timing 
[Supplementary references 176, 187]. 
Of the 16 studies providing guidance on valuing direct out-of-pocket health spending, 8 
contained some empirical comparison or validation, 2 presented results from an expert 
consultation, 1 presented results from a literature review, and 5 contained no analysis 
(Supplementary Table 7-4).  
Valuation of indirect costs 
I found 45 references addressing valuation of costs [Supplementary references 115-123, 
125-158, 160, 186], with the earliest reference published in 1985 
[Supplementary references 152] (Further detail in Supplementary Table 7-5). All references 
but one [Supplementary references 186] discuss the valuation of lost productivity or 
indirect costs in high-income settings. All references were published in peer-reviewed 
academic journals.  
The three most frequently recommended measurement approaches include the human 
capital approach (HCA), the friction cost approach (FCA), the willingness to pay approach 
(WTP) [Supplementary references 132, 136, 138, 142, 145, 146, 157]. The HCA model takes 
account of indirect costs of illness by measuring the monetary value of lost productivity – 
for example by measuring income loss due to a lost job or lost days of work, less uptake of 
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paid work, and the opportunity cost of time spent by caretakers providing informal care. 
The FCA, proposed by Koopmanschap in 1995, limits productivity costs to the ‘friction 
period’ before the ill person is replaced, and includes any lost productivity through 
presenteeism, lost productivity before a replacement is hired, and the costs of hiring and 
training a replacement worker. Finally, the WTP approach uses contingent valuation to 
solicit preferences of patients and their households. There is substantial literature devoted 
to the controversy surrounding choice between these methods for economic evaluation 
purposes [Supplementary references 123, 126, 127, 129, 130, 133, 135, 137, 144, 147, 150, 
153, 158]. There is also discussion in the literature around methods for valuing the time of 
housemakers [Supplementary references 116, 149] or informal caregivers 
[Supplementary references 119, 121, 125, 128, 148, 154, 156, 188], and valuing 
productivity loss without absence from work [Supplementary references 115, 120, 122, 
131, 139, 140, 143, 160]. Finally, there are several references which summarize the current 
state of the art [Supplementary references 132, 136, 138, 142, 145, 146, 157]. 
Of the 45 references, discussing methods for indirect costs, 24 are supported by some form 
of empirical analysis. An additional 7 conduct some other form of analysis; 5 show a 
worked example or case study, two are based on a literature review, and one reports 
results from an expert consultation. Thirteen references are theory-based.  
Reporting 
I found two studies providing guidance on reporting which was relevant to patient costing 
[Supplementary references 163, 164] (Further detail in Supplementary Table 7-6). Both 
were focused on reporting for economic evaluation in clinical trials, and both presented 
results from a literature review to illustrate their points.  
Accessibility of guidance 
References included two book chapters, 10 grey literature references published by 
international agencies (e.g. WHO, UNAIDS, and the Bill and Melinda Gates Foundation), and 
168 journal articles. Overall, only 20 of 180 (11%) references were published either in an 
open access journal or accessible as grey literature online; of these only one provided 
guidance specific to a LMIC setting.  
The majority of references were peer-reviewed, published in biomedical journals (81 
references) health economics, policy, services, and/or social science journals (78 
references), or other journals (9 references) (Table 7-1). The majority of journal articles 
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(103; 65%) provided some form of empirical comparison or validation; of these 8 were 
published in open-access journals [Supplementary references 10, 20, 54, 61, 68, 74, 86, 96, 
102, 104].  
Of the journal articles, 127 were specific to a high-income setting, 13 were relevant to any 
setting, and 9 were specific to a low- or middle-income setting. Of the 10 agency 
publications, 5 were relevant to any setting, 1 was specific to a high-income setting, and 1 
was specific to low- and middle-income settings. None of the agency publications 
supported their recommendations with any empirical analysis.  
Table 7-1 Accessibility of guidance 
 
Not open-access Open-Access 
 
Book 
chapter 
Journal 
article 
Agency 
publication 
Journal 
article 
What type of guidance exists?     
Methodological papers on one aspect of 
costing 
  132 1 6 
Purpose-written guidelines  2 13 7 3 
Costing study with methodological 
commentary 
  9   2 
Reviews of cost methods   4     
What topics does guidance cover? 
    
Broad costing guidance 2 15 7 4 
Estimating resource use 
 
80 
 
7 
Reporting 
 
2 
  
Study Design 
 
2 
  
Valuing direct costs 
 
15 1 
 
Valuing indirect costs 
 
44 
 
1 
What setting is guidance relevant to? 
    
High income 
 
135 1 9 
Low- and middle-income settings 
 
9 2 3 
All income levels (not country specific) 2 14 5 
 
Does any analysis underlie guidance? 
    
Case study / worked example 
 
11 
  
Empirical comparison / validation 
 
103 
 
8 
Expert consultation 
 
4 
  
Literature review 
 
9 
 
1 
No analysis (theory-based) 2 31 8 3 
 
The relevance of guidance to researchers in LMIC settings 
Across the literature, the majority of references (145 of 180; 80%) were conducted in or 
otherwise specific to a high-income country setting; of these, 66 were specific to a 
European or Central Asian country, and 65 were specific to a North American country 
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(Table 7-2). A further 21 references were not country-specific and applicable to any setting, 
while only 14 references were conducted in or specific to a low- or middle-income country.  
Of the 28 publications providing broad costing guidance, there were 18 authors from low- 
and middle-income countries, including Mexico, Brazil, Colombia, South Africa, El Salvador, 
France, Jamaica, Korea, Nigeria, Panama, Thailand, and Uganda. Twelve authors (10%) were 
from the Bill and Melinda Gates Foundation, and 7 (6%) were from the WHO. Other topics 
were dominated mainly by authors from high-income countries. Of the 58 authors 
providing guidance on valuing direct costs, 6 were from low- or middle-income countries, 
and of the 407 authors providing guidance on estimation of resource use, 1 was from a 
low- or middle-income country. All other authors were from high-income countries. 
Table 7-2 Relevance of Guidance 
 
High-income 
settings 
Low- and 
middle-
income 
settings 
All income 
settings 
(not country 
specific) 
What type of guidance exists? 
   
Methodological papers on one aspect of costing 125 5 9 
Purpose-written costing guidelines 6 8 11 
Costing study with methodological commentary 11 0 0 
Reviews of cost methods 3 1 1 
What costing purpose does guidance cover?    
Economic evaluation / priority setting 91 7 17 
Equity and poverty analyses 3 4 2 
Financial planning / management 0 2 1 
Purpose not specified / multiple purposes 51 1 1 
What topics does guidance cover?    
Broad costing guidance 9 8 11 
Estimating resource use 86  1 
Reporting 1  1 
Study Design 2   
Valuing direct costs 6 5 5 
Valuing indirect costs 41 1 3 
Does any analysis underlie guidance?    
Case study / worked example 10  1 
Empirical comparison / validation 107 3 1 
Expert consultation 2  2 
Literature review 7 1 2 
No analysis (theory-based) 19 10 16 
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Use of guidance in the development of costing methods 
The mean number of ‘total’ citations for all references was 64; this amounted to a mean of 
5 references per year (varying from 0 to 46.5). Articles providing insight into the valuation 
of indirect costs received the most citations per year (mean 6.5 citations per year), 
followed by broad costing guidance (mean 4.8 citations per year). The mean number of 
citations that articles received by other authors writing about costing methods 
(‘methodological citations’) was 2.19 (0.10 per year). The most ‘methodological citations’ 
were observed in papers on estimating resource use (mean 3.11; 0.18 per year) and 
valuation of indirect costs (mean 2.39; 0.17 per year). 
On average, the overview guides to costing received 54 total citations, amounting to a 
mean of 4.73 citations per year from the time of article publication. The most frequently 
cited guidance was Brouwer’s “Costing in Economic Evaluations”, in Drummond & McGuire 
(2001) Economic Evaluation in Health Care [Supplementary references 19], with 517 total 
references or 32 per year. Twenty-one of the 28 references had zero methodological 
citations. The reference with the most methodological citations was the “Empirical 
standard costs for health economic evaluation in Germany” [Supplementary references 23], 
with 5 methodological citations, or 0.4 per year. 
The top five papers on valuation of indirect costs with the most external citations were 
written by three authors (Koopmanschap 1995, 1992, 2008; Van den Hout 2010; Pauly 
2008) [Supplementary references 133-135, 140, 157], from two countries (the Netherlands 
and the United States). The two papers with the most ‘methodological’ citations 
(Koopmanschap 1995; Krol 2012) [Supplementary references 133, 136] are also both 
written by authors from Erasmus University in the Netherlands. References relying on a 
case study or worked example received the most citations overall and the most 
‘methodological’ citations.  
Of the top five papers on the topic of estimating resource use with the highest total 
citations, 2 were applicable to a low- or middle-income setting (Kessler (2003); Goossens 
(2000)) [Supplementary references 53, 69] and 3 applicable to a high-income setting 
(Roberts (1996); Bhandari (2006); Ritter (2001)) [Supplementary references 29, 92, 93]. Of 
references within this topic, those with some form of empirical comparison or validation 
received more ‘methodological’ citations than those with no analysis or with other forms of 
analysis, however higher numbers of total citations were observed for papers using a case 
study or worked example, or presenting results from expert consultation.  
Page 137 of 276 
 
Articles on valuing direct cost received a mean of 4.43 citations per year. The majority of 
these citations received zero ‘methodological’ citations. Two papers received one 
‘methodological’ citation each; both of these had some empirical analysis 
[Supplementary references 179, 185].  
Neither paper providing guidance on reporting received citations from other authors 
writing about methods, but both received citations generally in the literature (mean 3.26 
per year). 
Figures 7-3 and 7-4 illustrate the citation network for the top 100 references, grouped by 
guidance topic and country income group, respectively. As illustrated in Figure 7-3, the 
majority of ‘methodological’ citations occurred between different articles publishing on the 
same topic. Many of the references providing disease-specific broad costing guidance cite 
previous works on the estimation of resource use but do not cite any references on the 
valuation of indirect costs. One reference providing broad costing guidance cites references 
from both fields [Supplementary references 23]. There were four references providing 
guidance on estimating the quantity of patient time or productivity lost due to illness 
[Supplementary references 69, 97, 109, 159] – these references were not cited by other 
papers on estimating resource use but were cited by papers on valuation of indirect costs.  
As illustrated in Figure 7-4, the vast majority of ‘methodological’ citation between 
references occurred amongst papers set in high-income settings. Most papers set in a low- 
or middle-income setting, as well as most papers that were not country-specific, did not 
cite any pre-existing guidance and were not cited by any following guidance. The only 
exception to this is Hutton’s “Cost valuation in resource-poor settings” (2005) 
[Supplementary references 186], which cites a paper on the valuation of indirect costs 
[Supplementary references 135]. 
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Figure 7-3 Citation network by guidance topic 
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Figure 7-4 Citation network by country income group
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Use of guidance in patient cost data collection (TB case study) 
Table 7-3 summarizes the available TB-specific costing guidance, as well as any other 
guidance cited by articles on the patient costs of TB published since 2008. 
The detail of guidance available for TB-specific costing varied. One article briefly mentions 
patient costs but contains no direct guidance on collecting or analysing patient costs 
[Supplementary references 12]. Three agency publications provided more detailed 
guidance on TB specific costs, giving a detailed breakdown of the types of costs likely to be 
incurred by TB patients and their households and sample questions to estimate these costs 
[Supplementary references 14, 16, 17]. Sample questions for estimating direct costs 
consistently ask patients to recall their actual expenditure; none of the guidelines discusses 
the alternative approach of measuring resource use and valuing those resources 
separately. None of the three guidelines describes likely sources of bias associated with 
estimating direct costs (such as recall bias, desirability bias, or respondent bias), nor do 
they reference any empirical evidence on ways to counteract this bias through data 
collection methods. Where sample questions for estimating indirect costs are given, 
methods appear to follow the human capital approach. The benefits and drawbacks of 
alternative approaches to estimating productivity costs are not discussed, and no methods 
for using the FCA or WTP approaches are described or referenced. Finally, guidance on 
study design is minimal in all four TB-specific references. The three agency publications 
mention that patient/family/lay-person costs should be generated from a random sample 
of interviewees, but they do not provide guidance on methods for sampling or selection. 
Logistics for the survey are also not addressed; none of the tools indicates appropriate 
timing of the survey or which questions may be cut if practical constraints restrict the time 
available for the interview (40–42).  
Of the 63 TB patient costing papers reviewed, 30 provided no references in the methods 
section. Of those that did provide a reference in the methods section, 16 referred to a 
previous costing study conducted by their team, reporting that they had adapted a 
previously used questionnaire.  
Twenty-three articles made some reference to published costing guidance. Of these, 13 
referred to the Tool to Estimate Patient Costs (43). No other TB-specific costing guidance 
was cited by any articles. Several articles were cited which provide general high-level 
guidance on economic evaluation but do not provide any specific guidance on methods for 
estimation or valuation of resource use from the patient perspective (44–50). Three articles  
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Table 7-3 TB-specific costing guidance availability and uptake by costing practitioners 
Reference type 
Open 
access? 
Number of 
references 
citing 
guidance 
Guidance on 
study design / 
sampling? 
Guidance on 
estimation of 
resource use for 
patient costs? 
Guidance on 
valuation of 
direct costs? 
Guidance on 
valuation of 
indirect costs? 
Guidance on 
estimation of 
capacity to 
pay? 
Guidance on 
defining a 
threshold of 
affordability? 
Adaptation of previous 
questionnaire 
 28 n/a n/a n/a n/a n/a n/a 
TB-specific costing guidance         
WHO (1999)  Yes 0 No Yes No HCA only No No 
USAID (2008) (43) Yes 13 Partial Yes No HCA only No Partial 
Sohn (2009) No 0 No No No No No No 
WHO (2015) Yes 0 Yes Yes Yes HCA and outputs Yes Yes 
Other Costing guidance          
Drummond (1997) (49) No 2 No No No HCA only No No 
Creese and Parker (1994) (50) Yes 1 No No No No No No 
Rice (1967) (31) No 1 No No No HCA only No No 
Luce (1996) (46) No 1 No Yes Yes HCA and WTP No No 
WHO (2002) (47) Yes 3 No Partial Partial HCA and others No No 
Pizzi (2006) (48) No 1 No No No No No No 
Guidance unrelated to health  2       
No guidance cited  32 n/a n/a n/a n/a n/a n/a 
Page 142 of 276 
 
cited a reference which did not provide any specific guidance on patient costing (45,48,51). 
Two articles cited references which were unrelated to health. None of the articles referred 
to any stand-alone guidance on specific methodological issues such as sampling, recall, 
data collection methods, or valuation of time.  
DISCUSSION 
This paper has presented a bibliometric review of the literature base on methods for 
estimating patient costs, in order to determine the availability, relevance, accessibility, and 
use of costing guidance for researchers estimating disease-specific catastrophic costs in 
low- and middle-income settings. 
Overall, the availability of guidance was strong. I found a large literature base on methods 
for estimating patient costs, amounting to 180 publications in total. Availability of guidance 
varied somewhat by topic. For some methodological questions (for example, estimation of 
resource use), there has been a good deal of research published on the validity of different 
approaches. In contrast, there were only 2 references containing guidance on study design 
and 2 references providing guidance on reporting patient cost estimates. 
Although there were a large number of references, I found that the literature base 
contained few references that were accessible to researchers in a low- or middle-income 
country. Most references were published in peer-reviewed journals, and the majority of 
references (88%) were not published in open-access journals. The literature was also 
diverse, and difficult to find using standard keywords and searches. Several rounds of 
searches and snowballing were required to produce this dataset. For most topics, I found 
piecemeal and inconsistent recommendations from individual studies. Where literature 
reviews were conducted, they were mostly not accurate representations of the existing 
literature base. There is a clear need for consolidation of the literature into one easily 
accessible place to enable researchers to make informed choices about methods and for 
more consistent use of keywords and/or MeSH terms to identify costing guidelines.  
Many studies with methodological recommendations may also not have been relevant to a 
low- or middle-income setting. Some topics, such as estimation of resource use or valuation 
of indirect costs, had almost no papers relevant to a LMIC setting. For example, most 
papers discussing the estimation of resource use evaluated self-reported service use 
against administrative records. Administrative records are currently not suitably robust in 
many low-income settings; while this provides an excellent argument to encourage better 
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record-keeping, until this happens records may not be a viable option for researchers 
working in LMIC settings. Similarly, it is unclear whether the approaches to value indirect 
costs which were developed for a high-income country setting are also relevant to a low-
income setting where the labour market operates very differently. The friction cost 
approach has not been tested in a low- or middle-income country to date, and the value of 
time for informal caregivers may be valued differently in settings where there is high 
unemployment. There is a great need for further consideration of how to apply the lessons 
learned in a high-income country setting to LMICs. 
Throughout the literature base, the concern of much of the literature seems to be focused 
on estimating patient cost as part of economic evaluation, rather than estimating costs to 
the household in order to capture the effect of illness on equity or vulnerability. For 
example, at least 28 references were about the friction cost method of valuing indirect 
costs reflects the impact of illness on the economy, which fails to capture the increased 
vulnerability within the household that arises from lost time and productivity due to health 
issues. Similarly, all of the references on study design consider sampling for economic 
evaluation purposes, rather than any sampling to capture increased vulnerability. This is a 
reasonable approach for some settings such as the UK, where universal access to health 
care minimizes the likelihood of impoverishment due to health-related spending. However, 
in settings such as the US or in LMIC settings where there is not yet universal access, this 
limitation of methods may mean that important losses of welfare are not captured 
accurately. Improved guidance on the appropriateness of different methods for different 
uses of patient cost data is much needed.  
This review included 28 broad patient costing guides, published by international 
organizations and available freely online. These references were identified as receiving 
some of the highest ‘total’ citations, implying that they are some of the most commonly 
used sources of costing guidance cited by costing practitioners. In the relatively high level 
of use of these broad guides, there appears to be an assumption that these references 
draw on the existing literature base in order to draw conclusions as to the best approach. 
However, on closer examination of citation networks, I found many of these ‘broad’ costing 
guides do not currently draw on the substantial literature base. While a few ‘broad’ costing 
guidelines cite references on the estimation of resource use, they largely do not refer to 
the existing literature on other topics such as valuation of direct or indirect costs, study 
design, or reporting. References which provide guidance relevant to low- and middle-
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income settings do not draw on existing guidance at all, nor do those references that are 
not country-specific or those published by international agencies.  
The impact of the limited accessibility and relevance of methods for low- and middle-
income settings can be seen in the limited uptake of costing guidance as exhibited in the 
review of the TB costing literature. The review of the methods employed by existing patient 
cost studies has shown that remarkably little of the available literature base is cited by 
patient costing practitioners within the existing TB patient costing studies. No TB patient 
costing studies cited individual methodologically-focused studies with recommendations 
based on an empirical comparison of the validity of different approaches. The majority of 
authors do not cite any costing guidance in the methods sections of their papers, often 
relying instead on institutional knowledge within their own teams. The guidance that 
authors do reference in the methods section is often high-level and often does not provide 
any specific guidance on methods for estimation or valuation of resource use from the 
patient perspective.  
Overall, although guidance on estimating patient costs is available to some degree, this 
review has shown that the accessibility, relevance, and use of this guidance leaves much 
room for improvement. This review has highlighted a lack of discussion between authors 
making costing accessible to practitioners working in LMIC settings, where it could be said 
that the issue of patient costs is more critical than in HIC where there is often universal 
coverage, and those working at the ‘cutting edge’ of methods development. This limited 
discussion leads to an increased dependence on institutional knowledge, raising barriers to 
access for new researchers in the topic and leading different teams to take different 
methodological approaches. This results in reduced confidence in cost estimates, and 
limited comparability across estimates made by different teams. For cost estimates to be 
useful to policymakers, it is essential that cost estimates collected for different 
interventions and in different settings are comparable and that the potential sources of 
bias in cost estimates are clear. If estimates of cost in economic evaluations are not 
comparable between interventions within a country, this makes planning and decision-
making difficult for policymakers. In addition, if estimates of the prevalence of catastrophic 
cost are not comparable across countries, this diminishes the ability of international 
organizations such as the WHO to monitor country progress towards international targets. 
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Limitations 
This review has some limitations. Firstly, for practical reasons, I needed to constrain the 
review at some point. I excluded references from topics not relevant to health – for 
example, several references from labour economics, agricultural economics, and 
development economics were excluded despite offering some relevant guidance on valuing 
the time of people in low- and middle-income settings or measuring expenditures within 
LMIC households in the context of a household survey. This may have resulted in an under-
representation of the resources available to health economists considering patient cost in 
LMIC settings, as they could draw on this wider literature in developing methods.  
Secondly, the search process, as described in the Methods process and in Figure 7-1, was 
complex. The literature base on estimating patient costs is diverse – this is compounded by 
poor use of keywords throughout the literature, and by the fact that many key references 
are not published in economic journals. The extensive snowballing process used in the 
review helped to facilitate capture of relevant references, however there is still a chance 
that some relevant references were not included. 
Finally, the review included a number of references in the form of grey literature or 
publications by international agencies (for example WHO, UNAIDS, and USAID). Grey 
literature is usually not included in the Google Scholar or Web of Science databases. The 
number of ‘methodological’ citations for this literature base was counted manually, to 
ensure accurate estimates of the degree of internal discussion for grey literature. The 
‘citations’ search tool in the Scopus database was used for these references, giving a good 
approximation of the number of articles citing these references; however, citation data is 
less reliable for these references.  
Conclusions 
This review highlights the need for improved discussion and consensus for patient costing 
methods, and the need for improved accessibility to methodological guidance for 
researchers working in low- and middle-income countries. The database created in the 
process of writing this paper will be published online through the Global Health Cost 
Consortium. A central repository for patient costing guidance would facilitate access to the 
materials as well as discussion around methodologies.  
The increasing movement towards Universal Health Care has great significance for the 
topic of economic evaluation. Now more than ever, health economists are tasked with 
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providing policy-makers information on the impact of specific illnesses on economic 
vulnerability within the household. If further consideration were given in the 
methodological literature as to how these critical issues can most accurately be reflected, 
research could lead to better policy lessons surrounding economic vulnerability in the 
context of illness – not only in LMIC settings but also in high-income countries. Further 
research on appropriate methods for disease-specific patient cost measurement is essential 
in order to help answer important policy questions as countries look to expand access to 
health care. 
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CHAPTER 8. MEASURING INCOME FOR 
CATASTROPHIC COST ESTIMATES: LIMITATIONS 
AND POLICY IMPLICATIONS OF CURRENT 
APPROACHES 
PREAMBLE FOR RESEARCH PAPER #3 
Chapters 5 and 7 describe some potential reasons for widely varying methods observed 
across estimates of costs encountered by patients and their households. Methods can 
differ across studies due to practical constraints such as time and budget, and due to a lack 
of standardized guidance on appropriate methods. It is vitally important to recognize that 
these practical decisions can have a substantial impact on study results.  
The same issues can also impact the estimation of household income, which can lead to 
inconsistency in estimates of the prevalence of catastrophic costs. I assess this potential 
impact in Research Paper #3, using the example of individual income (used in the valuation 
of time lost as a result of TB) and household income (used in the estimation of capacity to 
pay for TB-related costs). Household and individual income are both notoriously difficult to 
estimate (Beegle, De Weerdt, Friedman, & Gibson, 2012; Howe, Hargreaves, & Huttly, 
2008). The costing literature, however, largely ignores this issue – with most costing 
guidelines suggesting only one or two questions to obtain income (eg. “How much do you 
estimate was the average income of your household per month BEFORE the TB illness?” 
and “How much do you estimate is the average income of your household per month 
NOW?” from the Tool to Estimate Patient Costs). 
Using data from a recent clinical trial conducted in South Africa (TB FastTrack), I compared 
six different approaches to estimate catastrophic costs. I explore the variation arising from 
different income estimation approaches and compared the number of households 
encountering catastrophic cost estimated through each approach. I found that the income 
estimation approach is critical in estimating catastrophic costs; results varied from 0% to 
36% of households encountering catastrophic costs depending on the estimation method. I 
conclude that the rapid methods for estimating income among patients attending a health 
facility are currently inconsistent, and advocate strongly for further development of 
methods for measuring income.  
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This was a multi-authored paper based on cost data collected during the TB FastTrack study 
(Fielding et al., 2015). SC designed the questionnaire with input from myself. SC and RM 
collected the data. All authors input on a final version of the paper. All other work, 
including paper approach, analysis, and writing the first and consecutive drafts of the 
paper, was my own. 
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MEASURING INCOME FOR CATASTROPHIC COST ESTIMATES: 
LIMITATIONS AND POLICY IMPLICATIONS OF CURRENT APPROACHES 
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University of the Witwatersrand, Johannesburg, South Africa 
Abstract 
There is increasing global policy interest in estimating catastrophic costs incurred by 
households because of ill health, and growing need for information on disease-specific 
household cost data. There are several methodological approaches used to estimate 
income and no current consensus on the best method for estimating income in the context 
of a survey at the health facility. We compared six different approaches to estimate 
catastrophic cost among patients attending a health facility in South Africa. We used 
patient cost and income data collected June 2014–March 2015 from 66 participants 
enrolled in a clinical trial in South Africa (TB FastTrack) to explore the variation arising from 
different income estimation approaches and compared the number of households 
encountering catastrophic costs derived for each approach. The total proportion of 
households encountering catastrophic costs varied from 0% to 36%, depending on the 
estimation method. Self-reported mean annual income was significantly lower than 
permanent income estimated using an asset linking approach, or income estimated using 
the national average. A disproportionate number of participants adopting certain coping 
strategies, including selling assets and taking loans, were unable to provide self-reported 
income data. We conclude that the rapid methods for estimating income among patients 
attending a health facility are currently inconsistent. Further research on methods for 
measuring income, comparing the current recommended methods to ‘gold standard’ 
methods in different settings, should be done to identify the most appropriate 
measurement method 
Keywords: South Africa, Catastrophic cost, Coping, Tuberculosis, Methods, Income 
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HIGHLIGHTS 
• Rapid methods for estimating income for catastrophic TB costs are inconsistent 
• Depending on income estimation approach, 0-36% households faced catastrophic 
TB costs 
• Quantitative indicators of catastrophe did not reflect extent of coping strategy use 
 
1. INTRODUCTION 
Costs incurred as a result of ill-health can aggravate household vulnerability (Alam and 
Mahal, 2014; Wagstaff and Lindelow, 2014). They can also contribute to delays in diagnosis, 
reduced adherence, and poorer health outcomes (Wingfield et al., 2014). Tuberculosis (TB) 
patients often encounter substantial costs in the form of out-of-pocket payments and lost 
income. In recognition of the impact of these costs, the End TB Strategy introduced a TB-
specific indicator of financial risk protection; this is labelled “catastrophic total costs due to 
TB”, and includes non-medical direct costs and income losses (Lönnroth et al., 2014). The 
End TB Strategy targets specify that no patient encounters catastrophic total costs due to 
TB by the year 2020 (World Health Organization, 2015). 
The indicator of ‘total catastrophic costs due to TB’ is relatively new and requires a 
different measurement approach and definition of ‘catastrophic’ compared to that used for 
general catastrophic health expenditure measured in the context of health financing. This 
paper aims to inform guidance on the measurement of catastrophic total costs due to TB 
from a sample of patients as part of a facility-based survey. We compare estimates of the 
prevalence of catastrophic cost using six approaches. We highlight the implications of these 
measurement approaches on the identification of catastrophic costs and resulting policy.  
1.1 Background 
To support countries seeking to meet the target of zero catastrophic costs due to TB by 
2020 (World Health Organization, 2015), the World Health Organisation (WHO) TB 
Programme established a Task Force in 2015 to develop a generic protocol for estimating 
the prevalence of catastrophic costs, building on methods used in previous studies of 
patient costs to provide guidance to countries on estimating catastrophic cost (World 
Health Organization, 2017). The aim of the ‘catastrophic total cost’ measure as described in 
the WHO handbook is to capture where health-related costs are likely to have a substantial 
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impact on the household’s ability to pay for basic subsistence needs; this is represented in 
terms of total costs as a proportion of household capacity to pay. For global monitoring of 
the End TB Strategy catastrophic cost indicator, the WHO has chosen to use a threshold of 
20% of annual household income. This threshold is currently used by National TB 
Programmes (NTP) implementing the WHO survey for annual reports to WHO (World 
Health Organization, 2018), however countries are also encouraged to undertake sensitivity 
analyses around the threshold. 
In the context of health financing, the numerator for the “catastrophic expenditures” 
equation has been traditionally measured as direct out-of-pocket expenditure (Xu et al., 
2005). However, over half of the economic burden encountered by households during an 
episode of TB comes in the form of lost income and lost productivity due to illness or time 
spent care-seeking (indirect costs) (Tanimura et al., 2014). The indicator of ‘catastrophic 
costs due to TB’ therefore includes indirect costs. Indirect costs are most commonly 
estimated through two approaches: first, household income can be estimated before and 
after the TB episode; any direct income loss due to TB is then captured by taking the 
difference. Second, the number of hours spent seeking care or otherwise unable to work 
due to TB can be estimated, and the value of these hours approximated with an estimate of 
the earning capacity of the patient for that time (e.g. hourly income). The first approach 
captures only the loss of paid work, while the second approach captures all time off work 
necessitated by symptoms and treatment seeking (but may not include any household 
mitigation of that loss). 
There are several potential indicators of household capacity to pay for health care, 
including: permanent income, current income, and wealth [Supplementary File 1]. The 
indicator of ‘catastrophic costs due to TB’ is intended to capture where costs associated 
with TB impose an economic burden that is non-recoverable, beyond typical day-to-day 
wealth management. Theoretically, permanent income is the best comparator to reach this 
aim. Measures of permanent income will more appropriately reflect the impact of health 
costs on the total resources available to the household, thus capturing any potential long-
term depletion in financial wellbeing in the household. According to the permanent income 
hypothesis, permanent income can be captured through consumption expenditure 
(Friedman, 1957), as consumption stays relatively constant according to one’s socio-
economic status (Garvy, 1948). A consumption expenditure module should therefore 
appropriately capture ability to pay for health-related costs. 
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However, pragmatically most surveys estimating catastrophic costs for specific diseases are 
conducted with patients attending a health facility, as disease prevalence is often too low 
to make household surveys efficient. Interviewing at the facility, often as part of clinical 
trials, introduces substantial time and cost restrictions on the survey. Short-form 
consumption expenditure questionnaires are not available for many contexts, and the 
limited time available often prevents full consumption expenditure surveys. The risk of 
survey fatigue for patients interviewed at a health facility is also much higher and large 
sample sizes are often not possible (Sweeney et al., 2016). Researchers have therefore 
opted to take various approaches to estimate ‘capacity to pay’, with the large majority 
using self-reported current annual income in the denominator of the catastrophic costs 
equation (Barter et al., 2012) WHO recommendations currently suggest equivalence 
between current income and annual household expenditure.  
Estimates of current income are subject to variation arising from different methods of 
measurement (diary vs. recall), recall periods, levels of detail in questions soliciting income, 
and level of respondent (individual vs. household). There is some evidence that each of 
these factors can lead to bias in income measurement. Bias can manifest in the form of 
error in reporting (i.e. due to recall error, telescoping, rounding error, cognitive errors, 
survey fatigue or misreporting), or in the form of non-response (Beegle et al., 2012; 
Browning et al., 2014; Deaton, 2001; Deaton and Grosh, 1999; Foster and Lound, 1993; 
Gibson, 2016; Jolliffe, 2001; Moore et al., 2000; Pudney, 2008; Winter, 2002, 2004). While 
it is possible to adjust analysis for partially observed data (i.e. through multiple imputation, 
mean imputation, or other assumed values) (Brick and Kalton, 1996; Sinharay et al., 2001), 
income data is susceptible to non-response not at random, making many forms of 
imputation likely inappropriate. Survey design is key in efforts to limit the amount of 
missing data. 
Another potential solution to the problem of bias in small facility-based surveys is using a 
proxy for income, either by assuming the national average income for all participants or by 
using household assets as a proxy for permanent income. Where national survey data exist, 
it is possible to use principal components analysis or multiple correspondence analysis 
(MCA) to compute factor weights at the national scale, which can then be applied to asset 
data for a smaller survey. This approach allows researchers to estimate permanent income 
without the large expense of conducting a national survey (Gwatkin et al., 2005; McKenzie, 
2005; Standards, 1997). There are some limits associated with this approach, however; 
assets are slow-changing and therefore may not capture changes in household economics 
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accurately, particularly for the lowest quintile (Booysen et al., 2008; Harttgen and Vollmer, 
2011). 
Finally, the issue of income measurement can be avoided entirely by adopting an indicator 
of financial catastrophe which is not dependent on estimating TB-related costs as a 
proportion of capacity to pay. Following indications that financial catastrophe is linked with 
coping strategies (Madan et al., 2015), presence of these strategies could be used as an 
indicator of catastrophic cost.  
2. METHODS 
2.1 Study Design 
We present and compare estimates of catastrophic cost using a range of existing methods 
to represent household capacity to pay for TB services, in the absence of a full consumption 
questionnaire. We use data from a patient costing study nested within the TB FastTrack 
study, a pragmatic, cluster randomised trial with 24 primary healthcare clinics randomised 
to implement algorithm-guided empirical TB treatment for ambulant HIV-positive adults 
who had a low CD4 count and were not yet on TB or HIV treatment (Fielding et al., 2015). 
Patients in the intervention arm were started on TB treatment if indicated by the study 
algorithm, and ART initiation was promoted either two weeks after the start of TB 
treatment, or at the earliest opportunity if TB treatment was not indicated; in the control 
arm, clinic staff initiated TB treatment and / or ART according to routine practice. Patient 
cost data was collected between June 2014 and March 2015. The patient cost study was 
not designed to draw any conclusions on the impact of the TB Fast Track intervention on 
income or cost. Ninety-nine participants were recruited from a pragmatic sub-selection of 
17 study facilities in Bojanala Platinum (28 participants), City of Ekurhuleni (9 participants), 
City of Tshwane (48 participants), and Greater Sekhukhune districts (14 participants). 
Bojanala Platinum and Greater Sekhukhune are both rural districts, located in North West 
and Limpopo provinces respectively. City of Tshwane and City of Ekurhurleni are peri-urban 
districts, both located in Gauteng province. All municipalities had high unemployment rates 
in 2011, ranging from 24.2% in City of Tshwane to 50.9% in Sekhukhune (Statistics South 
Africa, 2014).  
Participants were interviewed for this study at their 6-month follow-up trial visit. 
Questionnaires were adapted from the USAID Tool to Estimate Patient Costs for TB (USAID 
et al., 2008), and included a series of questions about patient demographics, asset 
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holdings, health care seeking behaviour, costs associated with seeking care, and income 
[Supplementary File 2]. Questionnaires included detailed questions on visits made to a 
range of providers, including the trial clinic, other public facilities, general practitioners, 
hospitals, traditional healers, and pharmacies. Questionnaires were designed to exclude 
visits that were made solely for research purposes. Data on household size from the survey 
was unreliable, as data was only available for 49 participants. To maintain consistency in 
the analysis we used the mean household size by municipality as obtained from Statistics 
South Africa as a measure of household size rather than individual household estimates.  
Data were entered into an Excel spreadsheet, and analysed using a combination of Excel 
and Stata 14. All cost and income data were inflated using the local inflation rate to reflect 
prices in October 2015, and then converted to USD using the average conversion rate in 
October 2015, R 13.08 = 1 USD (XE, n.d.). Participants were interviewed in a private space 
and all data were anonymised prior to analysis. The trial, including the costing study, was 
approved by the Research Ethics Committees of the University of Witwatersrand (approval 
number: R14/49 M111177), the London School of Hygiene and Tropical Medicine (approval 
number: 6099), and the Provincial Research Committees of Gauteng, North West and 
Limpopo.  
2.2 Components of Catastrophic Cost Estimates 
We estimated the proportion of households encountering catastrophic costs for each 
income estimation approach, following WHO definitions of catastrophic costs (World 
Health Organization, 2017):  
𝐸𝑝𝑖𝑠𝑜𝑑𝑒 𝑑𝑖𝑟𝑒𝑐𝑡 𝑐𝑜𝑠𝑡 + 𝐸𝑝𝑖𝑠𝑜𝑑𝑒 𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑐𝑜𝑠𝑡
𝐻𝑜𝑢𝑠𝑒ℎ𝑜𝑙𝑑 ′𝑐𝑎𝑝𝑎𝑐𝑖𝑡𝑦 𝑡𝑜 𝑝𝑎𝑦′
> 𝑇𝐻𝑅𝐸𝑆𝐻𝑂𝐿𝐷 𝑉𝐴𝐿𝑈𝐸 (%) 
Methods of estimation for each of these components is detailed below. For comparison of 
catastrophic cost incidence across estimation approaches, we use a threshold value of 20% 
as a base case, but also illustrate the impact of varying threshold on the total proportion of 
participants encountering catastrophic cost. We also considered the presence of coping 
strategies as an indicator of catastrophic cost. 
2.2.1 Estimation of household ‘capacity to pay’ 
We estimated the annual household income using four different approaches, described 
below. We did not attempt to estimate household consumption or expenditure, as at the 
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time of study design there were no validated short-form consumption questionnaires for 
use in South Africa.  
2.2.1.1 Approach #1: Self-reported current income (prompted ranges) 
On trial enrolment, we asked participants to self-report their monthly household income 
using a single question with prompted ranges of: less than $62, $62-$104, $104-$208, 
$208-$415, greater than $415, or not known. Households in each range were assigned the 
mid-point income for that range (i.e. $31 for those stating income less than $62, $83 for 
those with income $62-$104, and so forth).  
2.2.1.2 Approach #2: Self-reported current income (detail) 
During the patient costing questionnaire at the 6-month follow-up visit, we asked 
participants to recall the monthly income of the household with respect to 4 time-points: 
prior to symptom onset, at trial enrolment, at the start of TB treatment (or HIV treatment if 
not treated for TB), and at the 6-month follow-up visit. The onset of symptoms was self-
identified by participants as the date when they “first felt unwell”. Income was solicited 
this time with detailed questions surrounding the salary and non-salary income of the 
participant and that of other household members; questions included monetary income, 
non-monetary income (e.g. food), grants and remittances. Household income prior to 
symptom onset was used for the denominator of the catastrophic cost equation. 
2.2.1.3 Approach #3: Estimated permanent income based on asset scoring  
At trial enrolment, we asked participants about a range of assets held by the household 
and household characteristics, including: a stove, DVD player, motorcar, washing machine, 
satellite television, computer, radio, television, refrigerator, cell phone, bicycle, and 
indicators of housing quality (toilet facilities, source of water, wall materials, floor 
materials, and dwelling type). We used the same asset questions as the National Income 
Dynamics Survey (NIDS) in South Africa (Leibbrandt et al., 2009), a national panel survey of 
households. Coding for these questions was mapped to coding for the same questions from 
the NIDS.  
We conducted a multiple correspondence analysis (MCA) on NIDS survey data to estimate 
weights for each of the above-described assets and characteristics as reported in the most 
recent round of the survey, conducted in 2015 (Wave 4) (Booysen et al., 2008; Howe et al., 
2008). The first dimension explained 78% of variation in the dataset. Weights from the first 
dimension were applied to the TBFT dataset, and households were classified into five socio-
economic quintiles. For each income quintile, mean monthly expenditures were taken from 
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the NIDS dataset and assumed to represent the mean household permanent income for 
that quintile. This was used as the denominator for catastrophic costs.  
2.2.1.4 Approach #4: Estimated income based on the average net disposable income  
We compared the above income measures against a broad assumption that all households 
earned the average net adjusted after-tax income in South Africa, as estimated in the OECD 
Better Life Index (USD 8,712 per year) (OECD, 2017). Income estimates were inflated from 
the 2013 reference year given by OECD to October 2015. 
2.2.2 Estimation of direct costs 
We estimated direct medical and non-medical costs for the numerator of the catastrophic 
cost equation. Direct medical and non-medical costs were estimated for the period from 
the onset of symptoms to the 6-month follow-up visit. If participants had no symptoms, 
costs were estimated for the three months prior to enrolment to ensure all related care-
seeking costs were included. To standardize costs, we assumed a minimum 6-month 
follow-up period after enrolment for all participants. In cases where participants were 
interviewed before 6 months, we estimated an average monthly cost and then 
extrapolated this to six months. The 6-month recall period is longer than typically 
recommended to estimate costs; as the patient cost study was not designed to provide 
definitive conclusions on the cost of the TB Fast Track intervention we accepted some risk 
of bias in order not to interfere with the intervention implementation. 
Direct costs were defined as medical and non-medical expenses. Medical expenses 
included consultation fees and any out-of-pocket payment for medicines and diagnostics 
paid at any provider type. Direct non-medical expenses included any travel costs of 
participants and guardians, food costs incurred while in hospital, money spent buying any 
special foods or dietary supplements due to illness, and any interest incurred on loans 
taken out to meet the costs of out-of-pocket payments. Direct medical and non-medical 
costs were determined as the product of the reported expense for the most recent visit to 
each provider type and the number of visits made to that provider.  
2.2.4 Estimation of indirect costs 
We estimated indirect costs for the numerator of the catastrophic cost equation using two 
approaches. First, indirect costs were defined as the opportunity cost of time spent away 
from the daily productive routine. The number of hours included time spent travelling to 
health facilities and waiting and consultation time, excluding any extra visits made for 
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research purposes alone; any time spent by household members caring for the participant 
or covering household chores usually done by the participant was also included. The total 
time was multiplied by the estimated household income per person per minute, which was 
derived from each of the four respective measures of household income estimated as 
described above using the mean household size by municipality from Statistics South Africa 
and self-reported working hours per day (approaches #1-4). 
Next, we estimated the indirect cost using the self-reported income loss during the period 
from symptom onset to 6 months after study enrolment. Any gain or loss in income during 
this time which the participant attributed to illness were multiplied by the duration of the 
pre-enrolment, trial entry, and treatment periods respectively to come to a total indirect 
cost. This is labelled as approach #5.  
2.2.5 Coping strategies 
Finally, we consider use of coping strategies as an indicator of economic catastrophe 
(approach # 6). Participants were asked about their use of several coping strategies to meet 
the costs of TB, including asset sales, taking loans, reducing food consumption, and changes 
in household labour use (e.g. pulling children out of school to work).  
2.3 Analysis 
To facilitate comparison between different income measurement approaches, we began 
our analysis by dropping all participants for whom a household income was not calculable 
using any of the income estimation approaches described below due to missing data (n = 
33) and conducted a complete case analysis for the remaining participants (n = 66). We 
tested the reliability between different approaches of income measurement using Cohen’s 
kappa statistic (McHugh, 2012). Finally, we illustrate the resource implications of varying 
methods using the example of South Africa’s temporary disability grant, which is a monthly 
cash transfer providing income support to all South African citizens who are unable to work 
due to disease or disability (typically R1010 ($67.23) per month). We estimate the total cost 
of a years’ access to the temporary disability grant ($806.76) for each household identified 
as encountering catastrophic cost by each approach. This type of grant could protect 
households from the negative economic ramifications of catastrophic TB costs and reflects 
the potential cost of reducing catastrophic costs.  
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3. RESULTS 
3.1 Data and Demographics 
Ninety-nine people in total participated in the patient costing survey. Of these, we 
excluded 33 participants (33%) from the full analysis due to missing data for one or both 
self-reported income questions. Twenty-seven participants responded, “Don’t know” to the 
question “On average, what is your monthly household income: zero or less than R600 
($62), R601-1000 ($62-$104), R1001-2000 ($104-208), R2001-4000 ($208-415), or greater 
than R4000 ($415)”. When responding to more detailed income questions, two participants 
were unable to report their own income, and eight were unable to report the income of 
other household members.  
Table 8-1 Demographic characteristics of study participants, comparing those included vs. 
excluded in the main analysis 
Variable 
Participants included in 
analysis (n = 66) 
Participants excluded due to 
missing income data (n = 33) Difference 
Female n (%) 45 (68%) 19 (58%) 
chi2 = 1.08; 
p = 0.30 
Mean age (Std 
Dev) 
37 (8.0) 40.8 (11.9) 
t = -1.76;  
p = 0.08 
Black/African n (%) 66 (100%) 33 (100%) n/a 
Grade 8 and above 
n (%) 
59 (89%) 27 (82%) 
chi2 = 1.11; 
p = 0.29 
Unmarried n (%) 40 (61%) 21 (64%) 
chi2 = 0.09; 
p = 0.77 
Employed at 
symptom onset n 
(%) 
35 (53%) 9 (27%) 
chi2 = 5.91; 
p = 0.02* 
Employed at trial 
enrolment n (%) 
32 (48%) 10 (30%) 
chi2 = 2.98; 
p = 0.08 
Receiving any 
government grants 
n (%) 
51 (77%) 24 (73%) 
chi2 = 0.25; 
p = 0.62 
Receiving disability 
grant for HIV/TB n 
(%) 
1 (2%) 0 (0%) 
chi2 = 0.51; 
p = 0.48 
Median CD4 count 
at last test (IQR) 
90 (58) 73 (60) 
t = 0.57;  
p = 0.57 
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Asset quintile 
distribution  
(mapping to 
national asset 
index) n (%) 
Quintile 1: 3 (5%) 
Quintile 2: 7 (11%) 
Quintile 3: 27 (41%) 
Quintile 4: 18 (27%) 
Quintile 5: 11 (17%) 
Quintile 1: 6 (18%) 
Quintile 2: 2 (6%) 
Quintile 3: 8 (24%) 
Quintile 4: 6 (18%) 
Quintile 5: 11 (33%) 
chi2 = 10.23; 
p = 0.03* 
Coping strategies 
Coping: 24 (36%) 
Took loans: 20 (30%) 
0-25% interest: 6 (9%) 
≥ 25% interest: 14 (21%) 
Reduced food: 10 (15%) 
Sold assets: 2 (3%) 
Multiple strategies: 8 (12%) 
No coping: 42 (64%) 
Coping: 15 (45%) 
Took loans: 12 (36%) 
0-25% interest: 7 (21%) 
≥ 25% interest: 5 (15%) 
Reduced food: 0 (0%) 
Sold assets: 4 (12%) 
Multiple strategies: 2 (6%) 
No coping: 18 (55%) 
chi2 = 0.76; 
p = 0.38 
IQR interquartile range 
Table 8-1 shows the demographic data for those participants included in the analysis (n = 
66), and for those excluded (n = 33). Most participants included in analyses were female (n 
= 45), and between the ages of 30 and 44 (n = 47). All participants were of black African 
ethnic origin, and 89% were educated to grade 8 and above (n = 59). The majority (n = 40) 
were unmarried. Only 53% (n = 35) of participants reported being employed at the time of 
symptom onset (or 3 months prior to enrolment if no symptoms); this had dropped to 48% 
(n = 32) by the time of trial enrolment. Excluded participants were significantly more likely 
to be unemployed at symptom onset than those included in the analysis. 
Table 8-2 Mean number visits, direct costs, and time spent seeking care from start of illness to 
6-month trial visit (n=66) 
Facility type 
Mean total 
number visits 
Mean total direct 
medical cost 
Mean total direct 
non-medical cost 
Mean total hours 
care-seeking 
Main clinic 12.98 $0.00 $27.32 70.01 
Other clinic 0.12 $0.00 $0.31 1.03 
Pharmacy 1.44 $4.60 $0.86 1.51 
General practitioner 0.35 $7.56 $0.86 1.27 
Hospital-inpatient 0.12 $0.80 $4.49 8.25 
Traditional healer 0.21 $8.95 $0.69 1.56 
Specialist 0.57 $0.57 $1.19 1.97 
Radiologist 0.00 $0.00 $0.88 1.02 
DOT 0.00 $0.00 $0.00 0.00 
Total 15.80 $22.48 $36.60 86.62 
All costs in 2015 USD 
Many households undertook coping strategies to meet the costs of illness. Several 
households reported reducing food consumption (n=10), selling assets (n=2) or taking out 
loans (n=20), but no households reported taking children out of school to work. Some 
participants who were excluded from the analysis due to missing income data sold assets (n 
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= 4) or took loans (n = 12) to meet costs related to illness. The median CD4 count reported 
at enrolment was 90.  
3.2 Total direct costs 
Mean direct medical costs for all providers per episode were $23 and mean costs for travel 
and food during this period were $37 (Table 8-2). Sixteen participants visited general 
practitioners at least once at an average cost of $24 per visit, and seven participants were 
hospitalized at least once. No patients in this cohort received daily clinic-based directly 
observed treatment (DOT). Eight participants visited a traditional healer at least once, with 
consultation fees per visit ranging from $5 to $97 per visit. Direct non-medical costs were 
highest for participants’ main clinic – this reflects travel and food costs for participants and 
their guardians during the many visits to these facilities. Supplementary File 3 shows the 
visit and direct cost data for excluded participants.  
3.3 Total resources available to the household 
Table 8-3 shows the mean and standard deviation of the estimated resources available to 
the household, and the number of participants falling below the nationally defined lower-
bound poverty line of $43 per person / month for each of the four income estimation 
approaches (Statistics South Africa, 2014).  
The two methods with the highest correlation coefficient (0.373; p = 0.002) were approach 
#1 and approach #2. The mean monthly income per household measured using prompted 
ranges (approach #1) was $242 (median $156), and the mean income reported in response 
to detailed questions (approach #2) was $317 (median $222).  
Table 8-3 Monthly household income estimates using different approaches (n=66) 
Income estimation 
approach 
Households 
below 
poverty line 
Mean monthly 
income per 
household 
Median monthly 
income per 
household 
Standard 
Deviation 
Approach #1:  
current income 
(prompted ranges) 
40 $241.70 $156.00 221.03  
Approach #2:  
current income 
(detailed) 
33 $317.71 $221.80 340.88  
Approach #3: 
 permanent income 
(MCA) 
2 $497.33 $339.23 289.92  
Approach #4:  
national mean income 
0 $760.70 $760.70    -  
All income in 2015 USD 
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Weights for assets and household characteristics from the NIDS MCA exercise are listed in 
Supplementary File 4. All durable assets had positive factor loading scores while indicators 
of poor housing had negative loading scores. Durable asset ownership was moderately 
correlated with permanent income in the NIDS dataset (r = 0.40; p < 0.00). More 
participants in the TBFT dataset reported ownership of some durable assets and high-
quality housing characteristics, placing more participants in higher income quintiles than 
lower quintiles. Permanent income estimated using the MCA approach (approach #3; mean 
$497) was significantly higher than self-reported current income (approaches #1 and #2) (p 
< 0.002).  
The highest mean income was estimated using approach #4 (mean $761); income 
estimates for approach #4 were also significantly higher than those for approaches #1 and 
#2 (p < 0.00). Depending on the approach taken to estimate income, as few as zero or as 
many as 40 of the 66 (61%) households were estimated to fall below the poverty line.  
Table 8-4 Indirect costs for all estimation approaches from start of illness to 6-month trial visit 
(n=66) 
All costs in 2015 USD 
3.4 Total indirect costs 
Indirect costs were a function of income and followed the same pattern as that of income. 
The highest indirect costs were estimated using approach #4, and the lowest indirect costs 
were estimated using approach #1. Depending on the income estimation approach taken, 
mean indirect costs for the episode varied from a mean of $33 to $113. Differing 
approaches in income estimation therefore had wide-ranging impact on cost drivers 
overall. Indirect costs account for 64% of total cost when using approach #4 for income 
estimation, and 34% of total cost when using approach #1 (Table 8-4). Self-reported income 
loss (approach #5) was roughly double that of time loss valued in terms of current income 
Indirect cost estimation approach 
Mean 
indirect 
cost 
Standard 
deviation 
Indirect cost 
as % total 
cost 
Approach #1: current income (prompted ranges)  $33.33  53.16  34% 
Approach #2: current income (detailed)  $43.55   53.80  41% 
Approach #3: permanent income (MCA)  $74.75   77.62  54% 
Approach #4: national mean income  $113.77   95.96  64% 
Approach #5: self-reported income loss $85.85   744.08  57% 
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(approaches #1 and #2), and had a much larger standard deviation than any other 
approach – this was due to a few participants reporting substantial income loss as a result 
of job loss due to illness, and a few reporting substantial income gains (e.g. in grants or 
remittances) as a result of their illness.  
3.5 Catastrophic costs 
Figure 1 illustrates the proportion of participants in the study encountering catastrophic 
costs across a range of thresholds, by approach. Across thresholds and particularly at lower 
thresholds, the choice of income measure lead to very large differences in the proportion 
of catastrophic cost. Approaches #3 and #4 had the fewest participants encountering 
catastrophic costs, dropping to zero at thresholds above 10%.  
Table 8-5 presents the estimated prevalence of catastrophic cost for each of the six 
estimation approaches, and the potential cost of providing a disability grant to those 
encountering catastrophic costs. Under the national average income assumption, zero 
participants encountered cost over the 20% threshold. Using self-reported income data, six 
participants (9% of those included in analysis) encountered catastrophic costs. Using coping 
as an alternative indicator of catastrophic costs, 24 (36%) encountered catastrophic costs. 
There was minimal agreement between the five income measurement approaches in 
identification of catastrophic cost (Kappa = 0.2711, p < 0.000). Participants who reduced 
food consumption to meet costs were largely not classified as encountering catastrophic 
costs under approaches #1-4, however approach #5 reflected catastrophic costs for some 
of these participants.  
Table 8-5 Policy impact of catastrophic cost estimates 
  Number 
participants with 
catastrophic cost 
Total cost of providing 
one-year disability 
grant to all households 
with catastrophic cost (total n = 66)  
Approach #1: current income (prompted ranges) 6 (9%) $7,997.23 
Approach #2: current income (detailed) 6 (9%) $7,997.23 
Approach #3: permanent income (MCA) 0 (%) $0.00 
Approach #4: national mean income 0 (%) $0.00 
Approach #5: self-reported income loss 11 (17%) $14,661.58 
Approach #6: coping strategies 24 (36%) $31,988.90 
Catastrophic threshold for Approaches #1-#5: 20% 
All costs in 2015 USD 
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Figure 8-1 Prevalence of catastrophic cost, by income estimation approach and threshold value 
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Of all patients interviewed, only one was in receipt of a disability grant related to their 
HIV/TB status. If all those undertaking coping strategies were assumed to encounter 
catastrophic costs, the cost of providing disability grants to those people would be $31,988. 
In contrast, if the national average income is used to estimate income, zero participants 
would be found to encounter catastrophic costs and there would be zero cost to providing 
disability grants.  
4. DISCUSSION 
This paper illustrates the uncertainty around measuring income accurately when estimating 
disease-specific catastrophic costs. The gold standard for estimating permanent income is 
through a consumption expenditure questionnaire. In this setting, as in many real-world 
situations, it was not possible to conduct such a questionnaire due to time limitations and 
the lack of a validated short-form questionnaire. In the absence of such a gold standard, we 
illustrate the implications of alternative approaches. The four income measurement 
methods we employed gave substantially different estimates of the frequency of 
catastrophic costs with vastly different policy implications; different approaches in 
estimating income amongst the same population resulted in estimates varying from 0 to 
36% of respondents encountering catastrophic costs.  
It is clear from our results that all potential alternatives presented are problematic in some 
way. Self-reported current income, as estimated through approaches #1 and #2, is a poor 
proxy for permanent income. In addition, these data were the most difficult to collect 
amongst the five approaches. We lost 33 participants from our analysis due to missing data 
for one or both self-reported income estimation approaches. We lost a disproportionate 
number of participants who were unemployed and who adopted certain coping strategies, 
including selling assets and taking loans to meet the costs of TB, potentially biasing our 
results to reduce the estimated prevalence of catastrophic costs. This loss of data is not 
unusual for this kind of survey. The practical difficulties of collecting reliable income data 
are widely acknowledged (Deaton and Zaidi, 2002; Filmer and Pritchett, 2001), and it is 
often particularly difficult for participants to estimate income outside the purview of the 
survey respondent, which is critical for estimation of household income. It is crucial when 
estimating catastrophic costs to ensure that the analysis is not biased against capturing 
those who encounter serious difficulty in meeting the costs of illness.  
Income quintiles were estimable using the MCA approach (approach #3) for all 99 
participants; however, there are several potential limitations with this approach as 
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illustrated in this paper. Our sample had relatively high levels of durable asset ownership, 
placing many participants in the upper two quintiles and resulting in only two households 
being defined as below the poverty line using approach #3. This indicates that approach #3 
may have substantially overestimated household socioeconomic position, as consistent 
evidence indicates that both TB and HIV are most prevalent among lower income quintiles 
(Lonnroth et al., 2009; Steinert et al., 2017; Wabiri and Taffa, 2013). This approach also 
assumes that expenditure patterns of TB-affected households are similar to the national 
average, which is unlikely to be the case. Although theoretically promising, we must 
therefore draw the conclusion that asset indices are likely a poor proxy for consumption 
expenditure in the South African setting. This is consistent with indications that asset 
indices are poor proxies for consumption expenditure across a range of settings (Howe et 
al., 2009). Asset indices also may not be the best option available to researchers - asset 
questionnaires can be very lengthy in themselves, and mapping to a national dataset is not 
always possible. Researchers looking to use asset mapping to proxy permanent income 
should first check whether there is a national dataset that can be mapped to assets in a 
facility survey and whether there is a high correlation with permanent income in their 
setting. Increasing the number and range of indicators may help to improve agreement. 
As expected, the use of a mean national income in the denominator (approach #4) was 
highly problematic. The approach likely substantially overestimated household 
socioeconomic position and provided no real sense of the relative impact of TB costs across 
socioeconomic quintiles. This approach does not achieve the aim of the indicator of 
‘catastrophic costs due to TB’ and adds no value to a blunt estimate of total costs due to 
TB. 
Given the limitations of methods to estimate catastrophe quantitatively in absence of 
consumption expenditure, we also explored the use of alternative measures such as 
adoption of coping behaviours (approach #6) as an indicator of catastrophic costs. Unlike 
some quantitative measures explored, this information was easily collected for all 
households. Coping strategies may be a good indication of long-term financial hardship in 
the context of health-related costs. Health shocks are often costlier than other types of 
shocks, and households are often less able to recover following a health shock as compared 
with agricultural, natural, or legal shocks (Dhanaraj, 2016; Heltberg and Lund, 2009). This is 
especially the case when illness is repeated, or in the case of chronic illness, such as HIV 
and TB (Gertler and Gruber, 2002; Kenjiro, 2005; Wagstaff and Lindelow, 2014). Our data 
indicates that several households reduced food consumption to meet health-related costs, 
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which can lead to under-nourishment, increase susceptibility to infectious disease, reduce 
quality of life, and damage long-term productivity. Many households also took loans at high 
interest, potentially leading to unmanageable debt. Most of these participants were not 
classified as encountering catastrophic cost using approaches #1-#5, despite the potential 
long-term effects of these coping strategies.  
However, as noted by Collins et al., many households living near the poverty line frequently 
take loans and sell assets in their day-to-day management of resources (Collins et al., 
2009). The high frequency of coping strategies employed by all households in the sample 
could reflect households using all the resources available to them in a dynamic process of 
managing assets to raise funds to pay for illness-related expenses, rather than an act of 
desperation. Indeed, the greatest long-term difficulty might be encountered by those 
households which do not have assets to sell, are not creditworthy or otherwise unable to 
take out loans, or cannot further reduce food intake. Further research linking use of coping 
strategies to long-term economic outcomes within households would help to better 
identify the potential usefulness of this metric. 
This study was designed to illustrate and explore the challenges around measuring income 
at the facility level and has some clear limitations. Our sample size was small and was 
further limited by missing income data which led us to drop 33 participants from the 
analysis. While these limitations do not impact the validity of our observations about 
missing data and internal comparisons, results should not be taken as evidence 
surrounding catastrophic costs for people with TB/HIV in South Africa or any conclusions on 
the TB Fast Track trial. We did not include direct costs of childcare in our questionnaire, 
potentially underestimating direct costs. We used the average household size by 
municipality to estimate income per person, thereby introducing some uncertainty into our 
estimates. We did not collect information on which assets were sold, and therefore are 
unclear how asset sales may have impacted household placement in the asset index. We 
also were not able to compare against a gold standard of household income measurement 
such as a household consumption survey, and thus have no way to test the degree to which 
bias may have affected our findings. However, this paper highlights the extent of 
uncertainty around these measures and the need for greater clarity on the most 
appropriate measure of household resources for estimating catastrophic costs.  
We did not explore here the approach of using consumption-based measures for patients 
attending health facilities, yet these may also be considered. Short-form consumption 
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questionnaires have been successfully used in surveys in the past (Wagstaff and Lindelow, 
2014), although short-form questionnaires have not yet been validated for many settings. 
Further development and validation of short-form consumption questionnaires would 
greatly improve ability to measure permanent income in a facility-based setting. There 
should also be further investigation into whether short-form consumption questionnaires 
are needed at all, or whether a full consumption module might be preferable given the 
potentially high expected value of information associated with these surveys. In a recent 
implementation of the Living Standards Measurement Survey, the full consumption module 
took an average of only 25 minutes (Browning et al., 2014); it may therefore be feasible to 
implement full consumption modules in facility-based surveys if other questions can be 
reduced. 
There is growing concern to provide social protection to those facing catastrophic costs due 
to TB (Boccia et al., 2011; Siroka et al., 2016). Improved social protection could help to 
mitigate long-term costs through improved TB and other health outcomes, reduced periods 
of time off work, and increased productivity. As demonstrated in this paper, the additional 
costs faced by countries which will be liable for social protection for those facing 
catastrophic costs are potentially substantial. In the absence of a gold standard to identify 
those needing social protection, the substantial uncertainty identified in this paper opens 
the possibility of gaming, or choosing a particular method for measuring income to 
minimize the frequency of catastrophic costs, for example to appeal to funders or to 
minimize the cost of social protection. It is also possible that some countries will be unfairly 
judged as performing worse than others when the estimation method is simply different. 
Using existing data, this paper shows the potential implications of different measures of 
household resources in the denominator of the catastrophic cost equation. Further 
concerted research is needed to come to an acceptable recommendation for measurement 
of TB-specific catastrophic costs, and in the meanwhile countries and economic evaluators 
should use a range of approaches. New guidelines developed by the Global Health Cost 
Consortium (GHCC) highlight the importance of stating potential sources of bias clearly in 
cost estimates for health interventions (Vassall et al., 2017) for use in economic evaluation 
and more generally. We suggest that methods for estimating income, and potential sources 
of bias arising from these methods are clearly explained and discussed to facilitate 
interpretation. Our findings confirm the recommendation by the WHO Task Force to use 
multiple methods for income estimation, and stress that different approaches should not 
be used as substitutes for one another until these measures can be directly compared 
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against consumption modules. Further research is needed to evaluate the benefits and 
drawbacks of these different approaches, and to empirically validate rapid estimation 
methods which can be used in a facility setting.  
ACKNOWLEDGEMENTS 
The trial sponsor is the London School of Hygiene & Tropical Medicine, Keppel Street, 
London WC1E 7HT. We gratefully acknowledge the contribution of our study participants; 
the work of the study team and the cooperation of Department of Health staff in 
participating clinics. The study was funded by Joint Global Health Trials (UK Medical 
Research Council, UK Department for International Development, Wellcome Trust). This 
UK-funded award is part of the EDCTP2 programme supported by the European Union. The 
patient cost analysis presented in this paper was supported by a grant from the Bill and 
Melinda Gates Foundation (the Global Health Cost Consortium; grant number 
OPP1109722). The funders and study sponsor had no role in the study design, the 
execution of the study, analyses and interpretation of data, or decision to submit results for 
publication. We thank Salome Charalambous, Sefalane Monkwe, and Katherine Fielding for 
their contributions in data collection, as well as Carol Levin and the Secretariat of the Task 
Force on TB Impact Measurement who commented on the paper. 
Page 173 of 276 
 
REFERENCES 
Alam, K., Mahal, A., 2014. Economic impacts of health shocks on households in low and 
middle-income countries: A review of the literature. Global. Health 10, 21. 
https://doi.org/10.1186/1744-8603-10-21 
Barter, D.M., Agboola, S.O., Murray, M.B., Bärnighausen, T., 2012. Tuberculosis and 
poverty: The contribution of patient costs in sub-Saharan Africa - A systematic review. 
BMC Public Health 12, 980. https://doi.org/10.1186/1471-2458-12-980 
Beegle, K., De Weerdt, J., Friedman, J., Gibson, J., 2012. Methods of household 
consumption measurement through surveys: Experimental results from Tanzania. J. 
Dev. Econ. 98, 3–18. https://doi.org/10.1016/j.jdeveco.2011.11.001 
Boccia, D., Hargreaves, J., Lönnroth, K., Jaramillo, E., Weiss, J., Uplekar, M., Porter, J.D.H., 
Evans, C.A., 2011. Cash transfer and microfinance interventions for tuberculosis 
control: review of the impact evidence and policy implications. Int. J. Tuberc. Lung Dis. 
15, 37–49. https://doi.org/10.5588/ijtld.10.0438. 
Booysen, F., van der Berg, S., Burger, R., Maltitz, M. von, Rand, G. du, 2008. Using an Asset 
Index to Assess Trends in Poverty in Seven Sub-Saharan African Countries. World Dev. 
36, 1113–1130. https://doi.org/10.1016/j.worlddev.2007.10.008 
Brick, J.M., Kalton, G., 1996. Handling missing data in survey research. Stat. Methods Med. 
Res. 5, 215–238. https://doi.org/10.1177/096228029600500302 
Browning, M., Crossley, T.F., Winter, J., 2014. The Measurement of Household 
Consumption Expenditures (No. W14/07), IFS Working Paper Series. London. 
https://doi.org/10.1146/annurev-economics-080213-041247 
Collins, D., Morduch, J., Rutherford, S., Ruthven, O., 2009. Portfolios of the Poor. Princeton 
University Press, Princeton and Oxford. https://doi.org/10.1007/s13398-014-0173-7.2 
Deaton, A., 2001. Counting the World’s Poor: Problems and Possible Solutions, SSRN. 
https://doi.org/10.2139/ssrn.258997 
Deaton, A., Grosh, M., 1999. Consumption, in: Grosh, M., Glewwe, P. (Eds.), Designing 
Household Survey Questionnaires for Developing Countries: Lessons from 15 Years of 
the Living Standards Measurement Study. The World Bank, Washington, p. 518. 
Deaton, A., Zaidi, S., 2002. Guidelines for constructing consumption aggregates for welfare 
analysis. World Bank Publications. https://doi.org/DOI: 
Dhanaraj, S., 2016. Economic vulnerability to health shocks and coping strategies: Evidence 
from Andhra Pradesh, India. Health Policy Plan. 31, 749–758. 
https://doi.org/10.1093/heapol/czv127 
Fielding, K.L., Charalambous, S., Hoffmann, C.J., Johnson, S., Tlali, M., Dorman, S.E., Vassall, 
A., Churchyard, G.J., Grant, A.D., 2015. Evaluation of a point-of-care tuberculosis test-
and-treat algorithm on early mortality in people with HIV accessing antiretroviral 
therapy (TB Fast Track study): Study protocol for a cluster randomised controlled trial. 
Trials 16, 125. https://doi.org/10.1186/s13063-015-0650-0 
Filmer, D., Pritchett, L., 2001. Estimating Wealth Effects Without Expenditure Data--Or 
Tears: An Application to Educational Enrollments in States of India. Demography 38, 
115–132. https://doi.org/10.1353/dem.2001.0003 
Page 174 of 276 
 
Foster, K., Lound, C., 1993. A comparison of questions for classifying income. Surv. 
Methodol. Bull 32, 1–7. 
Friedman, M., 1957. The permanent income hypothesis, in: A Theory of the Consumption 
Function. Princeton University Press, Princeton, pp. 20–37. 
https://doi.org/10.1016/S0304-3932(98)00063-4 
Garvy, G., 1948. The Role of Dissaving in Economic Analysis. J. Polit. Econ. 56, 416–427. 
https://doi.org/10.1086/256725 
Gertler, P., Gruber, J., 2002. Insuring consumption against illness. Am. Econ. Rev. 92, 51–70. 
https://doi.org/10.1257/000282802760015603 
Gibson, J., 2016. Poverty Measurement: We Know Less than Policy Makers Realize. Asia 
Pacific Policy Stud. 3, 430–442. https://doi.org/10.1002/app5.141 
Gwatkin, D., Wagstaff, A., Yazbeck, A.S., 2005. Reaching the Poor with Health, Nutrition, 
and Population Services. The World Bank, Washington, D.C. 
Harttgen, K., Vollmer, S., 2011. Inequality decomposition without income or expenditure 
data: using an asset index to simulate household income (No. 2011/13), Human 
Development Research Paper. New York. 
Heltberg, R., Lund, N., 2009. Shocks, Coping, and Outcomes for Pakistan’s Poor: Health 
Risks Predominate. J. Dev. Stud. 45, 889–910. 
https://doi.org/10.1080/00220380902802214 
Howe, L.D., Hargreaves, J.R., Gabrysch, S., Huttly, S., 2009. Is the wealth index a proxy for 
consumption expenditure? A systematic review. J. Epidemiol. Community Health. 
https://doi.org/10.1136/jech.2009.088021 
Howe, L.D., Hargreaves, J.R., Huttly, S.R.A., 2008. Issues in the construction of wealth 
indices for the measurement of socio-economic position in low-income countries. 
Emerg. Themes Epidemiol. 5, 1–14. https://doi.org/10.1186/1742-7622-5-3 
Jolliffe, D., 2001. Measuring Absolute and Relative Poverty: The Sensitivity of Estimated 
Household Consumption to Survey Design. J. Econ. Soc. Meas. 27, 1–23. 
Kenjiro, Y., 2005. Why illness causes more serious economic damage than crop failure in 
rural Cambodia. Dev. Change. https://doi.org/10.1111/j.0012-155X.2005.00433.x 
Leibbrandt, M., Woolard, I., De Villiers, L., 2009. Methodology: Report on NIDS Wave 1, 
Technical Paper no. 1. Cape Town. 
Lönnroth, K., Glaziou, P., Weil, D., Floyd, K., Uplekar, M., Raviglione, M., 2014. Beyond UHC: 
Monitoring Health and Social Protection Coverage in the Context of Tuberculosis Care 
and Prevention. PLoS Med. 11, e1001693. 
https://doi.org/10.1371/journal.pmed.1001693 
Lonnroth, K., Jaramillo, E., Williams, B.G., Dye, C., Raviglione, M. 2009. Drivers of 
tuberculosis epidemics: the role of risk factors and social determinants. Soc. Sci. Med. 
68, 2240–6. https://doi.org/10.1016/j.socscimed.2009.03.041 
Madan, J., Lönnroth, K., Laokri, S., Squire, S.B., 2015. What can dissaving tell us about 
catastrophic costs? Linear and logistic regression analysis of the relationship between 
patient costs and financial coping strategies adopted by tuberculosis patients in 
Bangladesh, Tanzania and Bangalore, India. BMC Health Serv. Res. 15, 1–8. 
https://doi.org/10.1186/s12913-015-1138-z 
Page 175 of 276 
 
McHugh, M.L., 2012. Interrater reliability: the kappa statistic. Biochem. Medica 22, 276–
282. https://doi.org/10.11613/BM.2012.031 
McKenzie, D.J., 2005. Measuring inequality with asset indicators. J. Popul. Econ. 18, 229--. 
Moore, J.C., Stinson, L.L., Welniak, E.J.J., 2000. Income Measurement Error in Surveys: A 
Review. J. Off. Stat. 16, 31–361. 
OECD, 2017. OECD Better Life Index [WWW Document]. URL 
http://stats.oecd.org/Index.aspx?DataSetCode=BLI# 
Pudney, S., 2008. Heaping and leaping: survey response behaviour and the dynamics of 
self-reported consumption expenditure, ISER Working Paper Series. 
https://doi.org/10.1007/s10273-011-1262-2 
Sinharay, S., Stern, H.S., Russell, D., 2001. The use of multiple imputation for the analysis of 
missing data. Psychol. Methods 6, 317–329. https://doi.org/10.1037/1082-
989X.6.4.317 
Siroka, A., Lönnroth, K., Ponce, N., 2016. The impact of social protection on tuberculosis 
rates: a global analysis. Lancet Infect. Dis. 16, 473–479. 
https://doi.org/10.1016/S1473-3099(15)00401-6.The 
Standards, L., 1997. Measurement of Living Standards. Measurement 69–82. 
Statistics South Africa, 2014. General Household Survey 2013. Statistical release P0318. 
Statistics South Africa, Pretoria, South Africa. 
Statistics South Africa, 2014. Poverty Trends in South Africa: An examination of absolute 
poverty between 2006 and 2001. Pretoria. 
Steinert, J.I., Cluver, L., Melendez-Torres, G.J., Herrero Romero, R., 2017. Relationships 
between poverty and AIDS Illness in South Africa: an investigation of urban and rural 
households in KwaZulu-Natal. Glob. Public Health 12, 1183–1199. 
https://doi.org/10.1080/17441692.2016.1187191 
Sweeney, S., Vassall, A., Foster, N., Simms, V., Ilboudo, P., Kimaro, G., Mudzengi, D., 
Guinness, L., 2016. Methodological Issues to Consider When Collecting Data to 
Estimate Poverty Impact in Economic Evaluations in Low-income and Middle-income 
Countries. Health Econ. 25, 42–52. https://doi.org/10.1002/hec.3304 
Tanimura, T., Jaramillo, E., Weil, D., Raviglione, M., Lönnroth, K., 2014. Financial burden for 
tuberculosis patients in low- and middle-income countries: a systematic review. Eur. 
Respir. J. 43, 1763–1775. https://doi.org/10.1183/09031936.00193413 
USAID, KNCV, TBCTA, 2008. The Tool to Estimate Patients’ Costs 1–83. 
Vassall, A., Sweeney, S., Kahn, J.G.J., Gomez, G., Bollinger, L., Marseille E, et al., Marseille, 
E., Herzel, B., DeCormier Plosky, W., Cunnama, L., Sinanovic, E., Bautista, S., GHCC 
Technical Advisory Group, GHCC Stakeholder Group, Harris, K., Levin, C., 2017. 
Reference Case for Estimating the Costs of Global Health Services and Interventions, 
Global Health Cost Consortium. 
https://ghcosting.org/pages/standards/reference_case 
Wabiri, N., Taffa, N., 2013. Socio-economic inequality and HIV in South Africa. BMC Public 
Health 13, 1037. https://doi.org/10.1186/1471-2458-13-1037 
Wagstaff, A., Lindelow, M., 2014. Are health shocks different? Evidence from a multishock 
Page 176 of 276 
 
survey in Laos. Health Econ. 23, 706–718. https://doi.org/10.1002/hec.2944 
Wingfield, T., Boccia, D., Tovar, M., Gavino, A., Zevallos, K., Montoya, R., Lönnroth, K., 
Evans, C.A., 2014. Defining Catastrophic Costs and Comparing Their Importance for 
Adverse Tuberculosis Outcome with Multi-Drug Resistance: A Prospective Cohort 
Study, Peru. PLoS Med. 11, e1001675. https://doi.org/10.1371/journal.pmed.1001675 
Winter, J., 2004. Response bias in survey-based measures of household consumption. Econ. 
Bull. 3, 1–12. 
Winter, J.K., 2002. Bracketing effects in categorized survey questions and the measurement 
of economic quantities, Sonderforschungsbereich 504, No. 02-35. 
World Health Organization, 2018. Global Tuberculosis Report. World Health Organization, 
Geneva. https://doi.org/10.1001/jama.2014.11450 
World Health Organization, 2017. Tuberculosis patient cost surveys: a handbook. World 
Health Organization, Geneva. 
World Health Organization, 2015. The End TB Strategy. Geneva, Switzerland. 
https://doi.org/10.1017/CBO9781107415324.004 
XE, n.d. Historical exchange rate - October 2015 [WWW Document]. 
Xu, K., Evans, D., Carrin, G., Aguilar-Rivera, A.M., 2005. Designing health financing systems 
to reduce catastrophic health expenditure. Bull. World Health Organ. 85, 8. 
https://doi.org/10.1017/CBO9781107415324.004 
 
Page 177 of 276 
 
 
CHAPTER 9. ESTIMATING CATASTROPHIC TB-
RELATED COSTS IN THE CONTEXT OF ECONOMIC 
EVALUATION IN SOUTH AFRICA  
PREAMBLE FOR RESEARCH PAPER #4 
Chapters 5-7 evaluated the reasons behind the substantial inconsistency in methods currently 
in use to estimate patient costs for TB, and discussed the potential impact of this inconsistency 
on study results. Chapter 8 evaluated the impact of methodological inconsistency on the 
estimation of household income, making estimates of the prevalence of catastrophic costs 
from different studies potentially incomparable.  
WHO-TB have taken action to reduce this variability by developing standardized methods to 
estimate catastrophic costs as part of their End TB Strategy, using nationally-representative 
cross-sectional surveys. However, these surveys require ample resources and time to 
complete. In many settings, data on patient costs have been collected as part of trials or other 
smaller-scale projects. These data could provide a useful resource for countries looking for 
decision-making support without the substantial investment of implementing a national 
survey, however methods for using these data are not verified.  
In Research Paper #4, we attempt to identify whether it is possible to overcome the 
substantial methodological differences discussed in previous chapters and use existing data 
from small-scale studies to come to a country-level estimate of the prevalence of catastrophic 
cost. We conduct a pooled analysis of existing primary studies estimating patient costs for TB 
in South Africa. We obtained three datasets from authors working in South Africa and pooled 
the data into one combined dataset. We used two approaches to estimate the national 
prevalence of catastrophic costs associated with TB using the pooled dataset: a regression 
analysis with multiple imputation, and a meta-analysis linked to a decision model. We 
encountered uncertainty in our estimates of both the numerator (costs) and the denominator 
(income) of the catastrophic costs equation, but found that conducting an individual-level 
analysis does not necessarily improve uncertainty in national estimates. 
I designed the analytical framework, designed and conducted the analysis, and wrote the first 
and consecutive drafts of the paper. NC and DM collected the original data used in this pooled 
analysis. MS and GBG conducted the original systematic review of papers with patient cost 
estimates for GHCC. AV, GBG and MS provided input on analysis methods. All co-authors 
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contributed comments and edited the paper. We are also grateful to the following people who 
declined authorship: Nicola Foster (collected original data for the XTEND project), Carol Levin 
and Lorna Guinness (provided feedback on the draft paper), Carlos Jesus Pineda Antunez 
(developed a Stata program to facilitate data pooling, and advised on the analysis). 
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ESTIMATING CATASTROPHIC TB-RELATED COSTS IN SOUTH AFRICA 
Sedona Sweeneya, Anna Vassalla, Mariana Siapkaa, Natsayi Chimbindib, Don Mudzengic, Gabriela 
B Gomeza 
a London School of Hygiene & Tropical Medicine, Department of Global Health and Development; b Africa Health Research Institute, 
South Africa c The Aurum Institute, South Africa 
INTRODUCTION 
Despite recent improvements in biomedical interventions for prevention and cure of TB, 
progress towards elimination of TB remains slow. TB remains a leading cause of death 
worldwide, with 9.6 million people falling ill and 1.5 million people dying from TB in 2014 
alone [1]. South Africa has one of the world’s highest incidence rates for TB, with an 
estimated incidence of 450,000 people in 2014. Often those who are most affected by TB 
are the most vulnerable in society, and households affected by TB can face substantial cost 
associated with the disease. A recent systematic review found that across countries 
globally, costs associated with TB represented an average of 58% of household income 
(range 5%-306%) [7].  
In recognition of the potentially devastating impact of the costs of illness on households, 
the World Health Organization (WHO) has highlighted reduction of catastrophic costs due 
to TB as one of three priority targets for 2020 [1]. This is in line with, but distinct from, 
efforts to reduce catastrophic total health expenditures and improve access to Universal 
Health Care. The TB-specific measure includes direct non-medical and indirect costs in 
addition to the direct out of pocket costs captured in the measurement of catastrophic 
total health expenditures. From 2020, countries will be required to report on the number 
of patients encountering catastrophic total costs due to TB, and this will be one of three 
key metrics for monitoring country progress.  
The Global TB Program at the World Health Organization has developed guidelines for 
nationally representative cross-sectional surveys to estimate catastrophic costs as part of 
their End TB Strategy [11]. However, these surveys require ample resources and time to 
complete, and will not be feasible for all 130 member states to carry out routinely. This 
leaves many countries searching for another source of these estimates.  
The existing evidence on catastrophic costs due to TB in South Africa is minimal but 
highlights a significant burden. Evaluating a cohort of patients from a single study, 
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Mudzengi et al. [8] found that 31-46% of TB-only and 50-68% of TB/HIV patients encounter 
catastrophic cost depending on the threshold used. Verguet et al. [9] used modelled 
incidence and mortality for tuberculosis and patient-incurred cost estimates from one 
study, predicting that 16,848-24,278 households encounter catastrophic costs over 20 
years in a scenario where current standard of care continues, equivalent to 16-25% of 
those with TB [10]. Although there are several other studies reporting costs, and several 
suggesting that costs are likely to be catastrophic, no other studies report the prevalence of 
catastrophic cost.  
In many settings, data on patient costs have been collected as part of trials or other 
smaller-scale projects. This existing data could provide a useful resource for countries 
looking for decision-making support, in the absence of a national survey. As discussed in 
Chapter 4 of this thesis, there are several potential methods to combine information from 
existing studies, including a meta-analysis of summary data, and pooled analysis of primary 
data. There are a number of potential benefits associated with pooling primary data from 
multiple studies. It can increase the sample size and therefore improve statistical power 
[12], and improve the cultural and economic diversity of patient populations reflected in 
the data [13], which may increase the validity of extrapolations to different contexts. 
Increased diversity of patient populations in the dataset can help to reflect the full 
spectrum of economic backgrounds and responses to health shocks. However, it is often 
difficult to obtain access to primary data, and the pooling process can be arduous.  
Following a request from the Global TB Program at the World Health Organization to 
investigate the potential of using existing data to estimate national prevalence of 
catastrophic costs, the aim of this analysis is to investigate approaches to parameterize a 
cohort model of TB cases in South Africa, to estimate the national prevalence of 
catastrophic costs due to TB in South Africa. We use two approaches to parameterize a 
model with existing data from three facility-based studies: a meta-analysis using summary 
data, and a regression analysis of pooled primary data. 
METHODS 
Model description 
We created a nationally representative individual-level cohort model of TB disease which 
simulated progression through the course of illness in order to estimate both direct and 
indirect ‘patient-incurred’ costs and catastrophic costs for the entire treatment period, for 
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a representative population of South Africans with TB. The model contained a hypothetical 
cohort of 10,000 South Africans with drug-susceptible (DS) TB. HIV prevalence was 
modelled for each TB case based on the relative national prevalence of HIV-positive vs HIV-
negative drug-susceptible TB [14]. Drug-resistant TB (MDR-TB) was not considered in this 
model due to a lack of data; this is discussed further below. 
Each individual in the model was assigned into a household income quintile using data from 
Ataguba et al. on the distribution of TB cases across quintiles [15], and assigned a 
corresponding household income following the national income distribution, using the 
approach described by Harttgen and Vollmer [16], and income quintile cut-offs from 
Statistics South Africa [17]. We then used mean and standard deviation values from the 
most recent (2015) round of the South African National Income Dynamics Survey (NIDS) to 
assign each individual an employment status (differentially by income quintile) and 
household size (no significant difference between income quintiles) [18]. Individuals were 
then assigned an individual income corresponding to their household income, employment 
status, and household size; individual income took a value of zero if unemployed.  
The TB care cascade was defined as containing four distinct periods: 1) from symptom 
onset until a diagnosis is received, 2) from the time diagnosis is received until treatment is 
started, 3) the intensive phase of treatment, and 4) the continuation phase of treatment. 
The likelihood of seeking care in each of the four periods for each TB case was then 
determined using data from a national study of the TB care cascade in South Africa [14]; 
applied to HIV and non-HIV subgroups. Costs were assigned to each period. Cost categories 
we specified as: direct medical costs (including out of pocket payments for consultation 
fees, medicines, diagnostics, etc.); direct non-medical costs (including costs for 
transportation and accommodation); costs of food supplements and special foods; and 
indirect costs (the value of time spent travelling to health facilities and in consultation with 
health providers). Direct costs per episode for those seeking care were estimated as the 
sum of direct medical, direct non-medical, and food costs in each of the four periods. For 
individuals not seeking care or lost-to-follow-up, it was assumed that only the costs of food 
supplements and special foods were encountered. 
Total indirect costs were estimated as the sum of total hours spent travelling to health 
facilities and in consultation, multiplied by the hourly income of the individual (estimated 
assuming 20 working days per month and an 8-hour working day). Productivity loss due to 
illness was not included in the estimate of indirect costs due to a lack of data. Indirect costs 
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were assumed to be zero for those who were unemployed; this was tested in a sensitivity 
analysis. Total costs were defined as the sum of total direct and indirect costs per episode. 
Following the WHO handbook on estimating catastrophic cost [11], catastrophic cost was 
identified where the total cost of the TB episode (including direct and indirect costs) was 
greater than 20% of annual household income. 
The cohort model was simulated 500 times, to give 500 unique estimates of the national 
prevalence of catastrophic costs. Estimates from the 500 model runs are summarized using 
the median value, as well as the 5th and 95th percentiles. 
Model parameterization 
The process of building a model involves characterisation of parameter uncertainty around 
costs, events and population characteristics, and choice of methods to address this. Two 
approaches are commonly used in evidence synthesis in order to produce summary 
estimates from existing data for input into a model: meta-analysis and regression analysis. 
A meta-analysis requires only summary statistics from pre-existing datasets, whilst a 
regression analysis requires the researcher to obtain the full dataset. We used both 
approaches in order to understand their limitations and to evaluate whether either is 
sufficient to predict the national prevalence of catastrophic cost given existing data.  
Searches and data pooling 
A list of all research articles presenting estimates of patient costs due to TB in South Africa 
was collated using a database constructed by the Global Health Cost Consortium. This 
database was constructed following a systematic search of scientific databases and grey 
literature of TB costs worldwide; full methods for construction of the GHCC database are 
described by Alexander et al. [14]. 
Twelve papers were identified as presenting patient costs for TB in South Africa. Of these, 
four were excluded because they presented costs for outdated models of care, and one 
was excluded because no original cost data was presented. Corresponding authors of the 
seven eligible studies were invited to participate in the analysis, and access to a predefined 
set of variables was requested. Four datasets were obtained and pooled [8,9,21]; the total 
sample size per study is listed in Table 9-1. 
A data coding protocol, identifying variable names and formats to be included in the pooled 
dataset, was provided and discussed in depth with all authors who agreed to share data. 
Costs were distinguished by the type of healthcare provider, including: public facility (the 
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study site), another public facility, general practitioner, pharmacy, inpatient hospital, 
outpatient hospital, and traditional healer. Care was also taken to ensure that all studies 
defined relevant periods consistently (distinguishing particularly pre- and post-diagnosis). 
Data were collected for different periods during the TB episode for different studies, as 
illustrated in Figure 9-1.  
Given the data available, the scope of the analysis was restricted somewhat. First, as there 
were only 35 observations for the pre-treatment periods, we were only able to estimate 
total costs for periods 3 and 4 of treatment, rather than the whole illness episode from 
symptom onset. As discussed above, we were unable to include DR-TB due to unavailability 
of data. As all studies were conducted within the health facility, we were not able to 
capture costs of those not attending a health facility. Finally, none of the studies collected 
data on lost productivity due to illness; this was also therefore not included in the analysis. 
These restrictions on the analysis are likely to result in an under-estimation of true 
catastrophic costs. 
We conducted a descriptive analysis of sample characteristics and summary cost variables 
for each dataset and tested any between-study variance in the parameters of interest 
within the pooled dataset. Variables were summarized using the mean and standard 
deviation to reflect central tendency and dispersion of variables for each individual dataset 
and across the pooled dataset. We tested for significant differences in categorical variables 
(such as sex, level of education, and income quintile) using a chi-squared test, and tested 
for significant differences in continuous variables (such as visits to health providers, time, 
and cost) using a one-way analysis of variance (ANOVA).  
All cost and income data were reported in USD. Because some primary data was provided 
in USD with no original exchange rate from South African Rand (ZAR) provided, data was 
inflated to November 2017 using the US consumer price index [22]. All datasets had 
obtained ethical approval for the original study. Ethical approval for the pooled analysis 
was granted by the London School of Hygiene and Tropical Medicine (reference 14486). All 
data was anonymized before transferring. All data was transferred using encrypted files 
and kept in a secure file. 
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Figure 9-1 Data availability 
Period definitions: 
Period 1 Period 2 Period 3 Period 4 
Symptom onset Seeking Care Diagnosis received 
Treatment: Intensive phase Treatment: Continuation phase 
Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 
       
Data available: 
    
MERGE (Mudzengi et al. 2017) 
Provinces: Gauteng 
Income estimation: self-reported individual income   
XTEND suspects (Foster et al., 2015) 
Provinces: Gauteng, Mpumalanga, Eastern Cape, Free State 
Income estimation: self-reported individual income (brackets)       
   
XTEND cases (Foster et al., 2015) 
Provinces: Gauteng, Mpumalanga, Eastern Cape, Free State 
Income estimation: self-reported individual income (brackets) 
   
REACH (Chimbindi et al. 2005) 
Provinces: KwaZulu-Natal, Gauteng, Mpumalanga and Eastern Cape 
Income estimation: self-reported household expenditures (brackets) 
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Identifying income quintiles 
An advantage in pooling these datasets was that all datasets were collected using 
adaptations of the Tool to Estimate Patient Costs [23], and thus defined costs mostly in the 
same way, reflecting the definitions detailed above. However, methods for collecting data 
on income varied widely across datasets and were not reconcilable. As a first step in the 
analysis, it was necessary to assign households into income quintiles using a consistent 
estimation approach. We, therefore, dropped all collected income data and took a 
statistical approach to predict income for households in the dataset, using information that 
was consistent throughout the datasets including asset holdings, housing quality indicators, 
and basic demographics.  
We conducted a regression analysis using data from the most recent NIDS round to obtain 
coefficients representing the relationship of household income to covariates: urbanicity (1 
= rural), gender (1 = female), education level (1 = educated to grade 8 and above), marital 
status (1 = married or cohabitating), TB status (1 = current TB), employment status (1 = 
employed), asset quintile (quintiles 1-5), age group (1 = age 15-29; 2 = age 30-45; 3 = age > 
45) and province. Two model structures were explored, including a generalized linear 
model (GLM) with a gamma distribution and a log link, and a quantile regression approach 
which allows regression on a specified quantile of the data (e.g. 25th quantile, median, or 
75th quantile) (Supplementary Table 9-5). The quantile regression model was determined to 
be the more efficient of the two, and there was strong evidence that coefficients varied 
across income quintiles (Supplementary Figure 9-7). We, therefore, proceeded with 
coefficients from the quantile regression fit on the log of annual household income at the 
25th quantile, following evidence that the burden of TB falls overwhelmingly on those with 
lower socioeconomic status [15,24]. The regression model incorporated survey weights 
calibrated to the corresponding population totals as given in the mid-year population 
estimates released in 2015 [25].  
Regression coefficients were then applied to observations on the same covariates in the 
pooled dataset to create a predicted household income for each individual. Methods for 
income prediction are further described in Appendix 2. 
Identifying direct costs and time 
In order to parameterize the model with cost data, a second step was to identify a mean 
and standard error value for direct medical costs, direct non-medical costs, food costs, and 
total hours by SES quintile and HIV status per period. This predicted household income was 
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used to partition observations from the pooled dataset into socio-economic quintiles 
[19,26], using income cut-offs defined by Statistics South Africa [17]. We tested two 
different approaches for this: a meta-analysis using summary statistics from each included 
study, and a regression approach using pooled individual data from all studies. Using the 
mean and standard error values obtained through each method, we then randomly drew 
cost estimates for each individual following a gamma distribution.  
Meta-analysis 
A meta-analysis was conducted on summary statistics from each study to obtain adjusted 
mean values for the above-described cost categories for each treatment period: direct 
medical costs, direct non-medical costs, food costs, and time spent travelling to health 
facilities and in consultation. Adjusted mean values were estimated by HIV status and SES 
quintile. 
As depicted in Table 9-3, some studies did not collect cost data for certain provider types or 
periods. This data was not imputed for the meta-analysis. Data were log-transformed for 
the meta-analysis as they were highly skewed, and results were exponentiated following 
meta-analysis. Given that patient demographics varied significantly across datasets and 
assuming that patient costs vary according to demographics, we used a random effects 
meta-analysis approach, which does not assume that all studies investigate the same 
population [27]. Results from the meta-analysis are presented in Supplementary Figures 9-
1 through 9-5. 
Regression analysis 
We then conducted a regression analysis on the patient-level data to obtain better-
parameterized estimates to populate the model. The first step in the regression analysis 
was to address the missing values by using a multiple imputation of costs. As the datasets 
each studied a different period during the TB episode, there were no observations 
containing data on the total cost of the TB episode. These missing data could be a result of 
study design rather than the costs encountered, implying that data is missing completely at 
random (MCAR) and can be filled with mean imputation. However, there were significant 
differences in demographic characteristics across different datasets, including urbanicity, 
age, education, and SES quintile (Table 9-1). It is, therefore, more likely that data were 
missing at random (MAR) dependent on these observed factors. Some datasets had partial 
observations, where the number of visits to each provider type was observed, but costs for 
those visits were unobserved. In addition, the number of visits per month in both the 
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intensive and continuation phases varied as practice in the implementation of directly 
observed therapy (DOTS) varied substantially across facilities. In order to limit the 
uncertainty introduced by this variation, we used multivariate imputation with chained 
equations (MICE) as described in Chapter 4, using predictive mean matching (PMM) to fill 
unobserved data points for total visits, total direct costs and total hours spent seeking care 
by period and provider type, generating 20 imputations [28]. As discussed in Chapter 4, the 
non-parametric technique PMM is preferable to simple linear regression for cost data as it 
allows for skewness in the data [29,30]. Observed demographic variables including 
urbanicity, education level, HIV status, employment status, and income quintile, were used 
in the imputation; these variables were selected to maintain consistent specification for the 
imputation model and the final regression analysis. The total number of imputations for 
each data point is listed in Supplementary Table 9-2. As there were only two observations 
for the travel time associated with accessing a traditional healer, this data point was not 
imputed and travel time for traditional healers was assumed to be the same as travel time 
for the study clinic. 
Following imputation, we conducted a series of regression analyses, using the following 
variables as dependent variables: direct medical costs, direct non-medical costs, food costs, 
and total time spent travelling to health facilities and in consultation. Regression analyses 
used a Generalized Linear Model (GLM) approach, assuming a gamma distribution and a log 
link to accommodate skewed data [31]. For each regression analysis, independent variables 
were defined as: urbanicity (1 = rural), education level (1 = educated to grade 8 and above), 
employment status (1 = employed), HIV status (1 = HIV positive), SES quintile (quintiles 1-
5). These independent variables were identified following theory, as well as previous 
evidence that these factors are significant determinants of catastrophic cost [4,5,27–30]. 
Following the regression analysis, marginal estimates for each of the above-described cost 
variables were obtained by HIV status, income quintile, and employment status - with 
urbanicity and education values held constant at the mean observed among people with TB 
in the NIDS dataset (urbanicity = 0.327, education above grade 8 = 0.683). For input into 
the model, direct medical costs, direct non-medical costs, food costs, and total hours by 
SES quintile and HIV status per period were randomly drawn using a gamma distribution 
using the adjusted mean and standard errors from the marginal estimates.  
To help us interpret the results of the pooled regression, we also tested the extent to which 
cost drivers varied across datasets by conducting a regression on the raw unimputed data 
Page 189 of 276 
 
for each dataset separately.  As there were insufficient observations to do this for Period 3, 
we conducted this test only on observations in Period 4. 
RESULTS 
Data and Demographics 
The pooled dataset contained a total of 1,573 observations; this was made up of 1,219 
from the REACH study [21], 148 from the MERGE trial [8], 171 TB cases from the XTEND 
trial [9]. Data for 35 TB suspects from the XTEND trial [9] was not included as the small 
sample size limited analysis capability for the pre-treatment periods. Table 9-1 shows the 
demographic data for each dataset, as well as the pooled dataset. Overall, 82 participants 
(51%) were female, and 908 (52%) were from an urban setting. Participants were well 
educated on average; 1,025 (65%) completed grade 8 or above. Just over one-quarter of 
participants overall (430; 27%) were married or cohabitating; the remainder were single, 
divorced, or widowed. Many households undertook coping strategies to meet the costs of 
illness. Overall, 266 participants (17%) took loans and 38 participants (2%) sold assets to 
meet the costs of their TB. 
Several demographic variables, including urbanicity, age, education, and employment 
status, were significantly different across datasets. Although each dataset was randomly 
selected and should, therefore, be a representative sample of each respective study 
population, the datasets were not representative of the population of South Africa as a 
whole. For example, the MERGE trial only interviewed participants attending health 
facilities in urban areas. Some observations were also likely driven by the fact that TB 
affects certain populations more often than others; for example, the majority of 
observations in all datasets (1,058; 96% overall) were of black/African ethnicity, and only 
351 (22%) participants were employed at the time of interview. 
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Table 9-1 Demographics 
 
  
REACH MERGE XTEND Pooled Dataset 
Difference 
between 
datasets  
NIDS Dataset 
people with current 
TB 
Difference between 
pooled dataset and 
NIDS dataset  
  n = 1219 n = 148 n = 171 n = 1573 Chi-Squared  (n = 244)a Chi-Squared 
Total observations               
Period 1 0 0 0 0       
Period 2 0 0 0 0       
Period 3 103 1 169 273       
Period 4 1049 146 170 1365       
Female n (%) 638 (52%) 76 (51%) 77 (45%) 791 (51%) 8.92* 119 (39%) 0.40 
Urban n (%) 628 (52%) 148 (100%) 109 (63%) 885 (58%) 130.77*** 123 (35%) 4.56* 
Mean age (Std Dev) 37 (12) 35 (10) 40 (13) 37 (12)   41.1 (13.0)   
Black/African n (%) 1162 (95%) 145 (98%) 168 (98%) 1475 (96%) 4.13 212 (92%) 33.77*** 
Grade 8 and above n (%) 756 (62%) 125 (84%) 124 (72%) 1005 (65%) 34.20*** 138 (61%) 6.72* 
Married / Cohabitating n (%) 315 (26%) 48 (32%) 56 (33%) 419 (27%) 6.51 64 (23%) 0.14 
Employed at interview n (%) 195 (16%) 75 (51%) 64 (37%) 334 (22%) 132.73*** 82 (39%) 14.88*** 
Predicted SES quintile 
distributionb  
n (%) 
Quintile 1: 33 (3%) Quintile 1: 0 (0%) Quintile 1: 3 (2%) Quintile 1: 36 (2%) 123.58*** 14 (6%) 4.57 
Quintile 2: 618 (51%) Quintile 2: 23 (16%) Quintile 2: 65 (38%) Quintile 2: 706 (46%)   126 (46%)   
Quintile 3: 440 (36%) Quintile 3: 76 (51%) Quintile 3: 68 (40%) Quintile 3: 584 (38%)   83 (37%)   
Quintile 4: 120 (10%) Quintile 4: 49 (33%) Quintile 4: 34 (20%) Quintile 4: 203 (13%)   21 (11%)   
Quintile 5: 8 (1%) Quintile 5: 0 (0%) Quintile 5: 2 (1%) Quintile 5: 10 (%)    (0%)   
Coping strategies n (%) 
Coping: 223 (18%) Coping: 35 (24%) Coping: 21 (12%) Coping: 279 (18%) 9.31*     
Took loans: 212 (17%) Took loans: 32 (22%) Took loans: 19 (11%) Took loans: 263 (17%) 8.48*     
Sold assets: 26 (2%) Sold assets: 7 (5%) Sold assets: 5 (3%) Sold assets: 38 (2%) 4.82     
n number of observations; Std Dev Standard Deviation; SES socioeconomic a proportions weighted using survey weights to reflect the national average b Quintile based on predicted monthly 
household income from quantile regression: Quintile 1 < $135.60; Quintile 2 ≤ $288.93; Quintile 3 ≤ $587.38; Quintile 4 ≤ $1494.60; Quintile 5 > $1494.60 [17] *** p < 0.001; ** p < 0.01; * p < 
0.05
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Predicted Household Income Quintiles 
Coefficients for the regression to estimate household income are listed in Supplementary 
Table 9-5. Coefficients for most covariates were significant, and tests after the quantile 
regression indicate that coefficients varied significantly across quantiles. However, the 
predictive power for the quantile regression approach as indicated by the Pseudo R2 was 
relatively low (0.18), and the Shapiro-Wilk test indicates that residuals for the regression 
deviate significantly from a normal distribution.  
Predicted income values were adjusted using a Duan smear factor [36], and households 
assigned to SES quintiles based on the adjusted predicted income using upper-income 
thresholds from Statistics South Africa. Only two per cent of observations from the pooled 
dataset fell into the first quintile, while most predictions fell into the second and third 
income quintile (46% and 38% respectively). In comparison, it has been estimated 
nationally that 37% of those with TB fall into the first quintile [10]. 
Direct Costs and Time 
Table 9-2 lists the total visits per month, costs per visit, and time spent per visit by provider 
type and time period for each of the datasets. Availability of data varied by dataset and 
period. Data on direct non-medical costs and time spent per visit were unavailable for 
providers other than the study clinic in the REACH dataset. Costs and time for the intensive 
phase of treatment (Period 3) were only available for one participant in the MERGE 
dataset; participants were interviewed using a 1-month recall period, and most were 
interviewed more than one month after the start of the continuation phase of treatment. 
The majority of participants across all datasets accessed care primarily at the study clinic. 
However, the number of visits per month to the study clinic for the continuation phase of 
treatment varied significantly between datasets. Participants in the REACH study visited the 
study clinic an average of 8.3 times per month in the intensive phase of treatment and 8.9 
times per month in the continuation phase of treatment; in comparison, participants in the 
MERGE trial attended the study clinic only 4.3 times per month and participants in the 
XTEND trial attended the study clinic less than once per month in the continuation phase of 
treatment. Participants in the REACH study also used other providers such as pharmacies 
and GPs significantly more than participants in the MERGE and XTEND trials. There was also 
wide variation in the direct costs encountered for other providers; the direct cost per visit 
for GPs and traditional healers were particularly high in the MERGE and XTEND datasets.   
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Table 9-2 Mean visits, costs, and time by dataset and period from the pooled primary data 
 Period 3 Period 4 
 
MERGE REACH XTEND 
One-way 
ANOVA MERGE REACH XTEND 
One-way 
ANOVA 
 n = 1 n = 102 n = 172 (F statistic) n = 146 n = 1021 n = 172 (F statistic) 
Mean visits per month 
This clinic 2.0 8.3 6.3 1.99 4.3 8.9 0.8 74.39*** 
Pharmacy 0.0 0.2 0.0 4.03* 0.0 0.4 0.0 9.11*** 
General Practitioner 0.0 0.1 0.1 0.04 0.0 0.1 0.0 4.36* 
Outpatient Hospital 0.0 0.0 0.1 0.60 0.0 0.0 0.0 0.48 
Inpatient Hospital 0.0 0.1 0.1 0.01 0.0 0.1 0.0 1.52 
Traditional Healer 0.0 0.0 0.0 1.17 0.0 0.1 0.0 2.92 
Mean direct medical cost per visit  
This clinic $0.00 $0.00 $0.00   $0.00 $0.00 $0.00   
Pharmacy   $2.42 $54.13 2.50 $0.22 $1.84 $7.13 5.02** 
General Practitioner   $23.23 $110.46 0.62 $23.78 $17.38 $55.18 27.58*** 
Outpatient Hospital   $7.28 $40.05 0.11 $4.12 $2.87 $4.63 0.45 
Inpatient Hospital   $0.00 $104.72 0.15 $18.69 $1.14 $13.46 4.00* 
Traditional Healer     $90.37   $439.05 $20.58 $109.76 139.02*** 
Mean direct non-medical cost per visit  
This clinic $0.00 $1.65 $0.66 8.27*** $1.00 $2.06 $1.14 1.39 
Pharmacy     $3.42   $0.00   $3.29   
General Practitioner     $6.88   $26.56   $4.28 1.91 
Outpatient Hospital     $12.66   $9.88   $5.39 0.76 
Inpatient Hospital     $24.39   $17.57   $5.43 0.60 
Traditional Healer     $14.63   $21.95   $0.00 0.06 
Mean travel hours per visit  
This clinic 1.0 0.7 0.6 0.06 1.2 0.6 0.9 55.95*** 
Pharmacy     0.5   1.9   0.2 3.33 
General Practitioner     0.9   1.7   1.1 0.40 
Outpatient Hospital     0.2   2.0   1.5 0.30 
Inpatient Hospital     1.0   2.7   0.6 5.46* 
Traditional Healer     1.0   3.0   0.2   
Mean consult hours per visit  
This clinic 1.0 1.4 1.1 0.15 1.8 0.9 0.4 24.70*** 
Pharmacy     0.5   1.2   0.3 2.36 
General Practitioner     1.1   1.5   0.9 1.97 
Outpatient Hospital     2.7   5.3   2.6 7.85* 
Inpatient Hospital     126.3   104.0   26.4 3.80 
Traditional Healer     0.6   9.0   13.2   
Mean cost of ‘special foods’ or supplements 
Cost per period 27.44 4.21 15.60 7.80*** 50.83 4.21 15.60 185.70*** 
Cost per month 2.0 8.3 6.3 1.99 4.3 8.9 0.8 74.39*** 
* p<0.05, ** p<0.01, *** p<0.001 
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Table 9-3 Mean costs and time by period; from study summary statistics 
 
MERGE REACH XTEND One-way ANOVA 
(F statistic) 
 
n Mean Std Dev n Mean Std Dev n Mean Std Dev 
Period 3           
Direct medical costs  
Study clinic 1 0.00 0.00 102 0.00 0.00 172 0.00 0.00  
Other providers 1 0.00 0.00 104 4.01 16.94 165 30.24 191.11 0.98 
Direct non-medical costs  
Study clinic 1 0.00 0.00 102 12.44 38.13 159 2.94 7.43 4.70** 
Other providers 1 0.00 0.00 90 0.00 0.00 149 3.96 17.63 2.28 
Total travel and consult time  
Study clinic 1 8.00 0.00 89 13.12 12.21 17 4.54 9.96 3.76* 
Other providers 1 0.00 0.00 90 0.00 0.00 147 13.92 65.46 2.05 
Cost of ‘special foods’ or supplements  
Cost per period 1 54.88 0.00 104 8.41 21.70 162 31.19 57.14 7.80*** 
Period 4           
Direct medical costs  
Study clinic 146 0.00 0.00 1021 0.00 0.00 172 0.00 0.00  
Other providers 143 5.35 38.94 1050 12.71 50.4 167 5.42 19.40 2.96 
Direct non-medical costs  
Study clinic 146 14.49 33.52 1020 23.51 74.02 142 3.06 10.44 6.53** 
Other providers 145 4.07 22.60 854 0.00 0.00 152 0.54 2.24 15.91*** 
Total travel and consult time  
Study clinic 145 42.88 33.53 898 25.97 29.23 29 1.16 2.55 32.55*** 
Other providers 144 7.79 34.70 854 0.00 0.00 153 0.67 3.35 24.79*** 
Cost of ‘special foods’ or supplements  
Cost per period 140 203.34 301.17 1050 14.32 39.12 170 96.32 150.99 185.70*** 
* p<0.05, ** p<0.01, *** p<0.001 
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Participants in the MERGE and XTEND datasets also encountered comparatively high direct 
costs for food supplements and special foods. 
Model outputs 
Meta-analysis approach 
Supplementary Figures 9-1 through 9-5 show the adjusted mean estimates for direct 
medical costs, direct non-medical costs, food costs, and time respectively as identified in 
the meta-analysis. Table 9-4 and Figure 9-2 show the outputs from the model after 500 
model runs for both approaches, by quintile. The median direct medical cost produced 
using parameters obtained through the meta-analysis approach was $34.25, varying from 
$80.66 in Quintile 1 to $6.64 in Quintile 4. Median direct non-medical costs were $65.23 
(ranging from $94.92 in Q2 to $22.11 in Q4), and median costs of supplementary foods 
were $40.81 (ranging from $63.92 in Q2 to $20.04 in Q1). The median estimated hours 
spent seeking care (including travel and consultation time) was 82.8 hours (ranging from 
32.9 hours in Q1 to 171.39 hours in Q2). Overall, model outcomes from the meta-analysis 
approach show the majority of the catastrophic cost burden falling on the first income 
quintile. The median prevalence of catastrophic costs in Quintile 1 is 28%, dropping to 2% 
for Quintile 2 and 0% in Quintiles 3 and 4. Overall, 11% of people with TB nationally are 
predicted to encounter catastrophic costs using the meta-analysis approach. 
There was considerable uncertainty in adjusted mean estimates for some variables.  A one-
way analysis of variance (ANOVA) identified significant differences in mean time spent 
accessing the study clinic, and mean direct costs and time for spent accessing other 
providers in Period 4 (Table 9-3). This was likely partially due to small numbers of 
observations.  To some extent however, this could also reflect true variances in total costs 
in the different settings.  The extent to which TB and HIV services are integrated varies 
widely across South Africa; this could lead to a wide variety in the number of visits required 
for those with both TB and HIV in different places, for example. Similarly, the 
implementation of DOTS varies widely across participants in the pooled dataset, with the 
mean number of visits per month varying from 0.8 in the XTEND dataset to 8.9 in the 
REACH dataset as shown in Table 9-2. 
As the sample sizes of each dataset are unequal, and the pooled dataset does not reflect 
the demographics or geography of the country, a simple adjusted mean across datasets will 
not appropriately reflect the national mean if uncertainty is driven by factors not 
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accounted for in the meta-analysis. It was unclear to what extent uncertainty in meta-
analysis results was driven by demographic differences, and thus difficult to interpret meta-
analysis findings. This provided motivation for a regression analysis, which allowed 
inclusion of other explanatory variables in estimation of costs and time associated with 
accessing care. 
Regression approach 
The total number of imputations for the regression approach are listed in Supplementary 
Table 9-2, and coefficients for the regression analysis to identify inputs into the model are 
listed in Supplementary Table 9-3. Several determinants were found to have a significant 
effect on cost, including HIV status, urbanicity, and employment status. Income quintile 
had no significant effect on costs; education level had a marginally significant only on costs 
for special foods in Period 4.  
In our tests of the regression model on the raw un-imputed data separately for each 
dataset (Supplementary Table 9-3), some regression model coefficients were not consistent 
across datasets.  For example, both positive HIV status and employment had a positive 
effect on costs in the MERGE and REACH datasets but a negative effect on costs for the 
XTEND dataset. Rural location had a positive effect on travel and consultation time in the 
REACH dataset, but a small (non-significant) negative effect on time in the XTEND dataset. 
There were no substantial differences observed in significant coefficients across datasets; 
where multiple datasets had significant coefficients for a given variable, coefficients were 
in the same direction and largely similar magnitudes. 
The median direct medical costs produced using parameters obtained through the 
regression approach was $58.52, ranging from $21.06 in Q3 to $96.82 in Q1. Median direct 
non-medical costs were $35.00 (ranging from $30.90 in Q1 to $40.35 in Q1), and median 
costs of supplementary foods were $43.87 (ranging from $16.969 in Q4 to $75.50 in Q1). 
The median total estimated hours spent seeking care (including travel and consultation 
time) was 36.5 hours. The overall prevalence of catastrophic costs for the regression 
approach was 10%; again catastrophic costs were almost exclusively incurred by the lowest 
income quintile (median: 27%; 5th percentile: 19%; 95th percentile: 38%), falling to 1% at 
Quintile 2 and 0% at Quintiles 3 and above.  
Results of the sensitivity analysis testing the impact of methods for valuing the time of 
unemployed people are shown in Supplementary Figure 9-6. Valuing costs for unemployed 
people using their full potential individual salary per hour slightly increased the prevalence 
Page 196 of 276 
 
of catastrophic costs, but the overall impact of this increase was negligible. Estimating full 
costs in Periods 3 and 4 for those lost to follow-up increased cost estimates particularly for 
the regression approach. A combined sensitivity analysis with a full valuation of time for 
unemployed people and full costs for those lost to follow-up increased overall median 
catastrophic costs from 11% in baseline estimates to 17% for the meta-analysis approach, 
and from 10% in baseline estimates to 15% for the regression approach. The greatest 
impact of this change was observed in Quintile 1 - moving from a median 25% catastrophic 
to median 40% catastrophic for the meta-analysis approach and from median 10% 
catastrophic to median 39% catastrophic for the regression approach. 
Figure 9-2 Prevalence of catastrophic cost by approach and quintile (baseline results from 500 
model runs) 
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Table 9-4 Total Costs, Time, and Income by Quintile 
 
Direct medical costs  
(study clinic & other 
providers) 
Direct  
non-medical costs  
(study clinic & other 
providers) 
Direct  
non-medical costs  
(special foods) 
Travel and 
consultation time 
(study clinic & 
other providers) Total Indirect Costs 
Annual Household 
Income 
Prevalence of 
Catastrophic Costs 
 
Median 
(5th – 95th Pctile) 
Median 
(5th – 95th Pctile) 
Median 
(5th – 95th Pctile) 
Median 
(5th – 95th Pctile) 
Median 
(5th – 95th Pctile) 
Median 
(5th – 95th Pctile) 
Median 
(5th – 95th Pctile) 
Meta-analysis approach 
Quintile 1 
$80.66  
($51.97 - $121.39) 
$72.04  
($50.76 - $107.19) 
$20.04  
($19.04 - $21.16) 
32.9  
(23.5 - 46.0) 
$2.05  
($1.07 - $3.99) 
$1,313  
($1,227 - $1,400) 
28%  
(21% - 41%) 
Quintile 2 
$7.48  
($5.08 - $10.86) 
$94.92  
($67.54 - $135.09) 
$63.92  
($59.35 - $68.01) 
171.4  
(123.1 - 242.9) 
$48.68  
($26.98 - $79.71) 
$4,158  
($4,036 - $4,291) 
2%  
(0% - 4%) 
Quintile 3 
$7.21  
($4.94 - $10.14) 
$43.67  
($24.54 - $69.14) 
$56.28  
($45.90 - $68.24) 
70.8  
(49.6 - 99.1) 
$50.23  
($26.07 - $84.66) 
$8,391  
($8,118 - $8,670) 
0%  
(0% - 1%) 
Quintile 4 
$6.64  
($3.20 - $15.88) 
$22.11  
($12.01 - $48.48) 
$29.80  
($18.01 - $45.94) 
63.8  
(40.0 - 90.4) 
$163.34  
($76.24 - $345.58) 
$27,291  
($23,158 - $36,017) 
0%  
(0% - 1%) 
Overall 
$34.25 
 ($22.87 - $51.96) 
$65.23  
($47.84 - $93.67) 
$40.81  
($37.11 - $44.70) 
82.8  
(60.4 - 115.1) 
$52.60  
($30.76 - $85.37) 
$7,757  
($6,794 - $9,427) 
11%  
(7% - 16%) 
Regression approach 
      
Quintile 1 
$71.09  
($44.86 - $106.74) 
$41.94  
($31.71 - $58.80) 
$75.41  
($71.20 - $80.39) 
42.4  
(31.5 - 59.3) 
$3.52  
($1.98 - $5.68) 
$1,315  
($1,249 - $1,374) 
26%  
(19% - 37%) 
Quintile 2 
$21.77  
($16.15 - $31.69) 
$25.62  
($19.29 - $36.32) 
$35.46  
($32.10 - $39.32) 
33.5  
(25.1 - 47.6) 
$11.29  
($7.12 - $16.89) 
$4,156  
($4,071- $4,246) 
0%  
(0% - 0%) 
Quintile 3 
$23.36  
($17.13 - $33.31) 
$29.82  
($22.18 - $41.46) 
$18.78  
($16.96 - $20.86) 
25.2  
(18.5 - 34.7) 
$20.18  
($12.45 - $30.43) 
$8,379  
($8,173 - $8,595) 
0%  
(0% - 1%) 
Quintile 4 
$25.91  
($17.73 - $36.31) 
$32.93  
($24.54 - $45.97) 
$22.97  
($20.26 - $25.83) 
23.3  
(17.6 - 32.5) 
$73.52  
($43.56 - $118.50) 
$27,897  
($24,362 - $34,044) 
0%  
(0% - 1%) 
Overall 
$40.96  
($28.81 - $59.40) 
$33.39  
($25.95 - $47.08) 
$45.11  
($42.60 - $47.75) 
33.2  
(25.6 - 46.7) 
$20.55  
($13.61 - $30.45) 
$7,883  
($7,094 - $8,969) 
10%  
(7% - 14%) 
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DISCUSSION 
This paper has presented estimates of the prevalence of catastrophic costs associated with 
TB, employing an individual-level cohort model using two approaches to parameterize 
direct and indirect cost estimates: a meta-analysis approach using summary statistics, and a 
regression approach using pooled primary data. Overall, the median prevalence of 
catastrophic costs encountered at the population level using both approaches was 10-11% 
of households. There was some uncertainty around these estimates using both approaches, 
ranging from 7-15% (5th-95th pctile) for the meta-analysis approach and 7-14% (5th – 95th 
pctile) using the regression approach.  
Both estimation approaches showed that the majority of the burden of catastrophic cost 
falls on households in the first income quintile; the prevalence of catastrophic cost for the 
poorest quintile was estimated at 28% using the meta-analysis approach and 26% in the 
regression approach. Both approaches produced wide uncertainty around the prevalence 
of catastrophic costs for people falling in the first income quintile – ranging from 20-42% in 
the meta-analysis approach and 19-37% in the regression approach. This was largely due to 
uncertainty around costs encountered by the lowest quintile, particularly direct medical 
and direct non-medical costs associated with seeking care. 
The similarity of estimates using these different approaches suggests that an individual-
level analysis did not contribute any additional benefit over a study-level meta-analysis. 
There was no substantial reduction in uncertainty of cost estimates through the inclusion 
of additional determinants in the regression model.  
This finding is counter-intuitive; in theory, individual data can contribute a great deal of 
value. The small difference observed in results between the two parameterization methods 
may have been a result of strong underlying uncertainty in the data. As demonstrated in 
the individual regression analyses run by study, trends in regression coefficients varied 
across datasets.  This was likely partially a consequence of small sample sizes and varying 
demographics across datasets; where sample sizes for individual datasets were small the 
regression may not have effectively identified significant trends that were more easily 
observed in the larger pooled dataset.   
However, the varying trends in coefficients across datasets could also be a reflection of 
differing models of care in different settings. As described in the Results chapter, models of 
care differed substantially across datasets.  This could lead to differences not only in total 
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costs, but also in cost drivers.  For example, variation in the availability of integrated TB/HIV 
care could lead to a substantial difference in the degree to which positive HIV status is a 
driver of costs.  Differences in implementation of DOTS and frequency of visits could also 
lead to differences in cost drivers across datasets, for example increasing travel time for 
rural participants.  Unfortunately, due to the structure of the available data it was not 
possible to control for these possible differences in models of care; our model therefore 
retained substantial uncertainty and was therefore limited in its ability to predict the 
national prevalence of catastrophic costs with any specificity.   
The design of the model may also have contributed; representation of uncertainty in a 
cohort model is always conditional on its structural assumptions, and the structure of the 
modelling approach involves several assumptions that may have introduced bias into the 
estimates. The model was designed around determinants for which there was nationally-
representative data available - notably SES quintile, employment status, and HIV status. As 
shown in the regression results, urbanicity is also an important determinant of patient 
costs, however it was not possible to build this into the model as no data exists on the 
current prevalence of TB amongst rural vs urban households in South Africa. It was also 
impossible to incorporate interactions in the model; for example, although there is 
evidence available on the comparative risk of TB infection across quintiles [15,41], there is 
no existing published evidence on the prevalence of TB/HIV coinfection or on the 
prevalence of TB on employed vs unemployed individuals. 
A strength in using the cohort model as described is that it allowed adjustment for some 
demographics, and by time period. Demographics in the pooled data did not accurately 
reflect national demographics. One of the strongest potential benefits of pooling data is to 
improve the cultural and economic diversity of patient populations reflected in the data 
[13], theoretically making a pooled dataset more reflective of reality. However, pooling 
these particular data did not successfully eliminate sampling bias. Households in the pooled 
dataset on average fell into higher income quintiles than would be expected in South 
Africa, where 65% of TB cases are observed in households in the lowest two income 
quintiles. Use of the cohort model allowed us to adjust cases across income quintiles, 
matching the income distribution observed among TB patients in South Africa. The cohort 
model also allowed us to adjust for loss to follow-up along the patient pathway of care, 
more accurately capturing the costs of those in care. As more primary data on household 
costs of TB in South Africa becomes available, we may see socioeconomic diversity of the 
pooled primary data widens, which would reduce the need for this type of cohort model.  
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Another important caveat to this finding is that researchers must be sure that all variables 
are estimated in the same way before conducting a meta-analysis. This poses a particular 
concern where methods for estimating patient costs vary substantially across authors and 
institutions. This analysis required substantial effort in the recalculation of variables to 
reconcile cost estimation methods and time periods across studies before it was possible to 
conduct the meta-analysis. This analysis would not have been possible using only the 
summary statistics reported in the study papers. In order for meta-analysis to be a feasible 
alternative going forward, standardization of patient cost reporting is essential.  
Methods for estimation and reporting of income data in patient cost surveys are currently 
inconsistent, with limited guidance on methods to collect income data that is high quality 
[37]. The wide variety of methods for estimating income across the three studies made 
income data collected by the individual studies included in this analysis unusable and 
required a separate regression analysis to predict household income for observations in the 
pooled dataset. The predictive power of the regression analysis given the demographic 
variables available was relatively low, weakening confidence in the predicted income 
estimates. These estimates may have been improved through the inclusion of other 
determinants (such as household size and dependency ratio; age, sex, and occupation of 
the head of the household; or information on land ownership and income source [38–40]). 
However, going forward, standardization of methods to estimate household income is 
critical for any future attempts to pool data for drawing national estimates. Better guidance 
from national governments and international bodies like the WHO as to which income 
measures to use and how these data should be collected would facilitate future efforts to 
estimate catastrophic costs. Guidance on the appropriate measures of ability to pay in the 
denominator (e.g. household income vs household expenditures) would also improve the 
theoretical validity of the metric. 
Due to the above-mentioned limitations, the results from this model should be judged as 
indicative at best, and serve as inspiration for further analysis. A repeat of this analysis with 
additional primary data from South Africa added would test the validity of the main finding. 
Similar analyses conducted using data collected in different countries would also contribute 
to an understanding of the relative contribution of individual-level data on patient costs in 
a variety of settings. 
It would also be good to test our results against other national estimates of catastrophic 
cost in South Africa. There is currently only one published paper that presents estimates of 
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the national prevalence of catastrophic cost for South Africa, to which we can compare 
results. Model results from this analysis were roughly equivalent to the lower bound of 
baseline estimates presented by Verguet et al. [10], who use a similar approach to the 
national model presented here, drawing on data from one of the datasets included in our 
pooled analysis [9]. Our estimates improve on estimates from Verguet et al. in that they 
use a systematic approach to test two different methods for pooling data from multiple 
studies. However, the results of this analysis should be considered highly conservative. As 
discussed above, we consider only the costs of treatment for DS-TB; we did not consider 
the potentially higher costs of MDR-TB nor did we consider costs encountered before the 
start of treatment. Furthermore, we assumed patients who were lost to follow-up did not 
encounter further costs. We did not include the indirect costs associated with reduced 
productivity due to illness due to a lack of data. As all data were collected at the health 
facility level, we were unable to include any cost estimates for people unable to access 
care. This ignores some of the most vulnerable households impacted by TB, and thus likely 
results in an underestimate of the economic burden of TB. Finally, we do not include 
funeral costs for TB-related deaths, as there is limited evidence on these costs.  
The South African government is planning to conduct a nationally representative study to 
estimate catastrophic costs due to TB in the year 2019. The validity of our predictions 
should be tested against data from this nationally representative survey to support future 
estimation of the national prevalence of catastrophic cost using these approaches.  
Our findings on significant determinants of catastrophic costs due to TB as identified in the 
regression approach are largely supported by the existing literature. We found that HIV co-
infection was a significant determinant of some costs; this was also found in Nigeria [33]. 
We also found that employment was a significant determinant of costs in Period 3; this was 
also found in China [35] and South Africa [9]. Rural residence had a significant negative 
effect on direct costs and a positive effect on travel and consultation time; evidence is also 
mixed in previous studies - residence was found to be a significant determinant of 
catastrophic costs in Nigeria [33] Benin [34], and South Africa [9]. Several analyses also 
found that formal education increased the risk of catastrophic costs [33,34], while our 
analysis found no significant effect. We also found no significant effect of income quintile. 
Other potential determinants not included in our analysis which may be significant include 
delay in diagnosis [34], use of coping strategies [42], and smaller household size [30]. 
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This analysis evaluates the ability to use existing data to estimate ‘catastrophic total cost 
due to TB’, following the definition of this metric in the WHO Handbook for TB Patient Cost 
Surveys [11]. This was in response to a direct request from the World Health Organization. 
We were unable to conduct a direct meta-analysis of catastrophic cost as only one existing 
paper presents primary data on the prevalence of catastrophic cost among TB patients [8]; 
this is likely similar to other countries. We find that in the absence of nationally 
representative data, both modelling and regression approaches provide alternatives for 
estimating catastrophic prevalence. However, to improve estimates from such cost-saving 
approaches, there is an urgent need for more standardized methods to collect cost and 
income data, and standardized reporting of cost estimates. 
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CHAPTER 10. DISCUSSION 
This thesis set out to improve the measurement of disease-specific catastrophic costs 
collected in the context of facility-level intervention-focused studies for different policy 
purposes, drawing on research from a number of projects and focusing specifically on the 
case study of TB in South Africa.  
The thesis had five main objectives: 
1. Estimate the prevalence of catastrophic costs among a cohort of people with TB 
using primary data, collected using conventional methods 
2. Identify and critically review the methods used in measuring patient costs 
3. Evaluate the impact of methodological variation in catastrophic cost estimation on 
study findings 
4. Estimate nationally representative catastrophic costs due to TB in South Africa, 
using existing data 
5. Identify the policy implications and next steps for research in this area 
 
Through a series of analyses, the thesis has evaluated methods that are currently used, 
introduced frameworks to help researchers and policymakers recognize the impact of 
varying methodologies, and analysed the validity of current methods to address different 
policy questions. This last chapter summarises the findings of the thesis, its contributions to 
policy, the limitations inherent in the methods, and areas where further research is 
needed. 
MAIN FINDINGS 
Prevalence of catastrophic costs among a cohort of people with TB  
The first objective was addressed in Chapter 5, which estimated the prevalence of 
catastrophic costs encountered by a cohort of people with TB and/or in South Africa. In 
Chapter 5, I apply the best practice costing methods as currently understood, and as 
summarized in Chapter 4. The patient questionnaire was adapted from the USAID Tool to 
Estimate Patient Costs, and a descriptive analysis presents the monthly costs of people with 
TB-only, HIV-only, and TB/HIV. At the time this paper was written, there was no 
comprehensive evidence on the economic impact of illness on people with both TB and 
HIV, despite the fact that this population group accounts for over 60% of those with TB. 
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Chapter 5 provides the first empirical evidence of the patient costs incurred by people 
living with both TB and HIV in South Africa. It provides a strong argument for action by the 
South African government to reduce the economic impact of TB/HIV co-infection on 
households. The paper found that people with TB/HIV in South Africa are at high risk of 
catastrophic costs. Over 45% of participants in the study experienced catastrophic costs 
even at thresholds as high as 25% of individual income. People with both TB and HIV on 
average faced higher levels of post-diagnosis catastrophic costs than those with TB-only or 
HIV-only, an effect that was stronger at higher threshold levels of catastrophic costs. 
Evidence on disease-specific catastrophic costs can inform two distinct policy purposes: 
allocation of health expenditures, and the targeting of social protection. Chapter 5 notes 
several areas where changes in the way TB/HIV services are delivered could reduce the 
impact of catastrophic costs. Integration of TB/HIV services reduced the number of 
standalone TB/HIV service visits to the health facility and could reduce costs. The paper 
also noted that the frequent use of a ‘treatment buddy’ for people with HIV to support 
adherence often results in increased costs to the household; community-based approaches 
to HIV treatment supervision may alleviate this burden. Finally, the paper found that 
supplementary foods, often including foods outside of the typical South African diet, are an 
important cost driver and that further nutritional education may be needed to help 
households meet additional dietary needs within their household budgets. 
However, the extent of the impact on poverty found in the paper means that it is unlikely 
that catastrophic cost can be averted by service integration alone; other types of 
intervention are also needed by the government of South Africa to reduce the burden of 
catastrophic cost. Social and income protection policies are currently not effectively 
implemented in large part in South Africa, and the paper found that many of those with 
TB/HIV co-infection who should qualify for social protection were unable to access it. The 
paper also identifies potential avenues for better targeting of social protection, including 
unconditional immediate cash for TB patients, and subsidization of food supplements or 
travel costs. This chapter provides a powerful example of the potential for high-quality 
health economics research to inform policy. The insights from this chapter give the South 
African government several potential policy tools to reduce the burden of catastrophic 
costs on some of the most vulnerable households in society.  
However, this chapter also provides the first example in this PhD of practical challenges of 
measuring the impact of ill-health on costs incurred by households, and poverty. Although 
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Chapter 5 illustrates the application of the prevailing methods, implementation of ‘gold 
standard’ methods was not possible in some areas and in other areas there was no clear 
‘gold standard’ to implement. The sample size for the paper was small, due to recruitment 
constraints and because the patient cost questionnaire was time-consuming, risking patient 
and interviewer fatigue. A relatively long recall period of 3 to 5 months was used; this 
posed some risk of recall bias, which was weighed against the potential to miss costs. 
Following inconsistency in the literature regarding methods to estimate indirect costs [1–
4], reported income loss was used as the primary measure of indirect cost in order to avoid 
double-counting and possible bias against people with zero income. Individual income was 
used in the denominator of the ‘catastrophic costs’ estimate, as the survey did not include 
an estimate of household income. 
These decisions and their potential implications are described in the limitations section of 
the paper and set the frame for the remaining chapters of the PhD. The remainder of the 
PhD examines these and other constraints faced by researchers working in low- and 
middle-income settings, and systematically identifies opportunities for the research 
community to take action to improve the quality and reliability of patient cost data going 
forward.  
Methods used in measuring patient costs 
Chapters 6 and 7 address the second objective of this thesis: to identify and critically review 
the methods used in measuring patient costs.  
Chapter 6 builds on the lessons learned in the writing of Chapter 5, using various case 
studies to explore and reflect on the methodological challenges faced by researchers 
collecting patient costs in pragmatic intervention-based settings such as the one presented 
in Chapter 5. The paper finds that practical challenges resulted in different methodological 
approaches to data collection, including: comprehensiveness of survey design; time frame 
and recall; sample size and representativeness; data sources and survey administration.  
The paper concludes that it is inevitable that some degree of variation in methods will 
occur across studies where context and data availability vary, particularly where data 
collection is linked to intervention study design. In Chapter 6, I argue that economists first 
and foremost have a responsibility to communicate data requirements in the study design 
phase, advocate for the collection of patient cost data as an essential part of the economic 
evaluation, and highlight the key aspects that need to be reported. However, it is also 
important to recognize that research funding for health economic research is often limited, 
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and even the most well-funded trials often face some budget or practical limitations. A 
framework is therefore presented to enable researchers to think more systematically about 
trade-offs in collection of patient cost data under practical constraints.  
This framework does not provide easy solutions or ‘best practice’ methods for researchers 
faced with logistical limitations, but instead encourages consideration of potential biases in 
cost data collection and advocates for robust reporting of data collection methods. This 
necessarily includes detailed reporting of the methods used to facilitate standardization of 
methods and growth of the field, but also includes reflection of potential biases introduced 
by the methods to help policymakers understand and interpret findings. 
This paper was written with the purpose of estimating catastrophic costs to be included in 
economic evaluation in mind. Some elements of the discussion of the trade-offs and 
research options available may be limited to the economic evaluation setting; for example, 
the discussion of challenges in survey timing focuses on situations when data collection is 
structured around outcome measurement for an economic evaluation. These same 
limitations will likely not be present when conducting a national survey, although there 
may be different challenges. However, many of the methodological points are also relevant 
for researchers seeking to estimate the national prevalence of catastrophic costs, as they 
address more general points to help researchers consider the impact of methodological 
decisions on quality of data, and any potential for bias introduced by these choices. 
Chapter 6 concludes with the message that transparency in data collection for economic 
evaluation is critical, and presentation of cost data should be accompanied with a full, 
detailed description of how the data were estimated to prevent misuse or misapplication of 
the data for other purposes. It is essential that methodological choices are made with full 
understanding of the ‘gold standard’ approach, and how the chosen approach might 
introduce bias into cost estimates.  
Chapter 7 presents a bibliometric review of the literature to examine the extent to which 
existing guidance on estimating patient costs enables researchers to make informed 
choices on study design, considering their context and practical limitations. The aim of this 
paper was to understand which, if any, methodological resources are available and 
accessible to researchers estimating disease-specific patient costs in LMIC settings, to what 
extent the evolution of costing methods has involved the LMIC context, and to what degree 
the available guidance has been used in collecting disease-specific patient cost data in LMIC 
settings with specific reference to TB. 
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Overall, I found that although guidance on data collection for estimation of patient costs is 
available, it is mostly not accessible or relevant for researchers working in low- and middle-
income country contexts. Furthermore, I found that the ideas of researchers working in 
low- and middle-income country context have largely not contributed to the development 
of methods for patient costing; there was a lack of discussion between authors working at 
the ‘cutting edge’ of methods development, and those making costing accessible to 
practitioners working in LMIC settings. This has resulted in over-reliance on institutional 
knowledge, driving differences in methods undertaken by researchers from different 
institutions. 
Impact of methodological variation on study findings 
The current lack of clarity around methods for patient costing identified in Chapters 6 and 7 
has potential ramifications for efforts to estimate catastrophic costs; both to estimate 
national progress towards global WHO targets, and to include in economic evaluations. 
Economic evaluations, even if conducted within a defined setting, often aim to inform 
national resource allocation and need to be generalised within countries; where different 
methods lead to different results, this can result in limited generalizability. The risk of 
limited generalizability is somewhat reduced where countries are using the same 
standardized methods identified in the WHO Handbook to estimate catastrophic costs due 
to TB [5]. However, there remain some methods in the WHO Handbook which are not 
clearly specified. For example, the WHO Handbook is currently unclear as to how countries 
should measure household income; several different options are listed, and no clear 
guidance on the relative advantages or disadvantages of different approaches is provided. 
Chapter 8 presents the results of an analysis to address one of the key concerns in addition 
to patient cost measurement, the measurement of household income. Chapter 8 finds that 
different methods to estimate income result in substantially different estimates of 
catastrophic cost prevalence. Self-reported mean annual income was significantly lower 
than permanent income estimated using an asset linking approach, or income estimated 
using the national average. It further shows that income estimation methods can introduce 
substantial bias into studies. Self-reported income was unavailable for of 33 out of 99 
participants, a number of whom had to sell assets or take out loans to meet the costs of TB.  
The results of Chapter 8 are meaningful for efforts to estimate disease-specific catastrophic 
costs both in the context of economic evaluation and in estimating the national prevalence 
of catastrophic cost. The wide variation in frequency of catastrophic costs encountered by 
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the same study population, when estimated using different methods, confirms the 
importance of transparency and communication in reporting patient cost estimates. When 
this transparency and communication is not present in economic evaluations, policymakers 
cannot understand the implications of findings or compare across studies to inform policy 
decisions.  
Different methods for estimating income across individual studies also make a national 
estimation of catastrophic costs difficult. Pooling study data together to come to a national 
estimate will not be possible where income has been estimated in such different ways. The 
ability for organizations such as the WHO to use the indicator of catastrophic cost 
prevalence as a tracking mechanism is also diminished where national studies use different 
estimation approaches. At best, data from multiple countries will be incomparable. At 
worst, the potential for differing methods to lead to different findings introduces the 
possibility of gaming, or choosing a particular method to minimize the frequency of 
catastrophic costs in order to meet international targets or curry favour among donors.  
As with other chapters, Chapter 8 ends with a call to researchers to be more systematic in 
their data collection approaches, to be more transparent in their reporting, and to 
communicate more across institutions to further develop the field. 
National prevalence of catastrophic costs due to TB in South Africa 
Finally, Chapter 9 presents an evaluation of methods to combine data to estimate the 
national prevalence of catastrophic costs due to TB in South Africa, addressing objective #4. 
This analysis was conducted following a request from the Global TB Program at the World 
Health Organization to investigate the potential to use existing data to estimate the 
national prevalence of catastrophic costs; but also has implications for researchers 
conducting economic evaluations from a societal perspective. The paper evaluates to what 
degree the above-discussed limitations in the current data can be overcome with further 
analysis relying on modelling, exploring the extent to which cost data collected as part of 
trial-based economic evaluations can be used to estimate the national prevalence of 
catastrophic costs.  
This analysis identifies some limitations and some promising indications for going forward. 
First, I identified some limitations of data availability during the process of data pooling. 
There is not currently sufficient data to estimate costs encountered by households before 
the start of treatment. I was also unable to access data for people with MDR TB, or for 
people not receiving care at a public health facility. Finally, the pooled dataset contained 
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several missing variables due to variations across studies in time periods and provider types 
for which cost data collected. This lack of data availability introduced some complexity into 
the analysis and likely resulted in a substantial underestimate of the prevalence of 
catastrophic costs due to TB in the model.  
I also encountered limitations associated with compatibility of data across datasets – 
particularly in terms of differences in income estimation approaches, supporting findings 
from Chapter 8 that this area is vital. Current studies evaluate patient and household 
income in many different ways, making this data incomparable and impossible to use. The 
paper presents a potential solution for this issue in the regression analysis to predict 
household income, however this approach was imperfect. The regression results indicated 
a low predictive power and non-normally distributed residuals. For national estimates to be 
valid for tracking against international targets, methods for estimating income must be 
improved going forward.  
A promising aspect of the findings of Chapter 9 is that when cost and income estimates are 
standardized, an individual-level regression analysis did not result in any substantial 
reduction in uncertainty of estimates of the national prevalence of catastrophic cost. This 
would suggest that it may not be necessary to obtain individual-level data to produce 
national estimates, where a meta-analysis is a reasonable alternative approach. Although 
the quality of the data included in this analysis was somewhat artificial, as I obtained 
primary data and recalculated several variables before conducting the meta-analysis in 
order to standardize estimates, this is encouraging for future efforts.  
The results of Chapter 9 will be best interpreted in the context of findings from a national 
survey of TB-related catastrophic costs in South Africa, using methods articulated in the 
WHO Handbook. This study is currently being planned and is expected to be completed in 
2019. Once this nationally representative data is available, I hope to compare results 
against estimates from Chapter 9 in order to determine whether any systematic bias is 
introduced by using pooled study data.  
Chapter 9 shows that it is possible to use study-level data to estimate the national 
prevalence of catastrophic cost, if reporting of findings and methods for cost data 
estimation can be made more standardized and transparent. This finding could be vitally 
important for countries seeking to maintain surveillance on the prevalence of catastrophic 
cost within the country, without needing to conduct costly nationally representative 
surveys every couple of years. 
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OVERALL CONTRIBUTIONS OF THE THESIS  
This thesis has made substantial contributions to understanding of the economic challenges 
faced by households affected by TB in South Africa. These empirical findings can be used by 
policy makers in South Africa to improve TB care and social support for those affected by 
TB.  It has also made contributions in terms of advancing methods for estimating disease-
specific patient and household costs.  These lessons can be used by users and producers of 
patient cost data to improve the quality and use of cost data going forward. The 
contributions of this thesis are described below. 
Catastrophic costs for TB in South Africa 
The research presented in this thesis has confirmed that people in South Africa continue to 
encounter catastrophic costs due to TB and has provided some indications of potential 
areas where investment from the South African government can reduce this burden.  
The thesis contains three chapters presenting estimates of catastrophic costs incurred by 
people with TB in South Africa: Chapter 5, Chapter 8, and Chapter 9. The results of Chapter 
5 should be taken as specific to the MERGE study population. While some policy lessons 
can be drawn from these results on the economic impact of TB/HIV coinfection, they 
should not be taken as indicative of the national experience. Although catastrophic costs 
are estimated in Chapter 8, the results from this chapter should not be taken to be 
representative of the study population or the South African population due to the small 
sample size and high numbers of data loss. This paper, therefore, does not draw any policy 
lessons from these findings, but rather draws methodological lessons. The estimates 
presented in Chapter 9 can be taken as an estimate of the national prevalence of 
catastrophic cost, and therefore provide the most applicable policy lessons for South Africa.  
First, some lessons can be drawn about potential improvements the South African 
government can make to the way that health care is provided. All data presented in 
Chapter 9 consistently indicates that direct medical costs at the facility where people 
receive their primary treatment are zero. The findings from this paper also support 
previously published evidence that the use of private alternative providers is common in 
South Africa, and can introduce a substantial economic burden on the household [6–9]. 
Improved coordination of care across providers, and the introduction of risk pooling 
schemes for those seeking care at private or alternative providers, could reduce this 
burden. 
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Chapter 9 shows that people with TB lose a great deal of time due to TB-related travel and 
consultation time. The results of Chapter 5 indicate that these costs are highest for people 
with both TB and HIV. Chapter 5 was unable to directly estimate the potential of integrating 
TB/HIV services to reduce these costs, however in principle integration has the potential to 
reduce the overall number of visits. This chapter suggests that efforts to ensure ‘integrated’ 
visits are delivered by the same provider or within the same room, reducing waiting periods 
between multiple visits in a day, may reduce the burden of catastrophic costs due to TB. 
Chapters 5 and 9 also show that supplementary foods are important drivers of costs for TB 
patients in South Africa. This finding has also been reported by other costing studies from 
South Africa [10–12]. Previous studies have indicated that patients may perceive that TB 
and HIV drugs must be supplemented with higher food intake, often including foods 
outside of the typical South African diet including eggs, fruit, soft drinks, and meat. 
Improved nutritional education for people with TB in South Africa may help households 
meet dietary needs within their spending capabilities. 
The results presented in this thesis also provide some lessons to inform targeting of social 
protection in South Africa. As shown in Chapter 9, the national prevalence of catastrophic 
costs is 7-14%; this burden falls almost exclusively on those in the lowest income quintile. 
Currently, the South African government offers a temporary grant for patients who at the 
discretion of a doctor are deemed unfit to undertake remunerative work. However, across 
study populations from Chapters 5 and 9, access to these grants was consistently low. 
Better targeting of social protection is urgently needed to reduce the prevalence of 
catastrophic costs. As noted above, expenditures on special foods and food supplements 
were high across all patients in Chapter 9. Targeted social support in the form of food 
packages or vouchers may also be an important pathway to reduce the economic burden of 
TB on households. 
Implications for policy in South Africa 
Several of the above-listed contributions are directly applicable for policy makers in South 
Africa, including those working in the National TB Programme, the National Department of 
Health, and the Department of Social Development (among others). The evidence 
generated in this PhD supports several policies already included in the South African 
National Strategic Plan on HIV, TB and STIs 2017-2022. For example, this thesis shows that 
people with both TB and HIV experience a disproportionate economic burden; this 
supports the effective integration of HIV, TB and STI services and interventions is critical to 
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the success of NSP goals. This thesis also notes that social support (e.g. in the form of 
disability grants) is currently difficult for TB patients to access; this is also acknowledged in 
the NSP, with plans laid out to improve multi-sector engagement to address social and 
structural determinants of HIV, TB and STIs.  
Some additional findings from the thesis may also inform future approaches by the above-
listed agencies to reduce the economic burden of TB on households.  For example, the 
finding that the use of private alternative providers can introduce a substantial economic 
burden on the household makes a strong argument that improved risk pooling for these 
providers is needed to protect households from catastrophic costs. This could inform 
design of the National Health Insurance Scheme, currently in the second phase of 
implementation. This thesis further shows that supplementary foods are important drivers 
of costs for TB patients in South Africa. This could inform the Department of Social 
Development how best to to target efforts to reduce the economic impact of TB; 
nutritional support and education are strongly needed alongside income support for TB 
patients and their households.  
Methods to estimate disease-specific catastrophic cost in LMIC settings 
The above-described findings underline the importance of disease-specific catastrophic 
cost as a tool for decision-making. Information on disease-specific catastrophic costs can 
inform economic evaluation of new interventions and targeting of social protection, and 
help with program evaluation. These purposes cannot currently be addressed with more 
general estimates of catastrophic total health expenditures. However, this thesis identifies 
several limitations in the current implementation of methods to estimate disease-specific 
catastrophic costs, largely resulting from a lack of definitive guidance on best practice and 
study reporting. 
Chapters 6 and 7 have shown that the current quality of patient cost estimates is highly 
variable, due to often unavoidable practical limitations and limited accessibility, relevance, 
and use of guidance on how to estimate costs. This variability leads to substantially 
different estimates of the prevalence of catastrophic cost, as demonstrated in Chapter 8. 
Chapter 9 shows when methods for estimating patient costs across studies can be 
reconciled, they could be useful for national estimates of the prevalence of catastrophic 
cost. 
The results of this thesis make a strong argument in favour of a reference case on 
estimating disease-specific patient, household, and catastrophic costs. Reference cases 
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have been used to improve comparability of cost and cost-effectiveness analyses globally, 
most commonly from the provider perspective. Most recently, the GHCC has developed 
and promoted a Reference Case for Estimating the Costs of Global Health Services and 
Interventions from the provider perspective [13]. This signals an interest from economists 
globally to improve data collection methods, and recognition by global institutions that 
standardization of reporting on methods for data collection is needed. 
The World Health Organization has developed a handbook for national surveys to estimate 
catastrophic costs associated with TB [5]. This is a valuable resource however it is not an 
appropriate substitute for a reference case on patient cost data collection more widely. As 
discussed throughout this thesis, methods for estimating patient costs in the context of 
economic evaluations may differ from methods for nationally representative surveys on 
catastrophic cost. Data needs are often different, and researchers who estimate patient 
costs in the context of an economic evaluation may face some practical limitations that are 
not applicable to those conducting a nationally representative survey. Furthermore, in 
areas where no current ‘gold standard’ exists we would not wish to limit researchers 
testing different approaches in order to improve methods. However, transparency in 
reporting methods for data collection and analysis remain essential – not only so that the 
results of economic evaluations can be appropriately interpreted by policymakers but also 
so that cost data estimated in the context of economic evaluation can serve other 
purposes.  
This thesis has identified a number of priority areas where improved methods guidance and 
standardized reporting are particularly necessary. First, as discussed in Chapter 7, 
researchers working in LMIC settings need access to guidance clearly defining the ‘gold 
standard’ for patient cost data collection where this exists – particularly in the fields of 
estimation of resource use, and cost valuation where much work has been done to identify 
‘gold standard’ methods. Where this guidance does exist, it is mostly not currently 
accessible or relevant to researchers working in LMIC settings.  
Second, researchers need guidance to help them identify the likely impact of 
methodological compromises taken due to practical limitations. Practical concerns can 
introduce limitations in several aspects of study design, including: comprehensiveness of 
survey design, time frame and recall, sample size and representativeness, and data sources 
and survey administration. This can substantially influence data quality, as discussed in 
Chapter 6. As discussed in Chapter 7, there is not currently suitable guidance to help 
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researchers understand the impact of these decisions. Making this guidance available 
would help researchers to more accurately communicate the implications and limitations 
of their findings, resulting in a more informed policy.  
In some cases, no clear ‘gold standard’ exists, or the ‘gold standard’ is impossible to 
implement in LMIC settings. For example, Chapter 8 describes several possible methods to 
estimate individual and household income, all of which are problematic in some way. In 
cases like these, clear reporting of methods and improved communication across research 
groups is necessary to facilitate comparative analysis, until further research can help to 
identify a better solution.  
Finally, as discussed in Chapter 9, there is also a need for standardization of reporting for 
patient costs – specifically with relevance to time periods, cost types, and provider types. 
Gaining group consensus on standardized ‘outputs’ for a patient costing study would 
facilitate the use of this data for different purposes going forward. I learned how best to 
facilitate this type of discussion during my involvement in drafting the GHCC Reference 
Case for Estimating the Costs of Global Health Services and Interventions, which has 
identified these outputs from the provider perspective, facilitating the use of these costs in 
modelling estimates going forward. The same is possible for patient-perspective costs, 
which would facilitate the use of this data in national estimates of catastrophic cost. 
This thesis has made some preliminary progress toward providing guidance in all these 
areas. The framework presented in Chapter 6 provides a resource for helping researchers 
to think through the impact of methodological choices where practical limitations are 
encountered. The database compiled for the bibliometric review in Chapter 7 will be 
posted on the GHCC website and should help improve the accessibility of guidance for 
researchers working in LMIC settings. Chapter 8 contains a substantial theoretical 
discussion on differences behind different concepts of capacity to pay for health and 
provided a discussion of the economic theory behind the choice of permanent vs current 
income for estimation of catastrophic cost. The supplemental material for the paper also 
contains a detailed glossary defining these terms and clarifying concepts.  
Implications for users and producers of patient cost data 
The above-listed contributions all benefit users and producers of cost data. For researchers 
looking to collect this type of data, this PhD has provided resources to facilitate the process 
of designing a study whilst limiting bias as much as possible. In some cases, I have 
described a ‘gold-standard’ approach for best practice.  For example, the gold standard for 
Page 218 of 276 
 
estimating household expenditure for the denominator of the ‘catastrophic costs’ equation 
is through an expenditures module.  Two approaches are considered to be ‘gold standard’ 
for collecting information on resource use whilst seeking health care; including a review of 
administrative records and a diary approach.   
Unfortunately, in many cases the state of the literature is not sufficient to enable 
conclusive recommendations as to best practice where the gold standard is not 
implementable. For example, the empirical evidence on suitability of recall to estimate 
resource use in the place of records review is mixed; 32% of references found in Chapter 7 
that self-reported data was unreliable, while 26% of studies state that self-reported data is 
reliable. There is no existing research comparing the validity of different measures of 
household ‘capacity to pay’ for health care in the absence of a consumption module.  
Finally, in some cases a ‘gold standard’ does not exist.  There is no published research on 
methods for sampling when estimating disease-specific household costs. Nor is there any 
agreement in the literature as to the most appropriate method to value indirect costs as a 
result of time spent seeking health care (ie. through the ‘human capital’ or ‘outputs’ 
methods).  Finally, although generally a shorter recall period is considered to be better 
when interviewing patients about their resource use, the ideal length of recall has not been 
evaluated and depends substantially on context and the time frame for the disease in 
question.   
Implications for researchers 
on all of these points, there remains a need for group consensus on required reporting and 
further empirical research to confirm ‘best practice’. In looking towards my future career 
post-PhD, I would be motivated to take an active role in facilitating this type of discussion 
across research groups and conducting some further empirical research. There are two 
particular analyses which could be done in the near future thanks to the efforts of the 
WHO-TB programme in coordinating and supporting national patient costing surveys. First, 
several country surveys have collected income data using a variety of methods in a similar 
fashion to the data presented in Chapter 8, but also including an expenditure module. I am 
currently in negotiations to obtain access to this data, in order to conduct an analysis to 
validate the findings of Chapter 8 and test the appropriateness of an expenditure module 
to estimate household income. Second, as mentioned in Chapter 9, the South African 
government is planning to conduct a nationally representative study of catastrophic costs 
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due to TB in the coming year. Once this study has completed, I plan to negotiate access to 
this data in order to test the findings presented in Chapter 9. 
LIMITATIONS AND AREAS FOR FURTHER RESEARCH  
Somewhat fitting for a thesis about the practical limitations of cost data collection, this 
thesis has a number of limitations – often due to practical restrictions. First, as this was a 
staff PhD, it was reliant on data that had already been collected. This limited study design, 
often preventing implementation of a ‘gold standard’ against which I could compare 
estimates.  
For example, it would have been ideal to estimate household consumption expenditure for 
Chapter 8, in order to facilitate a direct comparison of commonly used estimates against 
the ‘gold standard’. This was not included in the original study design and was therefore 
not possible. Further research to develop and implement a short-form consumption 
expenditure module for use in low- and middle-income settings would greatly facilitate the 
estimation of catastrophic costs.  
Chapter 7 presents the results of a bibliometric review on availability, accessibility, and use 
of guidance. Double extraction is usually recommended for systematic reviews in order to 
minimize potential bias or errors in results. This was not possible as this exercise was done 
solely for the purposes of the PhD. Some further verification or checking of extraction by a 
second person will be necessary for this analysis to be publishable in future. 
As mentioned above, due to data limitations all of the papers included in this PhD focus 
only on the costs of people accessing care at public facilities, and only for drug-sensitive TB. 
I do not include any findings or methodological lessons on estimating the cost of care for 
those unable to access care, those with MDR-TB, or those receiving care exclusively from 
private or alternative providers. These people are often the most vulnerable, and methods 
need to be developed to help researchers estimate their costs. 
As shown in Chapters 5 and 9, households with TB often employ coping strategies in an 
attempt to smooth the impact of TB-related costs ex-post. This can involve selling assets, 
taking loans (sometimes at very high interest rates), or reducing consumption. Data on the 
use of coping strategies is relatively easily collected for all households, unlike some 
quantitative measures explored. Coping strategies may also be a better indication of long-
term financial hardship than the quantitative indicator of catastrophic costs. This thesis did 
not evaluate the long-term impact of coping strategies or appropriateness of their use as 
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an indicator for financial hardship, however this should be a priority area of research going 
forward. 
CONCLUSIONS 
This thesis has demonstrated the need for improved discussion and consensus for patient 
costing methods. Changes in the international policy environment in the last five years 
have created an opportunity for evidence on disease-specific catastrophic costs to have a 
greater impact than ever before. There is international motivation to reduce the 
prevalence of catastrophic costs due to TB, and a growing interest in incorporating 
estimates of catastrophic cost in economic evaluation. However, as noted by Graves et al., 
“No amount of statistical analysis can compensate for inadequate costing methods” [14]. 
There are currently gaps in data collection methods that prevent full realisation of the 
opportunities available. Researchers should be challenged to take this opportunity to 
address methodological gaps and come together as a community to strengthen data 
collection methods.  
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SUPPLEMENTARY FILES 
SUPPLEMENTARY FILES FOR CHAPTER 5 
Supplementary Figure 5-1 Catastrophic costs due to illness, by patient group (direct costs only) 
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Supplementary Table 5-1 Number of health facility visits, by patient group, provider type and visit type 
 
Number of participants visiting facility type 
 
Mean number of visits in post-diagnosis period  
among those participants visiting facility type 
 
Participant group 
TB/HIV 
(n = 116) 
TB only 
(n = 40) 
HIV only 
(n = 298) 
TB/HIV 
(n = 116) 
TB only 
(n = 40) 
HIV only 
(n = 298) 
Study Clinic 
      
TB/HIV visits 91 27 0 6.4 1.1  
TB visits 95 39 0 13.3 14.9  
HIV visits 52 2 298 4.4 1.0 4.6 
Other Clinic       
TB visits 6 5 0 1.3 4.4  
HIV visits 2 2 7 1.5 1.0 1.6 
Pharmacy       
TB visits 2 0 0 1.5   
HIV visits 2 0 10 1.5  1.2 
General Practitioner       
TB visits 4 1 0 1.8 1.0  
HIV visits 3 0 20 3.3  1.6 
Hospital (inpatient)       
TB visits 10 0 0 1.2   
HIV visits 3 0 2 1.0  1.0 
Hospital (outpatient)       
TB visits 3 0 0 2.0   
HIV visits 5 0 0 1.2   
Traditional Healer       
TB visits 1 0 0 1.0   
HIV visits 0 0 9   1.7 
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Supplementary Table 5-2 Detailed costs for all facility types, by participant group  
    TB/HIV 
(n=116) 
TB only 
(n=40) 
HIV only 
(n=298) 
    mean (SD) Mean (SD) mean (SD) 
D
ir
e
ct
 c
o
st
s 
Medical 
Study clinic 0.00 0.00 0.00 0.00 0.00 0.00 
Other clinic 0.00 0.00 0.00 0.00 0.00 0.00 
Pharmacy 0.00 0.01 0.07 0.42 0.00 0.00 
General practitioner 0.30 2.72 0.00 0.00 0.82 4.13 
Hospital-outpatient 0.11 0.70 0.00 0.00 0.00 0.00 
Hospital-inpatient 0.32 2.28 0.00 0.00 0.01 0.14 
Traditional healer 1.00 9.67 0.00 0.00 0.05 0.44 
Travel 
Patient 
Study clinic 4.12 8.91 1.69 3.31 1.25 3.07 
Other clinic 0.02 0.12 0.05 0.20 0.02 0.15 
Pharmacy 0.00 0.00 0.00 0.00 0.04 0.35 
General practitioner 0.30 2.70 0.00 0.00 0.13 1.10 
Hospital-outpatient 0.21 0.93 0.00 0.00 0.00 0.00 
Hospital-inpatient 0.06 0.43 0.00 0.00 0.03 0.60 
Traditional healer 0.04 0.48 0.00 0.00 0.01 0.13 
Guardian 
Study clinic 0.43 2.37 0.00 0.00 0.27 2.78 
Other clinic 0.00 0.00 0.00 0.00 0.01 0.08 
Pharmacy 0.00 0.00 0.00 0.00 0.01 0.18 
General practitioner 0.25 2.65 0.00 0.00 0.05 0.81 
Hospital-outpatient 0.12 0.83 0.00 0.00 0.00 0.00 
Hospital-inpatient 0.14 1.45 0.00 0.00 0.10 1.28 
Traditional healer 0.00 0.00 0.00 0.00 0.01 0.09 
Food 
Hospital 0.26 1.31 0.00 0.00 0.04 0.47 
Special foods 13.14 17.33 8.06 11.05 9.76 14.91 
Loan interest 0.93 9.78 0.00 0.00 5.68 89.11 
Total direct 21.72 29%1 9.86 14% 18.28 45%1 
In
d
ir
e
ct
 C
o
st
s 
Patient Income Loss 
Job loss income loss 15.40 126.17 17.78 76.69 2.99 24.30 
Care-seeking income loss 30.45 105.56 34.60 98.99 13.81 59.03 
Opportunity Costs of Time 
Guardian 
Study clinic 1.13 4.58 0.23 1.00 3.92 3.35 
Other clinic 0.00 0.00 0.03 0.17 0.03 0.36 
Pharmacy 0.00 0.00 0.01 0.06 0.00 0.04 
General practitioner 0.03 0.32 0.00 0.00 0.04 0.41 
Hospital-outpatient 0.05 0.65 0.00 0.00 0.00 0.00 
Hospital-inpatient 0.88 6.19 0.00 0.00 0.13 1.11 
Traditional healer 0.00 0.00 0.00 0.00 0.01 0.16 
Carer 4.42 11.35 5.81 13.52 1.19 5.77 
Total indirect 52.34 71%1 58.47 86% 22.13 55%1 
Grand total 74.07   68.33   40.41   
1 percentage of the overall total 
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SUPPLEMENTARY FILES FOR CHAPTER 7 
Appendix 1: Full Search Strategy 
Search Round 1 
Website / Database Search terms 
Web of Science 
 
TITLE: (("costing" or (cost NEAR collect*) or (cost NEAR estimat*) or (cost 
NEAR measur*) or (cost NEAR valu*) or (cost NEAR calculat*) or (cost 
NEAR analys*))) AND TITLE: ((method$ or methodology or valid* or 
generalizab* or compar* or approach* or standard$ or guideline$ or 
recommendation$ or accura* or bias)) AND TOPIC: ((HIV or "human 
immunodeficiency virus" or AIDS or "acquired immune deficiency 
syndrome" or TB or tuberculosis or malaria or immuniz* or vaccinat* or 
disease* or ill* or health* or treat* or care or medic*)) 
Embase 
 
 (("costing" or "cost collection" or "cost estimation" or "cost 
measurement") adj (method$ or methodology or valid* or generalizab* 
or compar* or approach* or standard$ or guideline$ or 
recommendation$ or accura* or bias)).mp. [mp=title, abstract, heading 
word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword]  
IBSS 
 
 ((ti("costing") or (ti(cost) NEAR/3 ti(collect*)) or (ti(cost) NEAR/3 
ti(estimat*)) or (ti(cost) NEAR/3 ti(measur*))) NEAR/3 (ti(method$) or 
ti(methodology) or ti(valid*) or ti(generalizab*) or ti(compar*) or 
ti(approach*) or ti(standard$) or ti(guideline$) or ti(recommendation$) or 
ti(accura*) or ti(bias))) AND (all(HIV) or all("human immunodeficiency 
virus") or all(AIDS) or all("acquired immune deficiency syndrome") or 
all(TB) or all(tuberculosis) or all(malaria) or all(immuniz*) or all(vaccinat*) 
or all(disease*) or all(ill*) or all(health*) or all(treat*) or all(care) or 
all(medic*)) 
Pubmed 
 
search: "costing"[Title/Abstract] OR "cost collection"[Title/Abstract] or 
"cost estimation"[Title/Abstract]) AND (method$ or methodology OR 
validity OR generalizability OR comparison OR approach OR standard$ OR 
guideline$ OR recommendation$) 
Econlit 
 
1 ("costing" or (cost adj collect*) or (cost adj estimat*) or (cost adj 
measur*) or (cost adj valu*) or (cost adj calculat*) or (cost adj 
analys*)).mp. [mp=heading words, abstract, title, country as subject] 
2 (method$ or methodology or valid* or generalizab* or compar* or 
approach* or standard$ or guideline$ or recommendation$ or accura* or 
bias).mp. [mp=heading words, abstract, title, country as subject] 
3 (HIV or "human immunodeficiency virus" or AIDS or "acquired immune 
deficiency syndrome" or TB or tuberculosis or malaria or immuniz* or 
vaccinat* or disease* or ill* or health* or treat* or care or medic*).mp. 
[mp=heading words, abstract, title, country as subject] 
4 1 and 2 and 3 
Global Health 
 
1 ("costing" or (cost adj collect*) or (cost adj estimat*) or (cost adj 
measur*) or (cost adj valu*) or (cost adj calculat*) or (cost adj 
analys*)).mp. [mp=heading words, abstract, title, country as subject] 
2 (method$ or methodology or valid* or generalizab* or compar* or 
approach* or standard$ or guideline$ or recommendation$ or accura* or 
bias).mp. [mp=heading words, abstract, title, country as subject] 
3 1 and 2 
World Bank website 
 (Google search) 
 (cost OR "costing" OR "cost collection" OR "cost estimation" OR "cost 
measurement") AROUND (method OR methodology OR valid OR 
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 generalizable OR compare OR approach OR standards OR guidelines OR 
recommendations OR accuracy OR bias) site:worldbank.org 
WHO website 
(Google search) 
 
 
 (cost OR "costing" OR "cost collection" OR "cost estimation" OR "cost 
measurement") AROUND (method OR methodology OR valid OR 
generalizable OR compare OR approach OR standards OR guidelines OR 
recommendations OR accuracy OR bias) site:who.int 
UNAIDS website 
(Google search) 
 
 
 (cost OR "costing" OR "cost collection" OR "cost estimation" OR "cost 
measurement") AROUND (method OR methodology OR valid OR 
generalizable OR compare OR approach OR standards OR guidelines OR 
recommendations OR accuracy OR bias) site:unaids.org 
 
Search Round 2 
Website / Database Search terms 
Web of Science 
 
 ((productivity OR indirect OR opportunity OR patient OR direct OR out-of-
pocket)) AND TITLE: ((cost OR loss burden OR expenditure OR spend OR 
economic OR catastrophic OR impoverishing)) AND TITLE: ((measure OR 
collect OR value OR calculate OR method OR analyse OR estimate))OR 
method OR analyse OR estimate)  
Embase 
 
1 (productiv* or indirect or opportunity or patient or direct or "out of 
pocket" or "out-of-pocket") title  
2 cost* or loss or burden or expenditure* or spend* or economic title  
3 1 AND 2  
4 (catastroph* or impoverish*) title  
5 3 OR 4  
6 (measur* or collect* or valu* or calculat* or method* or analys* or 
estimat*) title  
7 5 AND 6  
IBSS 
 
((ti((productiv* OR indirect OR opportunity OR patient OR direct OR "out 
of pocket" OR "out-of-pocket")) AND ti(cost* OR loss OR burden OR 
expenditure* OR spend* OR economic)) OR ti((catastroph* OR 
impoverish*))) AND (ti(measur*) or ti(collect*) or ti(valu*) or ti(calculat*) 
or ti(method*) or ti(analys*) or ti(estimat*)) 
Pubmed 
 
((measur*[Title] OR collect*[Title] OR valu*[Title] OR calculat*[Title] OR 
method*[Title] OR analy*[Title] OR estimat*[Title])) AND 
((((((productiv*[Title] OR indirect[Title] OR opportunity[Title] OR 
patient[Title] OR direct[Title] OR "out of pocket"[Title] OR "out-of-
pocket"[Title] OR OOP[Title]))) AND ((cost$[Title] OR loss[Title] OR 
burden[Title] OR expenditure$[Title] OR spending[Title] OR 
economic[Title])))) OR ((catastrophic[Title] OR impoverishing[Title] OR 
impoverishment[Title] OR catastrophe[Title])))  
Econlit 
 
1 (productiv* or indirect or opportunity or patient or direct or "out of 
pocket" or "out-of-pocket") title  
2 cost* or loss or burden or expenditure* or spend* or economic title  
3 1 AND 2  
4 (catastroph* or impoverish*) title  
5 3 OR 4  
6 (measur* or collect* or valu* or calculat* or method* or analys* or 
estimat*) title  
7 5 AND 6  
Global Health 
 
1 (productiv* or indirect or opportunity or patientor direct or "out of 
pocket" or "out-of-pocket") title  
2 cost* or loss or burden or expenditure* or spend* or economic title  
3 1 AND 2  
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4 (catastroph* or impoverish*) title  
5 3 OR 4  
6 (measur* or collect* or valu* or calculat* or method* or analys* or 
estimat*) title  
7 5 AND 6  
World Bank website 
 (Google search) 
 
(productivity OR indirect OR opportunity OR patient OR direct OR out-of-
pocket) AND (cost OR loss burden OR expenditure OR spend OR economic 
OR catastrophic OR impoverishing) AND (measure OR collect OR value OR 
calculate OR method OR analyse OR estimate) site:worldbank.org 
WHO website 
(Google search) 
 
 
(productivity OR indirect OR opportunity OR patient OR direct OR out-of-
pocket) AND (cost OR loss burden OR expenditure OR spend OR economic 
OR catastrophic OR impoverishing) AND (measure OR collect OR value OR 
calculate OR method OR analyse OR estimate) site:who.int 
UNAIDS website 
(Google search) 
 
 
(productivity OR indirect OR opportunity OR patient OR direct OR out-of-
pocket) AND (cost OR loss burden OR expenditure OR spend OR economic 
OR catastrophic OR impoverishing) AND (measure OR collect OR value OR 
calculate OR method OR analyse OR estimate) site:unaids.org 
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Appendix 2: Topic-specific study details 
Supplementary Table 7-3 Broad costing guidance  
 General Disease- or intervention-specific 
 
Number of 
references 
Mean 
methodological 
citations per year 
Mean total 
citations per 
year 
Number of 
references 
Mean 
methodological 
citations per year 
Mean total 
citations 
per year 
What kind of guidance exists?       
Methodological papers on one aspect of costing    2 0.07 1.04 
Purpose-written costing guidelines or costing tool 11 0.06 9.82 15 0.02 2.64 
Costing results with methodological commentary    1 0.11 1.33 
Does any analysis underlie guidance?       
Empirical comparison / validation    1 0.11 1.33 
Literature review    1 0.07 0.93 
No analysis (theory-based) 11 0.06 9.82 16 0.02 2.57 
What setting is guidance relevant to?       
All income levels (not country specific) 5 0.00 14.32 7 0.00 1.21 
High income settings 4 0.15 7.59 5 0.10 1.69 
LMIC settings 2 0.00 3.06 6 0.00 3.54 
Is guidance targeted towards a costing purpose?       
Economic evaluation / priority setting 11 0.06 9.82 14 0.04 2.75 
Equity and poverty analyses    2 0.00 0.43 
Financial planning / management    2 0.00 0.81 
Is guidance widely accessible?       
Not open access 9 0.08 11.56 8 0.05 1.81 
Open access or grey literature 2 0.00 2.02 10 0.02 2.69 
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Supplementary Table 7-4 Study design 
 
Number of 
references 
Mean 
methodological 
citations per year 
Mean total 
citations per 
year 
What kind of guidance exists?    
Methodological papers on one aspect of costing 2 0.05 4.83 
Does any analysis underlie guidance?    
Literature review 2 0.05 4.83 
What setting is guidance relevant to?    
High income 2 0.05 4.83 
Is guidance targeted towards a specific costing purpose?    
Economic evaluation / priority setting 2 0.05 4.83 
Is guidance widely accessible?    
Not open access 2 0.05 4.83 
 
  
Page 230 of 276 
 
 
Supplementary Table 7-5 Estimating resource use 
 General Disease- or intervention-specific 
 
Number of 
references 
Mean 
methodological 
citations per year 
Mean total 
citations per 
year 
Number of 
references 
Mean 
methodological 
citations per year 
Mean total 
citations per 
year 
What kind of guidance exists?       
Methodological papers on one aspect of costing 38 0.29 6.70 40 0.12 2.73 
Cost results with some methodological commentary 1 0.08 4.92 6 0.04 2.99 
Reviews of cost methods 1 0.00 0.06 1 0.00 1.00 
Does any analysis underlie guidance?       
Case study / worked example 2 0.21 11.11 4 0.03 2.64 
Empirical comparison / validation 36 0.30 6.41 42 0.11 2.77 
Expert consultation 1 0.00 6.50    
Literature review 1 0.00 0.06 1 0.00 1.00 
What setting is guidance relevant to?       
All income levels (not country specific) 1 0.00 0.06       
High income 39 0.29 6.65 47 0.10 2.72 
Is guidance targeted towards a specific costing purpose?       
Economic evaluation / priority setting 15 0.28 8.61 24 0.13 3.35 
Purpose not specified / multiple purposes 25 0.28 5.22 23 0.07 2.07 
Is guidance widely accessible?             
Not open access 38 0.30 6.67 42 0.11 2.75 
Open access or grey literature 2 0.00 3.03 5 0.06 2.49 
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Supplementary Table 7-6 Valuation of direct costs 
 General Disease- or intervention-specific 
 
Number of 
references 
Mean 
methodological 
citations per year 
Mean total 
citations per 
year 
Number of 
references 
Mean 
methodological 
citations per year 
Mean total 
citations per 
year 
What kind of guidance exists?       
Methodological papers on one aspect of costing 12 0.05 4.37 3 0.03 1.54 
Reviews of cost methods 1 0.00 7.25    
Does any analysis underlie guidance?       
Empirical comparison / validation 6 0.08 5.00 2 0.05 0.95 
Expert consultation 2 0.00 4.91    
Literature review 1 0.00 7.25    
No analysis (theory-based) 4 0.02 2.84 1 0.00 2.71 
What setting is guidance relevant to?       
All income levels (not country specific) 5 0.05 4.64       
High income settings 3 0.02 0.25 3 0.03 1.54 
LMIC settings 5 0.06 6.36       
Is guidance targeted towards a specific costing purpose?       
Economic evaluation / priority setting 2 2.00 4.87 1 1.00 1.09 
Equity and poverty analyses 8 10.00 4.95    
Financial planning / management 1 1.00 1.14    
Purpose not specified / multiple purposes 2 2.00 4.03 2 2.00 1.77 
Is guidance widely accessible?         
Not open access 12 0.05 4.81 3 0.03 1.54 
Open access or grey literature 1 0.00 1.14    
Page 232 of 276 
 
 
Supplementary Table 7-7 Valuation of indirect costs 
 General Disease- or intervention-specific 
 
Number of 
references 
Mean 
methodological 
citations per year 
Mean total 
citations per 
year 
Number of 
references 
Mean 
methodological 
citations per year 
Mean total 
citations per 
year 
What kind of guidance exists?       
Methodological papers on one aspect of costing 30 0.14 7.02 10 0.12 6.00 
Cost results with some methodological commentary    3 0.00 2.48 
Reviews of cost methods  1 0.08 9.00 1 0.00 6.00 
Does any analysis underlie guidance?       
Case study / worked example 3 0.60 18.34 2 0.16 6.66 
Empirical comparison / validation 13 0.19 5.81 11 0.10 4.92 
Expert consultation 1 0.07 7.73    
Literature review 1 0.08 9.00 1 0.00 6.00 
No analysis (theory-based) 13 0.18 5.57    
What setting is guidance relevant to?       
All income levels (not country specific) 3 0.00 1.00       
High income settings 27 0.23 7.96 14 0.10 5.24 
LMIC settings 1 0.00 1.80       
Is guidance targeted towards a specific costing purpose?       
Economic evaluation / priority setting 30 0.21 7.14 14 0.10 5.24 
Purpose not specified / multiple purposes 1 0.00 5.59    
Is guidance widely accessible?         
Not open access 31 0.14 7.09 13 0.09 5.19 
Open access or grey literature    1 0.00 6.00 
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Supplementary Table 7-8 Reporting 
 General 
 
Number of 
references 
Mean 
methodological 
citations per year 
Mean total 
citations per 
year 
What kind of guidance exists?    
Methodological papers on one aspect of costing 2 0.03 3.26 
Does any analysis underlie guidance?    
Literature review 2 0.03 3.26 
What setting is guidance relevant to?    
All income levels (not country specific) 1 0.07 4.27 
High income 1 0.00 2.25 
Is guidance targeted towards a specific costing purpose?      
Economic evaluation / priority setting 2 0.03 3.26 
Is guidance widely accessible?    
Not open access 2 0.03 3.26 
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SUPPLEMENTARY FILES FOR CHAPTER 8 
Supplementary File 1: Glossary 
Current income:  
The amount earned by a person or household at any one given time. This can include: cash 
and non-cash earnings from productive activities; rental income from the supply of land, 
capital, or other assets; businesses; current transfers from government or non-government 
agencies or other households, and/or investments (O’Donnell and Wagstaff, 2008; Wai-Poi 
et al., 2008). Current income tends to be lumpy and can be seasonal or dependent on the 
local labour market. Current income does not reflect important assets (such as savings) that 
can be drawn upon to finance health care without affecting economic wellbeing within the 
household (Flores et al., 2008; O’Donnell and Wagstaff, 2008).  
Permanent income:  
The long-term average income expectations of a person and/or household (Friedman, 
1957; Hall, 1978; Meghir, 2004). According to the permanent income hypothesis, 
households ‘smooth’ their income by spending less in times of high income and borrowing 
or drawing on savings in times of low income.  
Consumption: 
The resources actually consumed by a household, including: food items; non-food items; 
consumer durables; and housing. Consumption includes purchased items and items 
produced at home (e.g. food that is grown at home) (Deaton and Grosh, 1999; O’Donnell et 
al., 2007). 
Consumption expenditure:  
Money spent on goods and services consumed by the household (Howe et al., 2012). 
According to the permanent income hypothesis, consumption expenditure is a more 
accurate reflection of household living standards than current income (Friedman, 1957), as 
consumption stays relatively constant according to one’s socio-economic status (Garvy, 
1948). 
Coping strategies:  
A form of consumption smoothing, which allows households to manage the costs of 
financial shocks. For example, when faced with a minor illness, a household will typically 
cope by drawing upon its available resources to smooth the financial shock of illness, 
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reducing the impact on non-health spending and avoiding impoverishment (Wagstaff, 
2008). There are a variety of methods that households can employ to cope with health 
shocks, either by generating cash to meet out of pocket payments, or through rearranging 
human or social capital to cope with indirect costs. Common coping strategies include: 
mobilizing savings, deferring expenditure, selling assets, taking loans, income 
diversification, taking on additional labour, or relying on gifts/mutual support networks 
(Bharadwaj, 2014; Goldman and Smith, 2001; Sauerborn et al., 1996). In addition, in many 
subsistence-based economies family members will fill in for a sick person during the 
planting season in agriculture (Su et al., 2007). Coping strategies can help households 
manage transitory shocks (Wagstaff, 2008), however consumption smoothing or other risk 
management mechanisms can break down under repeated shocks or long-term shocks 
(Alderman, 1996; Dercon, 2002). When households are unable to manage shocks through 
coping strategies, they might take more desperate adaptive measures - such as depleting 
productive assets, removing children from school, reducing consumption, sex work, 
begging, and crime - which can lead to an increased cycle of vulnerability (Alwang et al., 
2001; Ilboudo et al., 2013; Sauerborn et al., 1996).  
Direct costs:  
Direct costs include any direct expenditures associated with illness, or with accessing care 
(Cooper and Rice, 1976; McIntyre et al., 2006; Rice, 1967). This includes direct medical 
costs (for example money paid for medicines, diagnostics, consultation fees, or informal 
payments made to health workers) and direct non-medical costs (for example transport 
costs to attend a health facility, accommodation costs whilst seeking care, costs of any 
special foods or supplements taken as a result of illness, or costs of childcare).  
Indirect costs:  
Indirect costs refer both to the opportunity costs of time spent by the patient and 
household members in seeking care (e.g. travel time, waiting time, and time in 
consultations), time spent by household members who provide informal care for the 
patient, and time spent unproductive as a result of illness (McIntyre et al., 2006).  
Productivity costs: 
Productivity costs are a subset of indirect costs, and refer to the time spent unproductive 
as a result of illness. Productivity costs are incurred in the form of absenteeism and 
presenteeism  
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Wealth: 
The aggregate value of all household assets and holdings (Wai-Poi et al., 2008). Households 
use a variety of assets as wealth stores, and can invest in or draw on these investments in 
order to mitigate income shocks (Alwang et al., 2001; Scoones, 1998; Sen, 1981). The 
specific assets available to a household have been classified in the literature differently 
depending on the framework (Bebbington, 1999; Moser, 1998; Scoones, 1998; Wallman 
and Baker, 1996), but often include: human capital (skills, good health and ability to labour, 
ability to pursue livelihoods), natural capital (land, water, environmental resources), 
physical capital (basic infrastructure of housing, water, transport, electricity), financial 
capital (savings, credit, pensions etc. which produce livelihood options), and social capital 
(networks, associations, institutions on which people can draw) (Scoones, 1998). 
Households can store, accumulate, exchange, deplete, or put these assets to work in their 
day to day management of risk and generation of income (Rakodi, 1999).  
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Supplementary File 2: Data Collection Questionnaire 
Data collection questionnaires are available freely online here: 
https://www.sciencedirect.com/science/article/pii/S0277953618304738#mmc2 
 
Supplementary File 3: Detailed costs for included and excluded 
participants 
Supplementary Table 8-9 Total costs for patients included and excluded from analysis 
  Participants included in analysis  
(n = 66) 
Participants excluded due to 
missing income data (n = 33) 
  
Average 
Number 
Visits 
Average 
Direct 
Medical 
Cost 
Average 
Direct 
Non-
Medical 
Cost 
Average 
Number 
Visits 
Average 
Direct 
Medical 
Cost 
Average 
Direct 
Non-
Medical 
Cost 
Study clinic 12.98 $0.00 $27.32 14.15 $0.00 $35.64 
Other clinic 0.12 $0.00 $0.31 0.24 $0.00 $0.97 
Pharmacy 1.44 $4.60 $0.86 0.55 $1.49 $0.92 
General practitioner 0.35 $7.56 $0.86 0.18 $2.51 $0.92 
Hospital-inpatient 0.12 $0.80 $4.49 0.18 $5.94 $2.56 
Traditional healer 0.21 $8.95 $0.69 0.33 $35.54 $0.78 
Specialist 0.57 $0.57 $1.19 0.25 $0.25 $0.39 
Radiologist 0.00 $0.00 $0.88 0.00 $0.00 $1.16 
DOTS 0.00 $0.00 $0.00 0.00 $0.00 $0.00 
Total 15.80 $22.48 $36.60 15.89 $45.73 $43.33 
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Supplementary file 4: MCA Results 
Supplementary Table 8-10 MCA Results 
 
TBFT 
Dataset 
Frequency 
NIDS 
Dataset 
Frequency 
Dimension 1 
Coordinates Contribution 
Assets     
Stove     
Owns a stove 86% 16% 1.05 1.1% 
Does not own a stove 14% 84% -0.20 0.2% 
Satellite television     
Owns a satellite television 38% 30% 1.75 5.9% 
Does not own a satellite television 62% 70% -0.77 2.6% 
DVD player     
Owns a DVD player 71% 36% 1.19 3.2% 
Does not own a DVD player 29% 64% -0.66 1.7% 
Motor car     
Owns a motor car 18% 18% 2.11 5.0% 
Does not own a motor car 82% 82% -0.46 1.1% 
Radio     
Owns a radio 77% 63% 0.44 0.7% 
Does not own a radio 23% 37% -0.74 1.3% 
Television     
Owns a television 87% 80% 0.54 1.5% 
Does not own a television 13% 20% -2.24 6.1% 
Computer     
Owns a computer 17% 16% 2.20 4.9% 
Does not own a computer 83% 84% -0.43 1.0% 
Refrigerator     
Owns a refrigerator 82% 76% 0.64 2.0% 
Does not own a refrigerator 18% 24% -2.08 6.3% 
Cell phone     
Owns a cell phone 97% 89% 0.20 0.2% 
Does not own a cell phone 3% 11% -1.63 1.8% 
Bicycle     
Owns a bicycle 11% 8% 1.76 1.5% 
Does not own a bicycle 89% 92% -0.15 0.1% 
Washing machine     
Owns a washing machine 36% 33% 1.83 6.9% 
Does not own a washing machine 64% 67% -0.91 3.5% 
Toilet type      
Flush toilet with onsite disposal 
(septic tank / soak-away) 54% 28% 1.31 2.9% 
Flush toilet with offsite disposal 3% 23% 1.03 1.5% 
Chemical toilet 0% 2% -1.38 0.3% 
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Pit latrine with ventilation pipe 
(VIP) 16% 16% -1.26 1.6% 
Pit latrine without ventilation pipe 25% 25% -0.93 1.3% 
Bucket toilet 0% 3% -1.54 0.5% 
None 1% 3% -2.67 1.4% 
Other 0% 0% -1.53 0.0% 
Main Walls Material     
Mud 0% 4% -2.89 1.9% 
Mud / cement 6% 7% -2.77 3.2% 
Corrugated iron / zinc 17% 9% -1.22 0.8% 
Prefab / wood 0% 1% -0.50 0.0% 
Bare 14% 77% 0.54 1.4% 
Plaster / finished 60% 1% 0.19 0.0% 
Other 2% 1% -1.10 0.1% 
Main Floors Material     
Natural floor (earth / sand / dung) 8% 9% -2.35 3.2% 
Rudimentary floor (bare wood 
planks) 0% 39% -0.68 1.1% 
Finished floor (parquet / polished / 
tiles / cement / carpet) 92% 52% 0.91 2.7% 
Dwelling Type     
Dwelling/house on a separate 
stand or yard or on farm 73% 72% 0.53 1.3% 
Traditional dwelling / hut made of 
traditional materials 1% 12% -2.44 4.3% 
Flat or apartment in a block of flats 1% 2% 0.67 0.1% 
Town / cluster / semi-detached 
house (simplex, duplex) 0% 1% 1.20 0.1% 
Dwelling / house / flat / room in 
backyard 6% 3% 0.33 0.0% 
Informal dwelling / shack in 
backyard 14% 4% -1.14 0.3% 
Informal dwelling / shack in 
informal/ squatter settlement 4% 5% -1.62 0.8% 
Room/flat let 2% 1% -0.55 0.0% 
Caravan/tent 0% 0% 0.03 0.0% 
Other (specify) 0% 0% -0.65 0.0% 
Source of water     
Piped inside dwelling 37% 39% 1.40 4.8% 
Piped inside yard 44% 30% -0.15 0.0% 
Piped inside community stand 14% 17% -1.53 2.5% 
No access to piped water 1% 3% -1.74 0.5% 
Borehole 2% 2% -0.69 0.1% 
Open source 2% 7% -2.32 2.3% 
Other 0% 1% -1.55 0.2% 
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Supplementary Table 8-11 Quintile results from MCA 
NIDS quintile Number Households 
(TBFT Dataset) 
Number Households 
(NIDS Dataset) 
Mean annual permanent 
income per household 
Standard 
Error 95% Confidence Interval 
Quintile 1 9 5,007 $193.30   3.89  $185.68 - $200.93 
Quintile 2 9 4,869 $263.30   4.42  $254.63 - $271.96 
Quintile 3 35 4,674 $339.23   4.84  $329.75 - $348.72 
Quintile 4 24 4,272 $501.82   14.58  $473.25 - $530.4 
Quintile 5 22 4,418 $1,109.88  17.46  $1,075.66 - $1,144.11 
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Appendix 1: Supplementary Tables and Figures 
Supplementary Table 9-1 Details of studies identified as relevant for analysis 
Study 
Study 
Name Provinces 
Number 
MDR-TB 
patients 
Number DS 
TB patients 
Included 
in 
analysis? 
Fairall (2010)  Free State 0 1,999 No 
Van Rie (2013)  Johannesburg 0 199 No 
Du Toit (2015)  Cape Town 153 0 No 
Ramma (2015)  Cape Town 134 0 No 
Chimbindi 
(2015) 
REACH 
KwaZulu-Natal, Gauteng, 
Mpumalanga 
0 1,219 Yes 
Foster (2015) XTEND 
Gauteng, Mpumalanga, 
Eastern Cape, Free State 
0 
171 (cases); 
35 (suspects) 
Yes 
Mudzengi (2016) MERGE Gauteng 0 148 Yes 
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Supplementary Figure 9-2 Meta-analysis results: direct medical costs (Periods 3 and 4) 
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Supplementary Figure 9-3 Meta-analysis results: direct non-medical costs (Period 3) 
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Supplementary Figure 9-4 Meta-analysis results: direct non-medical costs (Period 4) 
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Supplementary Figure 9-5 Meta-analysis results: travel and consultation time (Period 3) 
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Supplementary Figure 9-6 Meta-analysis results: travel and consultation time (Period 4) 
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Supplementary Table 9-2 Unimputed regression results by dataset 
 
Total travel and consultation time  
(study clinic & other providers) 
Direct medical costs  
(study clinic & other providers) 
 MERGE XTEND REACH Pooled dataset MERGE XTEND REACH Pooled dataset 
Constant 3.660*** (0.27) -0.57 (1.52) 2.732*** (0.25) 2.622*** (0.25) -10.97 ((.)) -4.04 (4.04) 0.87 (0.79) 0.82 (0.80) 
HIV Positive 0.557** (0.17) -0.18 (0.49) 0.17 (0.09) 0.171* (0.08) 26.41 (2096.90) -6.47 (19.84) 0.42 (0.28) 0.22 (0.24) 
Rural  -0.61 (0.51) 1.118*** (0.09) 1.189*** (0.09)  -7.32 (19.74) -0.916** (0.30) -1.071*** (0.29) 
Grade > 8 0.10 (0.22) 0.47 (0.47) -0.210* (0.08) -0.165* (0.08) -17.82 (2096.90) 12.61 (39.50) 0.22 (0.27) 0.17 (0.25) 
Employed 0.28 (0.17) -0.78 (0.45) 0.05 (0.11) 0.08 (0.09) 20.37 (2096.90) -0.29 (0.99) 0.08 (0.35) 0.01 (0.29) 
Quintile         
Quintile 2  2.26 (1.57) -0.17 (0.26) -0.16 (0.26)  5.74 (3.82) 1.636* (0.82) 1.728* (0.83) 
Quintile 3 -0.39 (0.23) 1.67 (1.59) -0.37 (0.28) -0.39 (0.27) -15.18 (2096.90) 6.15 (3.71) 2.051* (0.87) 2.198* (0.87) 
Quintile 4 -0.572* (0.28) 1.95 (1.74) -0.33 (0.30) -0.40 (0.29) -16.83 (2096.90) -0.64 (20.13) 2.011* (0.93) 1.877* (0.90) 
Quintile 5  3.82 (2.48) -2.304*** (0.56) -2.170*** (0.53)  9.34 ((.)) 2.41 (1.77) 3.03 (1.67) 
         
N 146 172 1050 1368 146 172 1050 1368 
AIC 1447.1 679.3 8399.1 11006.3 1473.8 599.7 7234.2 8992.6 
Standard errors in parentheses; * p<0.05, ** p<0.01, *** p<0.001 
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Supplementary Table 9-2 Unimputed regression results by dataset (continued) 
 
Direct non-medical costs  
(study clinic & other providers) 
Direct non-medical costs  
(special foods) 
 MERGE XTEND REACH Pooled dataset MERGE XTEND REACH Pooled dataset 
Constant 1.749** (0.58) 2.886* (1.43) 3.680*** (0.60) 3.745*** (0.61) 4.505*** (0.46) 3.616*** (0.79) 2.224** (0.75) 2.511*** (0.61) 
HIV Positive 1.084** (0.42) -0.02 (0.42) 0.38 (0.21) 0.14 (0.19) 0.630* (0.30) 0.796** (0.25) -0.16 (0.31) 1.408*** (0.20) 
Rural  -1.955*** (0.48) 0.10 (0.21) 0.07 (0.21)  -1.013*** (0.27) -2.829*** (0.32) -0.900*** (0.23) 
Grade > 8 -0.24 (0.60) 0.26 (0.43) 0.13 (0.21) 0.08 (0.20) 0.06 (0.39) -0.06 (0.28) 0.781* (0.30) 0.515* (0.21) 
Employed 1.035** (0.37) -0.52 (0.46) 0.25 (0.26) 0.10 (0.22) 0.02 (0.27) 0.23 (0.24) 0.20 (0.38) 0.728** (0.22) 
Quintile         
Quintile 2  -0.95 (1.45) -0.97 (0.62) -1.01 (0.63)  0.60 (0.84) 0.80 (0.79) 0.31 (0.64) 
Quintile 3 -0.24 (0.63) -1.69 (1.54) -0.90 (0.66) -0.97 (0.67) 0.15 (0.42) 0.92 (0.90) 0.93 (0.85) 0.41 (0.68) 
Quintile 4 -0.18 (0.68) -0.48 (1.60) -0.50 (0.72) -0.79 (0.71) 0.43 (0.46) 1.41 (0.93) 0.00 (0.91) 0.97 (0.72) 
Quintile 5  1.24 (2.35) -2.633* (1.33) -2.42 (1.27)  1.13 (1.37) -68.32 ((.)) -1.07 (1.30) 
         
N 146 172 1050 1368 140 170 1050 1360 
AIC 1093.2 542.1 8582.4 10871.8 1766 1860.2 5864.8 12066.7 
Standard errors in parentheses; * p<0.05, ** p<0.01, *** p<0.001 
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Supplementary Table 9-3 Data points imputed 
  Period 3 Period 4 
Provider Variable 
Number 
Imputed (%) 
Observed Mean 
(95% Conf Interval) 
Imputed Mean 
(95% Conf Interval) 
Number 
Imputed (%) 
Observed Mean 
(95% Conf Interval) 
Imputed Mean 
(95% Conf Interval) 
Study Clinic direct medical cost 0 (0%) 0.00 (0.00 - 0.00) 0.00 (. - .) 0 (0%) 0.00 (0.00 - 0.00) 0.00 (. - .) 
 direct non-medical cost 1277 (83%) 6.63 (0.00 - 353.64) 7.19 (5.07 - 9.31) 231 (15%) 20.29 (0.00 - 1237.76) 20.18 (16.61 - 23.76) 
 travel hours 1273 (83%) 3.26 (0.00 - 44.00) 3.46 (2.93 - 3.99) 307 (20%) 13.10 (0.00 - 234.67) 12.80 (11.69 - 13.91) 
 consult hours 1427 (93%) 6.50 (0.00 - 33.00) 6.39 (5.57 - 7.22) 424 (28%) 13.02 (0.00 - 186.00) 12.37 (11.51 - 13.23) 
Pharmacy direct medical cost 1266 (82%) 1.67 (0.00 - 241.48) 2.02 (0.61 - 3.43) 175 (11%) 1.88 (0.00 - 241.12) 1.87 (1.23 - 2.51) 
 direct non-medical cost 1274 (83%) 0.17 (0.00 - 8.78) 0.34 (0.21 - 0.46) 252 (16%) 0.01 (0.00 - 3.29) 0.09 (0.06 - 0.13) 
 travel hours 1274 (83%) 0.02 (0.00 - 1.00) 0.04 (0.03 - 0.06) 249 (16%) 0.02 (0.00 - 4.22) 0.05 (0.03 - 0.07) 
 consult hours 1274 (83%) 0.03 (0.00 - 2.00) 0.06 (0.03 - 0.08) 249 (16%) 0.02 (0.00 - 2.56) 0.04 (0.03 - 0.06) 
GP direct medical cost 1262 (82%) 7.45 (0.00 - 878.09) 8.12 (2.99 - 13.24) 173 (11%) 5.11 (0.00 - 502.34) 5.36 (3.87 - 6.85) 
 direct non-medical cost 1272 (83%) 0.63 (0.00 - 32.93) 0.51 (0.31 - 0.72) 247 (16%) 0.98 (0.00 - 241.48) 6.47 (4.18 - 8.77) 
 travel hours 1274 (83%) 0.07 (0.00 - 3.00) 0.07 (0.05 - 0.09) 247 (16%) 0.09 (0.00 - 12.00) 0.33 (0.06 - 0.59) 
 consult hours 1272 (83%) 0.11 (0.00 - 3.00) 0.12 (0.08 - 0.16) 247 (16%) 0.07 (0.00 - 6.00) 0.25 (0.14 - 0.36) 
Inpatient Hospital direct medical cost 1262 (82%) 6.35 (0.00 - 790.28) 5.81 (-1.77 - 13.38) 171 (11%) 0.44 (0.00 - 100.56) 0.43 (0.19 - 0.67) 
 direct non-medical cost 1271 (83%) 1.93 (0.00 - 155.86) 1.18 (0.01 - 2.34) 214 (14%) 0.81 (0.00 - 93.30) 1.01 (0.69 - 1.32) 
 travel hours 1268 (82%) 0.09 (0.00 - 5.00) 0.04 (0.01 - 0.07) 215 (14%) 0.09 (0.00 - 5.00) 0.11 (0.07 - 0.14) 
 consult hours 1267 (82%) 13.11 (0.00 - 480.00) 7.76 (2.26 - 13.26) 211 (14%) 4.94 (0.00 - 224.00) 5.01 (3.36 - 6.65) 
Outpatient Hospital direct medical cost 1262 (82%) 2.35 (0.00 - 351.24) 2.40 (0.41 - 4.39) 171 (11%) 0.31 (0.00 - 50.23) 0.31 (0.13 - 0.48) 
 direct non-medical cost 1270 (83%) 0.95 (0.00 - 65.86) 0.59 (0.18 - 1.01) 204 (13%) 0.37 (0.00 - 58.54) 0.91 (0.55 - 1.27) 
 travel hours 1263 (82%) 0.02 (0.00 - 1.33) 0.01 (0.00 - 0.02) 205 (13%) 0.08 (0.00 - 8.00) 0.15 (0.10 - 0.21) 
 consult hours 1268 (82%) 0.27 (0.00 - 7.00) 0.16 (0.08 - 0.24) 205 (13%) 0.19 (0.00 - 17.33) 0.33 (0.22 - 0.45) 
Traditional Healer direct medical cost 1265 (82%) 2.16 (0.00 - 439.05) 1.04 (-0.19 - 2.27) 173 (11%) 3.31 (0.00 - 502.34) 3.39 (1.77 - 5.00) 
 direct non-medical cost 1266 (82%) 0.52 (0.00 - 65.86) 0.14 (-0.11 - 0.39) 210 (14%) 0.07 (0.00 - 21.95) 0.31 (0.12 - 0.51) 
 travel hours 1266 (82%) 0.01 (0.00 - 1.00) 0.01 (0.00 - 0.02) 210 (14%) 0.01 (0.00 - 3.00) 0.04 (0.02 - 0.07) 
 consult hours 1266 (82%) 0.02 (0.00 - 1.00) 0.01 (0.00 - 0.02) 210 (14%) 0.07 (0.00 - 13.17) 0.30 (0.20 - 0.40) 
Food Supplements  1272 (83%) 22.41  
(0.00 - 548.81) 
19.85  
(16.36 - 23.34) 
1272 (83%) 44.03  
(0.00 - 1756.19) 
43.24  
(36.51 - 49.97) 
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Supplementary Table 9-4 Regression coefficients for cost estimates (regression approach) 
  Direct medical costs  
(study clinic & other providers) 
Direct non-medical costs  
(study clinic & other providers) 
Direct non-medical costs  
(special foods) 
Total travel and consultation time 
(study clinic & other providers) 
 
Period 3 Period 4 Period 3 Period 4 Period 3 Period 4 Period 3 Period 4 
 
Coeff (Std Err) Coeff (Std Err) Coeff (Std Err) Coeff (Std Err) Coeff (Std Err) Coeff (Std Err) Coeff (Std Err) Coeff (Std Err) 
Constant 3.88*** (1.01) 1.04 (0.81) 3.11*** (0.54) 3.70*** (0.49) 2.30*** (0.57) 2.48*** (0.58) 2.69** (0.83) 2.69*** (0.28) 
HIV positive -0.44 (0.64) 0.21 (0.23) -0.22 (0.29) 0.10 (0.16) 0.92** (0.28) 1.37*** (0.20) 0.41 (0.24) 0.28** (0.09) 
Rural -0.70 (0.61) -1.05*** (0.28) -0.64* (0.26) -0.10 (0.17) -1.43*** (0.33) -0.88*** (0.23) 0.74** (0.24) 0.89*** (0.10) 
Grade ≥ 8 -0.19 (0.61) 0.18 (0.24) -0.53 (0.31) 0.11 (0.17) -0.21 (0.23) 0.47* (0.20) 0.04 (0.21) -0.06 (0.09) 
Employed 1.88** (0.59) 0.02 (0.28) 0.66* (0.30) 0.02 (0.19) 0.86** (0.26) 0.74** (0.22) 0.46 (0.34) 0.03 (0.11) 
Quintile (ref: Q1)         
Quintile 2 -1.54 (1.17) 1.52 (0.83) -0.41 (0.59) -0.51 (0.51) 0.48 (0.63) 0.37 (0.61) -0.40 (0.84) 0.21 (0.30) 
Quintile 3 -2.04 (1.23) 1.98* (0.87) -0.29 (0.62) -0.39 (0.55) 0.95 (0.73) 0.48 (0.65) -0.97 (0.84) 0.02 (0.33) 
Quintile 4 -1.83 (1.61) 1.65 (0.90) -0.32 (0.76) -0.28 (0.57) 1.44 (0.82) 1.03 (0.69) -1.20 (0.88) 0.00 (0.35) 
Quintile 5 0.78 (2.43) 2.82 (1.60) 0.21 (1.42) 0.33 (1.09) 1.76 (1.47) -1.01 (1.24) -1.17 (1.46) -1.14 (0.60) 
         
N 1,539 1,539 1,539 1,539 1,539 1,539 1,539 1,539 
F statistic 2.52* 2.36* 2.42* 0.45 5.37*** 10.35*** 2.30* 14.67*** 
* p < 0.001; ** p < 0.01; * p < 0.05  
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Supplementary Figure 9-7 Model sensitivity analysis results 
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Appendix 2: Methods for estimating income 
This supplementary appendix describes in further detail methods for the regression used to 
predict income for the analysis presented in Chapter 9.  
Constructing the Asset Index 
We first constructed an asset index using information on housing quality and ownership of 
durable assets (1). The asset index was designed to reflect the relative socio-economic 
standing of households within South Africa as a whole, rather than the relative SES of 
households within the pooled dataset alone. We therefore used the South African National 
Income Dynamics Survey (NIDS) to draw weights for an asset index (2). 
Vyas and Kumaranayake (3) recommend a principal components analysis (PCA) approach to 
estimate a wealth index, however, PCA was designed for use with continuous, normally-
distributed variables and therefore its application to the categorical variables in a wealth 
index is considered by some to be inappropriate (4,5). MCA is analogous to PCA but is 
designed for use with discrete data and was more appropriate to the type of asset data 
available in the dataset.  
Inclusion of variables for the MCA model was tested before model finalization. The final 
model for the MCA included indicator variables for dwelling type, source of water, toilet 
type, main wall materials, and ownership of a number of durable assets including: a DVD 
player, a car, a radio, a television, a refrigerator, a cell phone, and a bicycle. Exploration 
with the MCA model indicated that inclusion of indicators of ownership of livestock and 
donkeys reduced the quality of the model rather than improved it; these were therefore 
left out of the final model. The MCA was conducted separately for rural and urban 
households, as asset ownership and inequality tend to be different in rural and urban areas 
(6).  
The first dimension from the MCA explained 62.5% of variation in the dataset for rural 
households, and 73.4% of variation for urban households. Dimension weights were 
predicted using the Stata ‘predict’ command; dimension weights are listed in Table 1. 
Weights were largely positive for ownership of durable goods and indicators of high-quality 
housing (e.g. flush to sewage toilet, piped water inside dwelling), and negative for 
indicators of poor housing (e.g. no access to piped water, bucket toilet). Households in the 
NIDS dataset were classified into five socio-economic groups through splitting the 
dimension weight into five quintiles. 
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Coding for asset variables from the pooled dataset was then mapped to coding for the 
same questions from the NIDS, and weights from the MCA were applied to asset data in the 
pooled dataset. Using MCA weights, the position of households from the pooled dataset in 
the country-level SES quintiles were interpolated to reflect nationally-representative socio-
economic quintile. The total number of households per quintile for each dataset is detailed 
in Table 9-1 in the main paper. 
Regression to predict income 
We then used data from the NIDS dataset to predict coefficients for a number of 
demographic factors on household income and individual income.  
Both household and individual income data were heavily right-skewed. In planning the 
regression we tested two regression approaches which have been recommended as 
appropriate for non-normally distributed data: a generalized linear model (GLM) with a 
gamma distribution and log link, and a quantile regression model (7).  
Both regression models for household income were fit on covariates that are commonly 
included as determinants of income: urbanicity (1 = rural), gender (1 = female), education 
level (1 = educated to grade 8 and above), marital status (1 = married or cohabitating), 
employment status (1 = employed); asset quintile (quintiles 1-5, as described above), age 
group (1 = age 15-29; 2 = age 30-45; 3 = age > 45) and province. Following evidence that 
the burden of TB falls overwhelmingly on those with lower socioeconomic status (8,9), TB 
status (1 = current TB) was also included as a covariate in both regression models and the 
quantile regression model was fit on the log of household income at the 25th quantile. Both 
regression models incorporated survey weights from the NIDS study calibrated to the 
corresponding population totals as given in the mid-year population estimates released in 
2015 (10). 
Robust standard errors were estimated in the quantile regression models to account for 
skewed data. Normality of residuals for both quantile regression and GLM models were 
tested using the Shapiro-Wilk normality test. The goodness of fit for a GLM is generally 
tested using the Akaike information criterion (AIC) and no R2 is reported for a GLM; direct 
comparison of the predictive power between the two models is therefore difficult. We 
report the pseudo R2 for the quantile regression model and AIC for the GLM. 
Regression coefficients for both regression approaches (quintile and GLM) to estimate 
individual and household income are listed in Supplementary Table 9-5. Coefficients for 
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most covariates were significant, and there was little difference in coefficients across the 
two approaches. Tests after the quantile regression indicate that coefficients varied 
significantly across quantiles, suggesting that the quantile regression approach was more 
appropriate than the GLM approach. Supplementary Figure 9-7 shows the predicted 
coefficients for each covariate across quintiles. However, the predictive power for the 
quantile regression approach as indicated by the Pseudo R2 was relatively low (0.18), and 
the Shapiro-Wilk test indicates that residuals for both approaches deviate significantly from 
a normal distribution.  
Coefficients from both regression analyses were used to predict the income for patients in 
the pooled dataset, and correlation of predicted income and self-reported income variables 
were tested. Each dataset contained different self-reported income variables; correlation 
coefficients for predicted income and income data collected in each dataset is listed in 
Supplmentary Table 9-6. All correlation coefficients are relatively low; this is partly due to 
poor predictive power of the model, but also because most self-reported income variables 
were individual, whilst both regression approaches predicted household income. Most 
correlation coefficients were significant. There was relatively little difference in the size or 
significance of correlation coefficients between the quantile regression approach and the 
GLM approach. 
The quantile regression approach was chosen as the best model, and income predictions 
using this model were used to classify households in the pooled analysis into nationally 
representative income quintiles.  
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Supplementary Table 9-12 MCA results 
  Frequency by Dataset Urban Rural 
  AHRI MERGE XTEND NIDS 
Dimension 1 
Coordinates Contribution 
Dimension 1 
Coordinates Contribution 
Stove                 
owns a Stove 36% 91% 82% 16% 0.72 0.01 1.18 0.02 
does not own a Stove 64% 9% 18% 84% -0.12 0.00 -0.20 0.00 
DVD player                 
owns a DVD player 45% 74% 63% 37% 0.92 0.03 1.54 0.05 
does not own a DVD player 55% 26% 37% 63% -0.62 0.02 -0.57 0.02 
Motor car                 
owns a Motor car 12% 19% 19% 19% 1.64 0.05 2.36 0.06 
does not own a Motor car 88% 81% 81% 81% -0.44 0.01 -0.32 0.01 
Radio                 
owns a Radio 75% 77% 80% 63% 0.49 0.01 0.53 0.02 
does not own a Radio 25% 23% 20% 37% -0.77 0.02 -0.86 0.02 
Television                 
owns a Television 69% 86% 84% 81% 0.49 0.02 0.84 0.04 
does not own a Television 31% 14% 16% 19% -2.37 0.08 -2.14 0.11 
Refrigerator                 
owns a Refrigerator 65% 69% 69% 77% 0.64 0.03 0.93 0.05 
does not own a Refrigerator 35% 31% 31% 23% -2.26 0.09 -1.91 0.10 
Cell phone                 
owns a cell phone 83% 99% 96% 90% 0.19 0.00 0.27 0.01 
does not own a cell phone 17% 1% 4% 10% -1.64 0.02 -1.82 0.04 
Bicycle                 
owns a Bicycle 9% 4% 8% 8% 1.65 1.65 1.65 1.65 
does not own a Bicycle 91% 96% 92% 92% -0.13 -0.13 -0.13 -0.13 
Toilet type                 
Flush to sewage 45% 70% 53% 29% 0.68 0.02 2.26 0.04 
Flush to septic tank 2% 16% 1% 24% 0.28 0.00 1.72 0.02 
Chemical 1% 3% 2% 2% -2.99 0.01 -0.58 0.00 
VIP 12% 3% 11% 15% -1.79 0.01 -0.29 0.00 
Pit without ventilation 27% 5% 31% 24% -2.65 0.03 -0.07 0.00 
Bucket 5% 1% 0% 3% -3.21 0.02 -1.13 0.00 
None 9% 1% 1% 3% -4.04 0.03 -2.59 0.03 
Other 0% 0% 1% 0% -4.11 0.00 -0.44 0.00 
Main Walls Material                 
Mud 5% 1% 3% 3% -3.65 0.01 -2.60 0.04 
Mud/cement 6% 20% 6% 6% -3.26 0.01 -2.32 0.05 
Corrugated iron/zinc 15% 18% 10% 10% -2.74 0.10 -1.13 0.01 
Prefab/wood 6% 1% 1% 1% -1.68 0.01 -1.25 0.00 
Bare brick/cement blocks 25% 22% 78% 78% 0.71 0.03 0.76 0.04 
Plaster/finished 42% 37% 1% 1% 0.61 0.00 -1.48 0.00 
Other 1% 0% 1% 1% -1.56 0.00 -1.74 0.00 
Dwelling Type                 
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House/concrete block 51% 33% 61% 72% 0.77 0.03 0.73 0.03 
Traditional 5% 0% 15% 11% -1.46 0.00 -2.14 0.08 
Flat 17% 3% 1% 2% 0.41 0.00 -0.25 0.00 
Cluster house 1% 5% 0% 1% 0.82 0.00 0.23 0.00 
backyard dwelling 6% 31% 2% 4% 0.07 0.00 0.15 0.00 
Informal 10% 12% 14% 4% -2.21 0.03 -1.72 0.01 
Informal squatter 10% 10% 6% 6% -3.39 0.09 -1.66 0.01 
Room on property 0% 5% 2% 1% -0.44 0.00 0.24 0.00 
Caravan/tent 0% 1% 0% 0% -0.49 0.00 -2.33 0.00 
Other 0% 0% 0% 0% -1.40 0.00 0.14 0.00 
Source of water                 
Piped inside dwelling 36% 30% 28% 41% 0.91 0.04 1.80 0.05 
Piped inside yard 31% 55% 44% 31% -0.58 0.01 0.55 0.01 
Piped community stand 18% 14% 21% 16% -3.70 0.09 -0.64 0.01 
No access to piped water 1% 1% 2% 3% -3.78 0.01 -0.87 0.00 
Borehole 1% 0% 1% 2% -3.97 0.00 0.29 0.00 
Open source 7% 0% 3% 6% -2.50 0.00 -1.94 0.04 
Other 5% 0% 1% 1% -4.03 0.01 -0.67 0.00 
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Supplementary Table 9-13 Regression coefficients for income prediction 
 
Quantile Regression  
(25th quantile; Log) 
GLM regression (gamma log) 
Constant  4.26*** (0.06) 5.24*** (0.08) 
Urban 0.15*** (0.04) -0.01* (0.04) 
Female 0.07* (0.03) 0.04* (0.03) 
Educated ≥ grade 8 0.27*** (0.04) 0.31*** (0.04) 
Married / cohabitating 0.21*** (0.04) 0.20*** (0.04) 
Has TB -0.28*** (0.04) -0.27** (0.10) 
Employed 0.33*** (0.03) 0.33*** (0.04) 
Asset quintile (ref Q1) 
  
Quintile 2 0.20*** (0.04) 0.25*** (0.03) 
Quintile 3 0.48*** (0.05) 0.57*** (0.04) 
Quintile 4 0.73*** (0.04) 0.73*** (0.04) 
Quintile 5 1.37*** (0.05) 1.66*** (0.06) 
Age group (ref age 15-29) 
 
30-44 -0.09** (0.04) -0.19*** (0.03) 
45 and over 0.10* (0.05) 0.10* (0.05) 
Province (ref: Eastern Cape) 
 
Free State 0.04* (0.07) -0.19* (0.13) 
Gauteng 0.26*** (0.05) -0.09* (0.13) 
Mpumalanga 0.13* (0.06) 0.13* (0.11) 
Western Cape 0.26*** (0.05) -0.08* (0.14) 
KwaZulu-Natal 0.24*** (0.04) 0.10* (0.10) 
   
N 16,396 16,396 
Pseudo R2 0.18   
AIC 
 
24947.96 
Shapiro-Wilk test  
for normality of residuals 
1.00*** 0.97*** 
*** p < 0.001; ** p < 0.01; * p < 0.05  
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Supplementary Figure 9-8 Variation of regression coefficients across quantiles 
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Supplementary Table 9-14 Correlation coefficients for predicted and self-reported income 
 Quantile 
Regression 
GLM 
Regression 
Self-reported individual income: symptom onset 
(collected in MERGE dataset) 
0.42*** 0.33*** 
Self-reported individual income: diagnosis 
(collected in MERGE dataset) 
0.39*** 0.29*** 
Self-reported individual income: intensive phase 
(collected in XTEND dataset) 
0.24** 0.25*** 
Self-reported individual income: continuation phase 
(collected in XTEND dataset) 
0.21** 0.23** 
Self-reported household expenditure 
(collected in REACH dataset) 
0.33*** 0.34*** 
*** p < 0.001; ** p < 0.01; * p < 0.05  
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